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Abstract 
Platinum resistance causes treatment failure in a variety of cancers including 
ovarian cancer. Epigenetic changes can contribute to platinum resistance, as 
the epigenome is highly divergent between platinum-resistant and -sensitive 
cells, and DNA demethylating agents partially resensitise resistant cells to 
platinum. The mismatch repair (MMR) gene MLH1 is epigenetically silenced in 
certain ovarian cisplatin-resistant cells and links between DNA damage and 
DNA methylation have been reported. This thesis aims to address the 
hypothesis that platinum-induced DNA damage causes aberrant DNA 
methylation, which can be selected for leading to drug resistance, and that the 
methylation response to platinum damage is influenced by MMR status.  
  
Two ovarian cancer cell lines, derived from A2780/CP70, containing a 
fragment of chromosome 3 with either actively expressed MLH1 (proficient) or 
an epigenetically silenced MLH1 (deficient) were used to derive individual 
clones after mock or 5 µM (IC95) cisplatin treatment. LINE-1 methylation was 
significantly increased only in MLH1-proficient clones after cisplatin treatment. 
Using the Infinium HumanMethylation450 BeadChip array, methylation was 
measured at ~480,000 CpGs genome-wide in mock- and cisplatin-treated 
MLH1-proficient and -deficient clones (n=11 per group). Cisplatin induced bi-
directional methylation changes, biased toward hypermethylation, in MLH1-
proficient and -deficient clones, with a higher number of DNA methylation 
changes in MLH1-proficient clones. No detectable genomic location or 
sequence specificity was observed. 
 3 
In peripheral blood mononuclear cell (PBMC) DNA of ovarian cancer patients 
treated with carboplatin as part of the SCOTROC1 clinical trial, significant 
methylation changes were detected using the Infinium methylation array when 
comparing matched samples collected pre-treatment and at relapse. These 
methylation changes were, again, biased towards hypermethylation post-
platinum treatment and occurred preferentially in non-promoter regions of the 
genome. 
 
This thesis demonstrates for the first time that platinum induces bi-directional 
DNA methylation changes in cell lines and in PBMCs of ovarian cancer 
patients and there may be both MLH1-dependent and MLH1-independent 
mechanisms involved in this response. 
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1.1 Epigenetics 
Genetics is a subject that has been widely studied for over a hundred years, 
with many key insights into the heritability of traits, notably Gregor Mendel’s 
work that lead to the theory of Mendelian inheritance (Mendel, 1901) and 
Darwin’s theories on the evolution of species (Darwin, 1859) being discussed 
long before the structure of DNA was understood (Franklin and Gosling, 1953; 
Watson and Crick, 1953). Many decades of research have focused on the role 
of DNA in life, from the early years of understanding how genes function in the 
cell and how they are copied and passed on down cellular and organismal 
generations to the more advanced studies of genome sequencing. The classic 
concept that DNA encodes RNA that encodes protein and, therefore, that 
DNA is the complete “blueprint” of life, detailing all the information required for 
an organism to exist, was the central dogma of the life sciences for decades 
(Crick, 1970). However, some significant flaws with this dogma remained. The 
idea that DNA encodes all the genes required for an organism to survive and 
function is accepted, but the fact that all cells within an organism contain the 
same DNA sequence and, therefore, the same blueprint would suggest that 
all cells are the same, structurally and functionally. Clearly, at the level of a 
multicellular organism, this is not the case; skin epithelial cells do not have the 
same structural properties as neural cells, nor do hepatocytes display the 
same functional abilities as contractile cardiomyocytes. These cells are all 
coded by the same DNA sequence but they are significantly different entities, 
with highly specialised functional properties. DNA is, therefore, not the only 
coding structure involved in the development and maintenance of a 
functioning multicellular organism. Additionally, through the successes of the 
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various genome projects, capitalising on the progress made in genome 
sequencing, it was discovered that only approximately 1.5 % of the human 
genome contained protein-coding sequence (Lander et al., 2001). There was 
initial understanding that vast amounts of the “other” sequence was highly 
conserved throughout evolution, but its function was unknown. The term “junk 
DNA” was coined in 1972 by early geneticist Susumu Ohno (Ohno, 1972) and 
for approximately 20 years, even following the completion of the human 
genome project, the genetic code that was not found to associate with a 
known gene structure was referred to in the literature, and in the field, as junk 
DNA - a strong suggestion that it served no particular function of importance. 
Addressing these holes in the “blueprint” DNA plot and enlightening our 
understanding of the complete genetic system was the concept of 
epigenetics. The term “epigenetics” is derived from the Greek “epi”, meaning 
over or above and was first coined by Conrad Waddington in 1953, when he 
described the developmental biology of chick embryos and discussed the 
concept of interactions between genes and their environments contributing to 
phenotypes (Waddington, 1953a, b). The term’s definition was then updated 
by Robin Holliday to describe “the study of the mechanisms of temporal and 
spatial control of gene activity during the development of complex organisms” 
(Holliday, 1990). 
 
Today, epigenetics refers to any mechanism that causes heritable changes to 
gene expression that is not coded for in the DNA sequence itself. There are 
four main branches of epigenetics that encompass the main mechanisms of 
epigenetic control in a cell: micro- and silencing-RNAs, nucleosome 
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positioning, histone modifications and DNA methylation. The former two 
mechanisms will not be discussed here. 
 
1.2 Histone modifications 
Histones are proteins that are involved in the packaging of DNA in order to 
condense the large quantities of DNA required for cells into the relatively 
small space of a cellular nucleus. DNA is wound around histone octamers, 
made up of a tetramer of two H3-H4 histone protein dimers bound to two 
separate H2A and H2B dimers, with varying degrees of tightness to form a 
nucleosome (Davey et al., 2002; Luger et al., 1997). Basic amino-terminal 
tails protrude from the histone proteins and interact with neighbouring 
nucleosomes. Various modifications to these histone tails affect their 
interaction with the DNA and other nucleosomes and, therefore, affect the 
tertiary DNA structure and chromatin (reviewed in (Kornberg and Lorch, 
1999)). Chromatin is grouped into two forms: euchromatin, which is more 
loosely packed with fewer histones distributed along a given length of DNA, 
and heterochromatin, which is the more densely compact form of chromatin 
and has the DNA more tightly wound around many histones (reviewed in (Li 
and Reinberg, 2011)). Although there are many nuances to the association 
between chromatin structure and gene expression, particularly as it can be 
highly transient, the simplest explanation of the relationship is that 
heterochromatin is typically associated with gene silencing, through the 
interactions of chromatin architectural proteins and complexes such as 
polycomb repressive complex 1 (PRC1) (Francis et al., 2004) and PRC2 
(Margueron et al., 2008), methyl CpG binding protein 2 (MeCP2) (Georgel et 
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al., 2003; Ghosh et al., 2010) and the silent information regulator (SIR) 
complex (Johnson et al., 2009). Euchromatin is typically associated with gene 
expression, mediated through the binding of proteins that counteract 
repressive chromatin structures such as high mobility group (HMG) proteins 
(Rochman et al., 2010; Rochman et al., 2009). This is largely due to the 
accessibility of DNA in a region of chromatin, as DNA in a more condensed 
nucleosome structure is physically less accessible to transcription machinery 
than DNA in more loosely structured chromatin (Weintraub and Groudine, 
1976). It is, therefore, clear that chromatin structure heavily influences and is 
influenced by the expression profile of a cell.  
 
Epigenetic histone modifications are chemical additions made to the tails of 
histone proteins that change their interactions with the DNA wound around 
them, the proteins that interact with them and neighbouring histone proteins. 
These modifications are, therefore, capable of altering the structure of 
chromatin at a given region, and in turn this can influence the expression of 
related genes either packaged within that region, or those relying on distal 
regulatory elements in that region. The three most studied histone 
modifications are acetylation, phosphorylation and methylation, depicted in 
figure 1.1. Additional histone modifications are known, including ubiquitylation, 
sumoylation and biotinylation, but their relationship with chromatin 
organisation is less well understood (reviewed in (Bannister and Kouzarides, 
2011)). 
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Figure 1.1 Histone modifications 
Schematic diagram demonstrating three key histone modifications on lysines 
(K) and serines (S) of the histone H3 tail: histone methylation (M), added by 
histone methyltransferases (HMTs) and removed by histone demethylases 
(HDMs), histone acetylation (A), added by histone acetylases (HATs) and 
removed by histone deacetylases (HDACs) (that can be blocked by HDAC 
inhibitors (HDI)), and histone phosphorylation (P), added by protein kinases 
(PKs) and removed by protein phosphatases (PPs). Histone modifications are 
added to different amino acids of histone tails and the type and location of the 
modifications dictates whether they are activating or repressing to the local 
chromatin region. The type and position of these modifications are an 
example and are not exhaustive. Image taken from http://www.lubinlab.com 
(Lubin). 
Demethylation Demethylation 
Methylation 
(repressing) 
Methylation 
(activating) 
PK PP 
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1.3 Histone acetylation 
The addition of acetyl groups to the lysine (K) residues of histone tails of H3 
and H4 histone proteins helps to maintain a less condensed chromatin 
structure that is more accessible to transcription machinery, DNA repair 
machinery and other binding proteins by reducing the positive charge of the 
lysine and, therefore, decreasing the strength of the electrostatic interactions 
between the histones and negatively charged DNA (Hebbes et al., 1994; 
Krajewski and Becker, 1998). Acetylated histones cause localised chromatin 
to be “permissive” to gene expression, however a direct link between histone 
acetylation and gene expression has not been found. Acetylation is mediated 
via the opposing actions of histone acetyl transferases (HATs) that add acetyl 
groups to lysines, and histone deacetylases (HDACs) that remove them. The 
human genome is largely hypoacetylated, and the chromatin regions of active 
genes are decondensed through acetylation of histones by the selective 
activity of HATs. Acetylation at promoter and enhancer regions is often 
associated with gene expression, however broader acetylation profiles across 
the genome exist in the absence of expression, indicating that specific histone 
acetylation locations and patterns are required for the expression of DNA in a 
permissive chromatin region (Deckert and Struhl, 2001; Turner, 1993; 
Vogelauer et al., 2000). Histone acetylation itself may not influence the higher 
structure of chromatin by a significant margin (Wang et al., 2000), however it 
recruits chromatin remodelling complexes, such as the human SWI/SNF ATP-
dependent complex, that then proceed to open the chromatin up to increase 
accessibility by weakening histone:DNA interactions and allowing for histone 
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core relocation (Jaskelioff et al., 2000; Lorch et al., 1999; Whitehouse et al., 
1999). 
 
Contrasting the action of HATs are the transcription repressor HDACs. Unlike 
HATs, HDACs have low specificity for their substrate residues and they are 
often found bound in specific complexes with other HDAC and chromatin 
remodelling proteins (Yang and Seto, 2008). It is, therefore, likely that each 
HDAC has a specific enzymatic role in each complex, rather than on their own 
(reviewed in (Delcuve et al., 2012)). HDACs are known to be recruited to DNA 
sites by DNA methyltransferases (DNMTs) and methyl-CpG-binding domain 
(MBD) proteins, suggesting that DNA methylation, discussed later, dictates 
histone modifications as it leads to histone deacetylation and chromatin 
compaction (reviewed in (Bird and Wolffe, 1999)). Conversely, it has also 
been shown that inhibition of HDACs with trichostatin A causes site-specific 
loss of DNA methylation and an inability for new DNA methylation to occur, 
indicating that, in some instances, histone modifications can dictate DNA 
methylation (Santoro and Grummt, 2005; Selker, 1998). 
 
1.4 Histone phosphorylation 
Histone phosphorylation occurs on the serine (S), threonine (T) and tyrosine 
(Y) residues of histones, primarily on the N-terminal histone tails, and results 
in an increased negative charge of the histone tails (Dou and Gorovsky, 
2000). Histone phosphorylation is carried out by histone kinases and is 
removed by histone phosphatases. Phosphorylation is typically associated 
with transcription activation (Chadee et al., 1999; Choi et al., 2005; Lau et al., 
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2011), and transcription response to stimuli such as ultra-violate B (UVB) 
radiation, androgens and DNA damage (Metzger et al., 2008; Shimada et al., 
2008). Importantly, as with other epigenetic modifications, histone 
phosphorylation does not act in isolation. For example, H3S10, T11 and S28 
phosphorylation has been shown to associate with H3 acetylation and various 
studies have shown concerted interactions between H3S10 and the HAT 
GCN5 to promote H3K14 acetylation and subsequent transcription activation 
(Cheung et al., 2000; Clements et al., 2003; Lo et al., 2000). Along with 
promoting transcription activation through acetylation, histone phosphorylation 
also acts through suppression of transcription repression. For example, 
H3S28 displaces polycomb repressive complexes (PRCs) from promoter 
regions and causes H3K28 demethylation and acetylation, leading to 
transcription activation (Lau and Cheung, 2011). An important role in the DNA 
damage response is the phosphorylation of the histone protein variant H2AX 
(called γH2AX when phosphorylated). Kinases Ataxia telangiectasia mutated 
(ATM) and Ataxia telangiectasia and Rad3-related (ATR) are involved in this 
phosphorylation process, which can spread across kilobases of DNA in 
mammals. It is a damage signalling response associated with a range of DNA 
repair pathways (Burma et al., 2001; Rogakou et al., 1998; Ward and Chen, 
2001) and aids in the recruitment of DNA repair proteins and complexes 
(Stucki et al., 2005). 
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1.5 Histone methylation 
Histone tails can be methylated at the three basic residues - lysine, with mono 
(me1), di (2me) or tri (3me) methylation; arginine (R), with mono, symmetric 
(me2s) or asymmetric dimethylation (me2a) and histidine (H) with 
monomethylation (Byvoet et al., 1972; Murray, 1964). Histone methylation 
may be fixed long-term and inherited through meiosis as a mechanism for 
silencing chromatin regions, and it is also transient in active regions of the 
genome where marks are controlled through the opposing actions of histone 
methyltransferases (HMTs) and histone demethylases (Shi et al., 2004). 
Recruitment of HMTs to chromatin regions is directed in a variety of ways, for 
example through DNA sequence recognition (Chan et al., 1994; Fritsch et al., 
1999; Woo et al., 2010) or via non-coding RNAs ((Fukagawa et al., 2004; 
Pandey et al., 2008; Rinn et al., 2007; Wang et al., 2011). Crosstalk also 
exists between histone methylation and DNA methylation, where H3K9 
methylation can direct DNA methylation to satellite repeat sequences 
(Lehnertz et al., 2003), and DNA methylation can effect chromatin remodelling 
through the binding of MBD proteins, which in turn recruit HDACs and/or 
HMTs resulting in histone methylation and repression (Fuks et al., 2003b; 
Sarraf and Stancheva, 2004). Additionally, histone deacetylation may be 
required to prime a region for histone methylation, demonstrating high 
degrees of interaction between all elements of the epigenetic regulatory 
system (Rea et al., 2000). 
 
Although these histone modifications work in cooperation with each other 
rather than functioning alone, many individual marks have been found to 
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represent specific functional areas of the genome. The roadmap epigenomics 
project is a project that commenced in 2007 and set out to measure the 
epigenetic landscape of human genomes from a variety of normal and 
disease tissues to provide a reference for comparison, in much the same way 
as the human genome project has done for genetics (National Institutes of 
Health, 2007). One of the summary papers describes the coverage of 111 
human normal epigenomes and the regions mapped (Kundaje et al., 2015). 
From information gathered through the mapping of histone methylation and 
acetylation marks, DNA methylation levels, DNase I hypersensitivity sites 
(regions of the genome sensitive to the endonuclease activity of DNase I due 
to their being free of bound proteins or heterochromatin) and RNA expression 
profiles it was possible to establish with a high degree of accuracy the 
relationship(s) between epigenetic marks and genetic control. This paper 
confirmed what many smaller research projects have shown or hinted at 
previously, that low DNA methylation and high chromatin accessibility due to 
histone modifications indicate promoter states, high DNA methylation and low 
chromatin accessibility is indicative of transcribed regions, and intermediate 
DNA methylation and chromatin accessibility are typical of enhancer regions 
that need the ability to switch between active and inactive states more readily 
than other areas of the genome (Kundaje et al., 2015). This paper, and the 
data from many other roadmap epigenomics publications, confirms the role of 
concerted cooperation between multiple epigenetic mechanisms to direct 
cellular expression profiles. 
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1.6 DNA methylation 
As mentioned above, in addition to histone modifications, there are also 
chemical modifications of the DNA itself that contribute to the epigenetic 
landscape of the cell. DNA methylation is the addition of a methyl group to the 
5-position of a cytosine (C) residue (5mC), typically when it is in a dinucleotide 
with a guanine (G) residue (a CpG site). Cytosines can also be methylated in 
a non-CpG context, however this is related to embryonic development and will 
not be covered here (Lister et al., 2009). DNA methylation has roles in 
genomic imprinting, where genes are expressed in a parent-of-origin-specific 
manner, X-chromosome inactivation, where one X chromosome is inactivated 
in female cells, silencing of repetitive elements and regulation of gene 
expression (Jaenisch and Jähner, 1984; Ng and Bird, 1999; Surani, 1998). 
Although it was originally thought that DNA methylation exclusively associated 
with DNA compaction and transcription silencing in relation to expression 
regulation, a more nuanced understanding of its role has emerged in recent 
years, with research showing methylation in promoter regions associated with 
repression and methylation in gene bodies often associated with expression 
(Ball et al., 2009; Lister et al., 2009). 
 
1.7 DNA methyltransferases 
DNA is methylated by several enzymes called DNA methyltransferases. There 
are three DNMTs that carry out this role in human cells and they each have 
different functions, summarised in table 1.1. DNMT1 is considered a 
maintenance protein as it preferentially methylates hemi-methylated DNA 
(Bestor et al., 1988; Yoder et al., 1997a) and loss of DNMT1 in embryonic 
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stem cells leads to non-specific loss of DNA methylation across the genome 
(Lei et al., 1996; Li et al., 1992). This protein localises to regions of replication 
during S phase through its interaction with ubiquitin-like plant homeodomain 
and RING finger domain 1 (Uhrf1), a protein with strong binding preference for 
hemi-methylated DNA. Its role in this context is to copy DNA methylation over 
from a template strand to a newly synthesised strand of DNA (Bestor et al., 
1988; Bostick et al., 2007; Leonhardt et al., 1992; Yoder et al., 1997a). 
DNMT3 is a family of DNMTs, containing DNMT3A, DNMT3B and additionally 
the DNA methyltransferases-like factor DNMT3L. DNMT3A and DNMT3B 
have similar roles in that they both act as de novo methyltransferases when 
methylating DNA during early development (Chen et al., 2003; Hata et al., 
2002; Okano et al., 1999) and they are also involved in heritable methylation 
in some repetitive and site-specific regions (Chen et al., 2003). More recent 
work has also indicated distinct roles for both DNMT3A and DNMT3B, for 
example in the development and differentiation of neural and blood stem cells 
(Challen et al., 2014). DNMT3L has no catalytic activity of its own, however it 
has been shown to cooperate with DNMT3A and DNMT3B to establish 
imprinting (Chedin et al., 2002; Hata et al., 2002) and also stimulates 
DNMT3A to conduct de novo methylation of non-imprinted genomic loci 
(Chedin et al., 2002). DNMT3L has also been linked to the cross-talk between 
DNA methylation and histone modifications as DNMT3L is unable to bind to 
DNA when H3K4 is methylated, yet strongly binds to unmethylated H3K4 and 
recruits DNMT3A, providing a link between DNMT3L binding ability, H3K4 
modification status and the subsequent de novo methylation of DNA (Ooi et 
al., 2007). 
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Table 1.1 Roles of DNMTs 
Table summarising the various roles of the different DNMT and DNMT-like 
proteins. 
 
1.8 DNA demethylases 
Interestingly, the mechanism of DNA demethylation has proven to be far more 
elusive to understand (Ooi and Bestor, 2008). GADD45α (growth arrest and 
DNA damage-inducible protein 45 alpha) is a stress-inducible protein thought 
to act as a demethylase, associating with the nuleotide excision repair (NER) 
endonuclease Xeroderma Pigmentosum G (XPG) to carry out the removal of 
5mC, presumably through a NER pathway (Barreto et al., 2007). GADD45α 
was shown to have a role in hypomethylation following UV DNA damage and 
to be required for the demethylation of repetitive element long interspersed 
nuclear element 1 (LINE-1) and for the maintenance of the expression of MutL 
homologue 1 (MLH1), a DNA repair protein known to be epigenetically 
regulated through promoter gene silencing (Barreto et al., 2007). However, 
controversy surrounded this research, with a subsequent paper published 
refuting the role of GADD45α in active demethylation (Jin et al., 2008). An 
DNA methyltransferase Role 
DNMT1 Maintenance methylation eg. after replication Targets hemi-methylated DNA 
DNMT3A De novo methylation 
DNMT3B De novo methylation 
DNMT3L 
Facilitates roles of DNMT3A and DNMT3B 
Facilitates DNA methylation/histone modification cross-talk 
Has no catalytic capabilities 
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additional pathway for DNA demethylation has been discovered with the 
function of the ten-eleven translocation (TET) family of proteins. TET proteins 
are enzymes capable of sequentially oxidising 5mCs to 5-
hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine 
(5caC) (He et al., 2011; Ito et al., 2010; Ito et al., 2011; Tahiliani et al., 2009). 
There are several mechanisms then involved in turning these modified bases 
into unmethylated cytosine. Firstly, replication-dependent dilution of these 
modified bases would result in demethylation, as the maintenance 
methyltransferase DNMT1 does not recognise or bind to 5hmC, 5fC or 5caC 
and, therefore, does not methylate the newly synthesised DNA strand, leading 
to loss of methylation (Valinluck et al., 2004). Secondly, it is thought that the 
thymine (T) DNA glycosylase (TDG) enzyme excises 5fC and 5caC bases 
paired to a guanine base, leaving an abasic site that is subsequently resolved 
by BER (Cortellino et al., 2011; He et al., 2011; Maiti and Drohat, 2011). 
Recently GADD45α has been shown to play a key role in demethylation by 
mediating the TET-TDG pathway, linking earlier work demonstrating 
GADD45α as a demethylating factor to the TET-dependent demethylating 
mechanism (Li et al., 2015). Additionally, the presence of 5hmC may itself act 
in a demethylating capacity in that proteins such as MeCP2 do not recognise 
or bind to this base and, therefore, do not recruit co-repressor complexes to 
the sites of 5hmC, resulting in loss of promoter silencing (Feng and Zhang, 
2001; Nan et al., 1998; Valinluck et al., 2004). 
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1.9 Genomic distribution of DNA methylation 
To understand the functions of DNA methylation it is important to first 
understand the distribution of CpG sites throughout the genome. Most regions 
of the human genome have less CpG sites than would be expected given the 
G-C content of the genome (21 % of expected), due to the deamination rate of 
cytosine (2.6 x 10-13 s-1) and methylated cytosine residues (5.8 x 10-13 s-1) to 
thymine residues resulting in a loss of CpG sites over time (Arndt et al., 2003; 
Bibikova et al., 2011; Bird, 1980; Lander et al., 2001; Venter et al., 2001). 
Throughout the genome this depletion of CpGs is interspersed with CpG-
dense regions, referred to as CpG islands, or CGIs. CGIs are long regions of 
around 1 kb that contain a high density of CpG sites that are typically 
hypomethylated compared to single CpGs throughout the genome and are 
less frequently deaminated compared to methylated cytosine (Lander et al., 
2001; Shen et al., 1994; Venter et al., 2001). CGIs are found throughout the 
genome at specific sites, primarily the 5’ promoter of all housekeeping and 
some tissue-specific genes and at the 3’ (typically exonic) end of some tissue-
specific genes alone or as well as with 5’ CGIs (Gardiner-Garden and 
Frommer, 1987). CGIs at promoter regions are associated with 
transcriptionally-permissive chromatin states, and only around 2-3 % of 
promoter-associated CGIs are hypermethylated (Shen et al., 2007; Weber et 
al., 2007). Hypermethylation of promoter CGIs results in stable transcriptional 
repression (Bird, 2002) and the relatively low number of CGIs in this state 
demonstrates a small class of genes that require tissue-specific gene-
silencing (Shen et al., 2007). Conversely, CGIs in non-promoter regions are 
more likely to be hypermethylated, with studies suggesting between 9-25 % of 
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all promoter-distal CGIs are hypermethylated (Eckhardt et al., 2006; 
Illingworth et al., 2008; Rauch et al., 2009). This difference indicates different 
roles of CGIs. In promoter regions it is thought the preservation of CGIs 
through hypomethylation is due to transcription machinery and related binding 
proteins protecting these regions from methylation during early development 
by blocking DNMT access to the DNA. Therefore, the absence of transcription 
factor binding at non-promoter-associated CGIs results in these regions being 
methylated (Brandeis et al., 1994; Cuadrado et al., 2001; Macleod et al., 
1994). This notion is further supported by the work of Hodges et al. who 
showed that hypomethylated CGIs were also present in some intragenic 
regions, but that these regions also associated with transcription factor 
binding (Hodges et al., 2011). 
 
1.10 Function of DNA methylation 
The function of CpG methylation is debated. Although in many genes a clear 
correlation between CGI promoter methylation and transcriptional repression 
exists (for example (De Smet et al., 1999; Weber et al., 2007)), there are also 
instances where little to no correlation between CGI hypermethylation and 
repression is found (Illingworth et al., 2008; Rauch et al., 2009). Interestingly, 
where CGI promoter methylation did not correspond to transcription 
repression, expression was found to be due to alternative transcription start 
site (TSS) usage, indicating a role for methylation in differential promoter use 
(Maunakea et al., 2010; Rauch et al., 2009). 
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Although CGIs are typically unmethylated, approximately 80 % of CpG sites in 
the genome are methylated (Jabbari and Bernardi, 2004). Non-CGI 
methylation occurs throughout the genome at enhancer regions, repetitive 
elements, centromeres and in gene bodies and methylation at enhancer 
regions is often highly variable (Stadler et al., 2011). Many enhancer CpG loci 
are referred to as low-methylated regions (LMRs) and it is thought these 
regions are variably methylated due to their differential enhancer function in 
different temporal- or tissue-specific environments. Methylation at enhancers 
has been shown to associate with inactivation of enhancer activity and their 
high degree of variability indicates a role of DNA methylation in the transient 
control of enhancer function (Schmidl et al., 2009; Wiench et al., 2011). 
Methylation of repetitive elements and centromeres has been suggested to 
silence repetitive sequences and to protect against genomic instability 
(Moarefi and Chédin, 2011; Yoder et al., 1997b). Indeed DNMT1 has been 
shown to protect against microsatellite instability (MSI) (Dion et al., 2008; Kim 
et al., 2004), demonstrating a role for methylation in maintaining the stability 
of the genome. 
 
The function of gene body methylation has been widely debated for many 
years. Several studies have shown increased levels of gene body methylation 
to correlate with increased gene expression, and functions that have been 
suggested include silencing intergenic repeat sequences (Yoder et al., 
1997b), silencing antisense RNA strands to prevent them becoming lncRNAs 
(long non-coding RNAs) that would, in turn, silence the mRNA of the gene 
(Shenker and Flanagan, 2012), or to act as regulatory marks of splicing, as 
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exon-intron boundaries are positions of transition of degrees of methylation 
(Laurent et al., 2010; Shukla et al., 2011). Recent research through the 
roadmap epigenomics project found that intermediate DNA methylation, 
averaging 57 % across loci, is a conserved methylation signature involved in 
gene regulation and exon usage, as it associates with intermediate gene 
expression levels and intermediate levels of exonic inclusion (Elliott et al., 
2015). This strongly indicates a continuous level-specific relationship between 
DNA methylation, expression and splicing.  
 
The mechanisms through which DNA methylation affects transcription and 
genetic regulation are via a multitude of protein interactions and changes to 
chromatin structure (see figure 1.2). As previously discussed, epigenetic 
modifications do not effect changes in a solitary capacity, but rather through a 
network of crosstalk. Methylated DNA can act as a prerequisite for certain 
histone modifications, as MBD proteins must first interact with methylated 
DNA before recruiting HDAC-containing chromatin remodelling complexes to 
cause transcriptional repression (Bird, 2002), and has been shown as the 
dominant initiating factor in transcriptional repression through the use of DNA 
demethylating agents and HDAC inhibitors (Cameron et al., 1999). However, 
in some instances, the opposite is true. H3K9 acetylation has been shown to 
act as a recruiting signal at pericentric repeat sequences to DNMTs in 
mammals (Lehnertz et al., 2003), and DNMT1 is known to interact with H3K9 
HMT protein Suv39h1 to cause DNA methylation in a histone methylation-
dependent manner (Fuks et al., 2003a). Enhancer of Zeste homolog 2 (EZH2) 
is a histone methyltransferase that is a component part of the repressive 
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complexes PRC2 and PRC3. It has been shown that DNMT1, DNMT3A and 
DNMT3B all interact with EZH2 in vivo and that EZH2 is required for the DNA 
methylation and subsequent silencing of EZH2-target promoters, again 
showing that histone modifications can precede DNA methylation (Viré et al., 
2006).  
 
The complex relationship between DNA methylation and histone modifications 
in the regulation of the chromatin environment is important for normal cellular 
functions in development, differentiation, gene expression, DNA repair and 
genome maintenance. Dysregulation of any one aspect of this network of 
genome regulation can, therefore, on a cellular level, lead to the disruption of 
replication and transcription, accrued DNA damage and cell death. On a 
multicellular level, sustained dysfunction in this network through mutation or 
epigenetic changes, causing changes to expression, can lead to significant 
disease phenotypes including carcinogenesis. 
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Figure 1.2 Structure of the epigenome 
Diagram shows the interactions between various histone and DNA 
modifications leading to activation or inactivation of genes and enhancers in 
euchromatin and heterochromatin. H3K27me3 is a histone medication found 
at repressed areas of the genome, whereas H3K4me3 and H3K and H4K 
acetylation association with active areas of the genome. Promoter CpG 
islands (pale blue circles) tend to lack DNA methylation and are in active 
regions of the genome. Heterochromatin protein 1 (HP1) is a key protein 
found in condensed heterochromatic regions of the genome where high levels 
of DNA methylation and repressed genes are found. Image taken from  
(Baylin and Jones, 2011) with licence. 
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1.11 DNA methylation and cancer 
DNA methylation patterns are known to be highly tissue specific, with different 
stages of development and different tissue types displaying vastly different 
methylation profiles (Ehrlich et al., 1982; Kundaje et al., 2015). Additionally, 
diseased tissues often also have unique DNA methylation patterns that can, in 
some cases, contribute to the disease’s progression or treatment success. 
Cancer is one such disease in which methylation patterning is vastly different 
from normal tissue and where methylation profiles can indicate a variety of 
factors such as the progression of the disease, the treatment response, and 
the likely overall survival of a patient. Cancer genomes are typically less 
methylated than normal tissue, known as hypomethylation, and they also 
contain specific regions, often CpG islands, of much higher methylation, 
known as hypermethylation (Esteller, 2008; Gama-Sosa et al., 1983) (figure 
1.4). 
 
1.12 Hypomethylation in cancer 
The genome-wide, or “global”, hypomethylation phenomenon is seen across a 
variety of tumour tissue types, disease stages and grades (for example, 
(Bedford and van Helden, 1987; Cheng et al., 1997; Kim et al., 1994)). A 
longstanding debate exists regarding the sequence of events leading to 
hypomethylation and carcinogenesis, as it is unclear whether hypomethylation 
is a cause or consequence of cancer. It is now thought that both situations are 
true, with global hypomethylation occurring as a precursory step to 
carcinogenesis in some tissues, as well as being a by-product of 
transcriptional silencing in cancer cells. 
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Global hypomethylation occurs most frequently at highly repetitive sequences 
of the genome in cancerous and/or pre-cancerous cells, including in the 
tandem centromeric satellite a (a type A large tandem of 171 bp repeat units), 
juxtacentromeric (centromere-adjacent) satellite 2 (a type 2 large tandem 
repeat close to centromere regions in most chromosomes), the short 
interspersed Alu element (a repetitive element of around 300 bp), and LINE-1 
(a retrotransposon) (Ehrlich et al., 2006; Gao et al., 2014; Hoffmann and 
Schulz, 2005; Kim et al., 2009; Narayan et al., 1998; Pfeifer and Rauch, 2009; 
Rodriguez et al., 2008). Due to this phenomenon, LINE-1 methylation is 
commonly used as a surrogate marker for global DNA methylation (Ostertag 
and Kazazian, 2001; Yang et al., 2004). Although hypermethylation is the 
typical state of aberrant methylation for CpG sites encompassing coding 
regions, hypomethylation has also been shown to occur in such regions and 
cause changes in gene expression (for example, (Lindsey et al., 2007; 
Pulukuri et al., 2007; Rosty et al., 2002)). DNA hypomethylation has been 
detected in early non-neoplastic cells as well as in cancer cells (Goelz et al., 
1985), and the degree of hypomethylation typically increases as cancer 
progresses (Kim et al., 1994; Roman-Gomez et al., 2005). This has been 
leveraged as a prognostic and predictive marker in several cancers, including 
for predicting risk of relapse and overall survival time in ovarian carcinoma 
(Widschwendter et al., 2004). Interestingly, global hypomethylation and site-
specific hypomethylation in blood cells has been found to associate with risk 
of various cancers, either due to or independent of environmental factors such 
as smoking (Brennan and Flanagan, 2012; Moore et al., 2008; Shenker et al., 
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2013a). This research is particularly interesting as it demonstrates that blood 
cell epigenomes reflect some of the methylation changes caused by 
environmental exposures, be they from the external or internal environment, 
and thus indicates that the consequences of epigenetic altering factors can be 
systemic. From a clinical perspective, further opportunities to explore the 
association between blood cell DNA methylation and the internal environment 
of a patient, such as cancer risk, cancer progression or cancer treatment-
response may aid diagnostic power and stratification of treatment in the clinic. 
 
Global DNA hypomethylation is not dependent on DNA hypermethylation in 
cancer cells, even though both phenomena co-exist in most, if not all, cancer 
cells (Ehrlich et al., 2006; Lee et al., 2009). This means the mechanism for 
hypomethylation is not derived from the cell compensating for 
hypermethylation. Genomic regions containing intermediate methylation are 
more likely to undergo bi-directional methylation changes in different tissue 
types. For example, the non-satellite centromeric repeat NBL2 is 
intermediately methylated in normal tissue, but appears hypermethylated in 
some ovarian carcinoma samples and hypomethylated in others (Nishiyama 
et al., 2005a; Nishiyama et al., 2005b). This may indicate that characteristics 
pertaining to intermediate methylation, such as bivalent histone modifications 
that allow both the activation and repression of a region of chromatin and 
DNA, may be important in the carcinogenic aberrant methylation 
mechanism(s), and suggests that aberrant methylation is still guided in some 
way by the original epigenetic landscape of the cell. 
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Hypomethylation has been demonstrated as a carcinogenic-precursor in 
studies using DNMT inhibitors or DNMT-deficient mice showing increased 
neoplastic lesions upon genome hypomethylation (Carr et al., 1984; Gaudet et 
al., 2003). This is supported by studies relating to dietary deficiency of 
methylation precursory compounds such as folate (figure 1.3) that also 
indicated a cancer-causing effect from DNA hypomethylation (Kim, 2005; 
Pogribny et al., 1995; Poirier, 1994). Several mechanisms linking 
hypomethylation to the initiation or progression of carcinogenesis have been 
suggested. The loss of methylation at repeat sequences throughout the 
genome has been shown to contribute to the loss of genomic stability and 
result in chromosomal rearrangements, which have, in turn, been directly 
linked to carcinogenesis (Eden et al., 2003; Ehrlich, 2005; Kawano et al., 
2014). Hypomethylation of repeat sequences has also been found to interfere 
with gene expression, for example where a LINE-1 promoter is 
hypomethylated and activates an alternative transcript of the MET oncogene 
in bladder cancer (Wolff et al., 2010). CGI-specific hypomethylation results in 
altered gene expression of cancer-associated genes including imprinted 
genes, with promoter hypomethylation triggering increased expression of 
oncogenes and decreased expression of tumour-suppressors (Gaudet et al., 
2003; Merlo et al., 1995) and gene-body hypomethylation silencing tumour 
suppressors (Hon et al., 2012; Pogribny and Beland, 2009). Some of these 
genes, including synuleic-γ (a protein involved in neurofilament network 
regulation) are also associated with metastasis (Ateeq et al., 2008; Liu et al., 
2005), reinforcing the link between hypomethylation and cancer progression. 
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The trigger for global hypomethylation in a cell is still unknown. Several 
studies have indicated that the causal factor may be hypoxia, a condition 
found in early cancer cell development where lack of organised blood flow 
causes oxygen deprivation to rapidly dividing cells, even in the early stages 
(Harris, 2002). Hypomethylation has been shown to associate with hypoxia in 
cell culture (Pal et al., 2010; Shahrzad et al., 2007) and in mouse xenograft 
studies (Shahrzad et al., 2007) and it is thought that hypomethylation may 
result from a deficiency in the methyl donor S-adenosylmethionine (SAM), as 
its synthesis is decreased through hypoxia-induced inactivation of the SAM-
producing methionine adenosyltransferase (MAT) enzyme (Avila et al., 1998; 
Shahrzad et al., 2007). A further hypothesis is that hypomethylation occurs 
when cancer cells change their differentiation state (Frost and Kerbel, 1983; 
Heppner, 1984; Heppner and Shekhar, 2014). As somatic cells undergo 
demethylation when being de-differentiated to induced pluripotent stem cells, 
it is possible that a similar demethylating process occurs for cancer cells 
(Frost and Kerbel, 1983; Mikkelsen et al., 2008). Further hypotheses include a 
mutation or epimutation causing the down-regulation of DNMT enzymes, 
resulting in passive demethylation through loss of methylation maintenance, 
or an upregulation of demethylating enzymes or recruiting proteins, causing 
an increase in the demethylation rate, perhaps in conjunction with a loss of 
demethylating regulatory proteins (De Smet and Loriot, 2010). 
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Figure 1.3 Folate and methionine cycles 
In the methionine cycle, the transfer of a methyl group from methyl-
tetrahydrofolate (methyl-THF) to homocystein is catalyzed by methionine 
synthase (MS), and produces THF and methionine. Adenosine triphosphate 
(ATP) then activates methionine, generating S-adenosylmethionine (SAM), 
which is the universal methyl-group donor. SAM then methylates an acceptor, 
yielding S-adenosylhomocysteine (SAH). Homocysteine is then regenerated 
by SAH hydrolase. In the folate cycle, single carbon units from serine are 
accepted by THF and methylene-THF and glycine are formed. The reduction 
of methylene-THF by methylene tetrahydrofolate reductase (MTHFR) forms 
methyl-THF. Cystathionine β-synthase (CBS) then catalyses the synthesis of 
cystathionine from homocysteine and of cysteine by cystathionase in the 
transsulfuration pathway. SAM inhibits MTHFR, but activates CBS. This 
image was taken from (McCaddon et al., 2002, Wolters Kluwer Health 
Lippincott Williams & Wilkins©). 
 
 
 
 
 
 
 
 
 
 
 53 
 
1.13 Hypermethylation in cancer 
The hypermethylation of promoter CGIs is common to virtually all cancers 
(Baylin and Jones, 2011), however its role in carcinogenesis and cancer 
progression is unclear. Many studies have pointed to the methylation of 
promoters as a key mechanism driving tumour progression through the 
epigenetic silencing of tumour suppressor genes and other genes associated 
with cell cycle regulation, metastasis and DNA repair (for example, (Baylin 
and Herman, 2000)). However, more recent studies of whole epigenomes 
have demonstrated that the majority of hypermethylation events occur at CGIs 
of genes already epigenetically silenced (Easwaran et al., 2012; Hinoue et al., 
2012; Sproul et al., 2012; Sproul et al., 2011). Most importantly, the 
mechanisms causing hypermethylation in cancer are largely unknown. 
 
Key tumour suppressor genes such as cell cycle regulator Retinoblastoma 1 
(RB1) and DNA repair genes Breast Cancer 1, early onset (BRCA1) and 
MLH1 are epigenetically silenced through promoter hypermethylation and 
predispose carriers to, usually tissue-specific, cancers (Cunningham et al., 
1998; Esteller et al., 2000; Greger et al., 1994; Ohtani-Fujita et al., 1993). 
These epimutations can occur in tandem with genetic mutations of these 
genes, providing epigenetic silencing as a mechanism for the so-called 
“second hit”, where one allele is mutated and the other then silenced, 
resulting in carcinogenesis (Esteller et al., 2001; Esteller et al., 2000; 
Myöhänen et al., 1998; Ohtani-Fujita et al., 1997), however these incidences 
appear to be infrequent (Dworkin et al., 2009). Interestingly, hypermethylation 
 54 
and silencing of these genes typically occurs with the same tissue specificity 
as genomic mutation predisposition, as in the case of MLH1 and BRCA1, 
where mutational loss-of-function predisposes carriers to colorectal cancer 
and ovarian and breast cancer, respectively (Kinzler and Vogelstein, 1996; 
Koi et al., 1994; Sproul et al., 2012). This gives further evidence to the 
previously discussed notion that original cellular epigenetic landscapes may 
shape the aberrant methylation pattern of cancer cells, as the 
hypermethylation of tumour suppressor gene promoter CGIs is generally 
highly tissue-specific. 
 
It is clear that CGI promoter hypermethylation plays a role in the development 
and progression of some cancers, however, this may not play as large a role, 
or be as widely occurring, as once thought. Methylation profiling of cancers 
from multiple cell lineages has demonstrated that, although aberrant 
hypermethylation occurs in prompter CGIs broadly and in a tissue-of-origin-
specific manner, the majority of these methylation changes are in promoters 
of already silenced genes (Easwaran et al., 2012; Hinoue et al., 2012; Sproul 
et al., 2012; Sproul et al., 2011) and do not often correlate with altered 
expression levels (Levanon et al., 2011; Pike et al., 2008). The fact that most 
promoter CGIs that become hypermethylated in cancer are already silenced, 
and that many expressed genes are protected from hypermethylation, 
indicates that there may be different DNA methylation pathways for active and 
repressed genes (Gebhard et al., 2010; Sproul et al., 2012; Sproul et al., 
2011), such as the case for active and inactive genes on the inactivated X 
chromosome (Gendrel et al., 2012).  
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Although hypermethylated CGIs may be “driver” mutations, subject to 
selection due to their cancer-promoting properties if relating to silencing of 
tumour suppressors, other hypermethylation events not associated with 
expression changes may also be driving tumour progression through other 
mechanisms. One hypothesis is that hypermethylated CGIs are contributing to 
the stem-cell-like nature of cancer cell plasticity (Widschwendter et al., 2007). 
Hypermethylated promoter CGIs are often the same promoters that are 
repressed by PRCs in embryonic stem cells (Schlesinger et al., 2007; 
Widschwendter et al., 2007). These genes are typically transcription factors 
and are repressed during development to prevent cell differentiation (Bracken 
et al., 2006). The hypermethylation of these genes in cancer may, therefore, 
also contribute to the plasticity and stem-cell-like features of cancer cells. 
Indeed, a pan-cancer study by Kim et al. found that over 50 % of 
hypermethylated CGIs were associated with developmental genes and the 
rest were transcription factors, with a large overlap between these genes and 
PRC2 target genes (Kim et al., 2012). Another hypothesis is that the 
hypermethylation of promoter CGIs is a protective cellular mechanism used to 
silence oncogenes and genes important for movement to, and survival in, new 
niches through metastasis (Sproul and Meehan, 2013). This would explain the 
fact that cancer patients with high degrees of hypermethylation (named the 
CpG island methylator phenotype or “CIMP”) generally respond better to 
platinum treatment and have better clinical outcomes than those without this 
phenotype, with many of these genes associated with metastasis (Brennan et 
al., 2013; Fang et al., 2011; Noushmehr et al., 2010; Ogino et al., 2009). It 
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also would explain why pre-neoplastic cells display promoter 
hypermethylation early on (Feinberg et al., 2006), as the cell attempts to shut 
down its ability to become cancerous.  
 
Although each of the proposed mechanisms for the causes and 
consequences of global hypomethylation and CGI hypermethylation come 
with their own merits and caveats, the true nature of these epigenetic changes 
is yet to be convincingly demonstrated. It is most likely that a combination of 
all of these causes and consequences contribute to carcinogenesis, be they in 
unison or in different circumstances. 
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Figure 1.4 DNA methylation and cancer 
Diagram depicting the various types of DNA methylation changes and how 
they relate to cancer progression. In repetitive sequences (a), DNA becomes 
hypomethylated allowing genomic instability. In CpG island promoters, DNA 
can become hypermethylated, silencing (tumour suppressor) genes such as 
MLH1 and BRCA1 by preventing TF binding. At CpG island shores, 
hypermethylation can occur preventing the progression of transcription 
machinery. At gene bodies, DNA can become hypomethylated leading to the 
expression of oncogenes. Image taken from (Varela-Rey et al., 2013). 
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1.14 Epigenetics of platinum resistance 
Chemotherapy resistance is a serious issue for many patients being treated 
for cancer. Patients often develop drug resistance after an initial course of 
therapy, presenting back to the clinic with relapse disease several months or 
years down the line that is either initially platinum-resistant or initially 
platinum-sensitive, becoming resistant later (Agarwal and Kaye, 2003). There 
are a variety of pathways that lead to the development of drug resistance, 
however epigenetic mechanisms are known to be involved, and in some 
cases highly important, in the emergence of drug resistant cells (Brown and 
Glasspool, 2007). 
 
1.15 Platinum drugs 
One of the earliest treatment strategies for cancer patients was to impart high 
degrees of DNA damage to cancer cells such that their repair responses were 
overwhelmed, leading to cell death. Although a relatively crude method of 
treatment, not least due to the systemic effects that this has on normal healthy 
tissues, these early treatments have remained the cornerstone of cancer 
therapies today. One such group of drugs is the platinum agents. 
 
Platinum-based chemotherapy has been in use to treat solid tumours since 
the mid-1980s and its success in treating a variety of cancers including 
testicular, cervical, ovarian and bladder cancer means it remains a first-line 
therapy in many cancers. However, a key limitation to the success of platinum 
drugs is that resistance is a common occurrence for many patients. Significant 
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focus has therefore been on understanding the cytotoxic and resistance 
mechanisms of these drugs in order to improve patient outcomes. 
 
1.16 Cisplatin and carboplatin DNA damage 
Two of the main platinum drugs used in chemotherapy are cisplatin (cis-
diammine-dichloro-platinumII) and carboplatin (cis-diammine(cyclobutane-1,1-
dicarboxylate-O,O')platinumII). Cisplatin was the first platinum drug to be 
created and tested as an anti-cancer treatment and is the simplest of the 
platinum agents (Rosenberg et al., 1965; Rosenberg et al., 1969). Cisplatin is 
formed from a platinum atom surrounded by two ammine (NH3) and two 
chloride (Cl) groups (figure 1.2 A). Carboplatin is a derivative of cisplatin, 
which contains a cyclobutane dicarboxylic acid (CBDCA) ligand in place of the 
two chloride atoms of cisplatin (figure 1.2 B). Both cisplatin and carboplatin 
are DNA crosslinking agents. Cisplatin binds DNA through the aquation of one 
of the chloride groups in the low chloride concentrations (100mM or less) 
found inside cells, replacing it with a water ligand (Davies et al., 2000). This 
mono-aquated species is highly reactive and the water ligand is readily 
displaced, allowing binding to the nucleophilic N7 position of the imidazole 
ring of purine bases (guanine or adenine). This interaction is preferentially at 
guanine bases and the second chloride ion of cisplatin then goes through the 
same steps to form a bi-functional adduct (Fichtinger-Schepman et al., 1985). 
Carboplatin binds DNA through a similar mechanism, although less readily, 
with one “arm” of the CBDCA becoming aquated and then binding to a purine 
base, followed by the other arm (van der Vijgh, 1991). Once bound to DNA, 
the adducts created by cisplatin and carboplatin are identical as they share 
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the same cis-diammine carrier ligands (Chaney et al., 2004). The crosslinks 
made by these compounds can occur within one strand (intrastrand 
crosslinks) or across two strands (interstrand crosslinks) of DNA. The majority 
of the adducts formed are either GpG (60-65 %) or ApG (30 %) 1,2 intrastrand 
crosslinks (Gelasco and Lippard, 1998; Takahara et al., 1995), with around 2 
% of adducts binding only in one place forming monofunctional adducts, 
another 2-5 % of crosslinks occurring at two purines with a base in between 
them forming GpXpG 1,3 intrastrand crosslinks (Teuben et al., 1999), and 
finally another 1-3 % of adducts forming between guanines on different DNA 
strands to form G-G interstrand crosslinks (ICLs) (Eastman, 1987; Huang et 
al., 1995). DNA crosslinks are thought to elicit the main toxic effects of these 
drugs. Platinum DNA:protein crosslinks have also been observed (figure 1.5 
C)  
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Figure 1.5 Cisplatin and carboplatin and intrastrand, interstrand, mono-
adduct and protein:DNA binding 
Schematic diagram representing the structure of cisplatin (A) and carboplatin 
(B) and depicting the cis-diammine ligand bound to DNA in the same strand 
(intrastrand crosslink), across two strands (interstrand crosslink), as a mono-
functional adduct and bound as a protein:DNA crosslink (C). Image C taken 
from (Conconi, 2013). 
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1.17 Nucleotide excision repair of platinum intrastrand adducts 
Platinum crosslinks are primarily repaired by the nucleotide excision repair 
(NER) pathway (Zamble et al., 1996). This pathway recognises the platinum 
lesion through the distortion of the DNA and the severity of distortion caused 
by platinum lesions influences the efficiency of repair, through increased 
recognition of more severe distortions by repair proteins (Moggs et al., 1997). 
The 1,2 intrastrand platinum crosslink is less distorting than the 1,3 intrastrand 
crosslink, and therefore the 1,3 intrastrand crosslink is more readily repaired 
by NER (Bellon et al., 1991). 
 
NER is a pathway required for the repair of bulky adducts, such as those 
caused by UV damage as well as those induced by platinum drugs (Cleaver, 
1968; Lehmann et al., 1975). Hereditary genetic loss of NER leads to a high 
incidence of cancer and extreme sensitivity to damage by sunlight, as seen in 
Xeroderma Pigmentosum, and impaired growth and development as well as 
premature ageing, as seen in Cockayne Syndrome (Nance and Berry, 1992). 
NER consists of two pathways of recognition and repair - transcription-
coupled (TC-NER) and global genome (GG-NER), depicted and described in 
figure 1.6. NER-deficient cells, such as in testicular cancers that have low 
levels of XPA and ERCC1/XPF, are known to be highly sensitive to platinum 
treatment (Köberle et al., 1999), and overexpression of NER proteins and 
complexes such as XPA, ERCC1 and ERCC1/XPF is associated with cisplatin 
resistance in ovarian cancer (Ferry et al., 2000), demonstrating a significant 
role of NER in platinum repair and sensitivity. 
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Figure 1.6 NC- and GG-NER pathways  
TC-NER repairs lesions in active genes that cause blockages to transcription 
machinery, whereas GG-NER repairs lesions in non-transcribed regions of the 
genome (Hanawalt, 2001). TC-NER relies on lesion detection by RNA 
polymerase II, followed by binding and signalling of Cockayne Syndrome A 
(CSA) and CSB proteins to activate the general NER pathway, whereas GG-
NER requires the XPC/HR23B dimer for lesion recognition and signaling 
(Fousteri and Mullenders, 2008). In the general NER pathway the lesion is 
recognised through subunits XPA and replication protein A (RPA), which bind 
to DNA with preference for DNA structural distortion (Moggs et al., 1997). 
XPA recruits the general transcription factor subunit TFIIH (Park et al., 1995), 
which has helicase activity, essential for excision repair, thought to create 
single stranded DNA around the lesion to allow exonuclease cutting (Mu et 
al., 1995; Prakash et al., 1993). XPC directs nuclease proteins to the correct 
site while protecting the rest of the DNA from unwanted degradation (van 
Hoffen et al., 1995; Venema et al., 1990; Verhage et al., 1994). The nuclease 
proteins are XPG and heterodimer Excision Repair Cross-Complementation 
Group 1 (ERCC1) - XPF. XPG makes the incision on the 3’ side of the lesion 
(Matsunaga et al., 1995) and ERCC1-XPF makes the 5’ incisions (Matsunaga 
et al., 1995; Weeda et al., 1990). The excised region is then repaired via 
synthesis by DNA polymerases pol ε or pol δ after Replication Factor C (RFC) 
allows the stable loading of the polymerase clamp Proliferating Cell Nuclear 
Antigen (PCNA) to the DNA (Overmeer et al., 2010), and the newly 
synthesised patch is then sealed by ligase (LIG3) (Sancar, 1996). Image 
adapted from (Curtin, 2012). 
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During replication, lesions can block replication machinery leading to fork 
stalling or collapse. The result of lesions at replication is dependent on the 
strand in which the lesion resides. When on the lagging strand, platinum 
lesions block the progression of polymerase, however, the replication 
machinery is able to restart beyond the lesion, leading to a daughter strand 
gap (DSG) in the DNA (Rupp et al., 1971; West et al., 1981; Zdraveski et al., 
2000). This gap is then repaired via recombination using the newly 
synthesised homologous strand on the leading arm of the replication fork as a 
template (Zdraveski et al., 2000). This results in persistence of the platinum 
lesion, which can later be removed by NER (figure 1.7). When on the leading 
strand, platinum lesions lead to complete stalling of replication as the leading 
and lagging strands become uncoupled. The lagging strand is digested back 
in an attempt to restore the replication fork and this can lead to Holliday 
junction formation and cleavage, creating DSBs (Zdraveski et al., 2000). 
Mismatch repair has been implicated in the prevention of recombination repair 
of such DSBs as it recognises the remaining platinum adduct as a mismatch, 
indicating non-homology, and prevents strand exchange (figure 1.8) (Calmann 
and Marinus, 2004). 
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Figure 1.7 Cisplatin intrastrand crosslink on lagging strand of 
replication fork 
Diagram representing the HR-mediated bypass of an intrastrand cisplatin 
crosslink on the lagging strand of the replication fork, leading to the 
persistence of the cisplatin lesion. Image adapted from (Calmann and 
Marinus, 2004). 
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Figure 1.8 Cisplatin intrastrand crosslink on leading strand of replication 
fork 
Diagram representing the HR-mediated resolution of replication fork stalling at 
an intrastrand cisplatin crosslink on the leading strand of the replication fork, 
resulting in the persistence of the cisplatin lesion. MMR recognition of the 
lesion prevents strand exchange as MMR recognises the lesion as a 
mismatch and prevents non-homologous recombination from occurring. 
Image adapted from (Calmann and Marinus, 2004). 
  
image ref. The Roles of DNA Mismatch Repair and Recombination in Drug Resistance: A Dissertation, 2004, Melissa A. Calmann, University of Massachusetts 
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1.18 Mismatch repair pathway role in platinum response and resistance 
Although NER is the main pathway responsible for recognising and repairing 
platinum DNA lesions it is not the only pathway involved. The mismatch repair 
(MMR) pathway identifies and repairs incorrectly paired bases and short (1-4 
base) insertions and deletions that result from slippage errors during 
replication (Modrich and Lahue, 1996; Romanova and Crouse, 2013). MMR 
has been implicated in the cytotoxic effects of cisplatin as loss of key MMR 
proteins such as MLH1 and MutS homologue 2 (MSH2) have been shown to 
confer cisplatin resistance to cancer cells in vitro and in vivo (Brown et al., 
1997; Gifford et al., 2004; Pani et al., 2007; Strathdee et al., 1999). Epigenetic 
silencing of MLH1 has been shown to occur in cisplatin-exposed cells and 
tumours and contributes to increased resistance. Re-expression of MLH1 
through the use of demethylating agent 5-azacytidine partially restores 
platinum sensitivity in these cells, indicating that MMR is involved in, but not 
solely responsible for, the cytotoxicity of platinum in cancer cells (Ding et al., 
2009; Papouli et al., 2004; Plumb et al., 2000; Steele et al., 2009; Strathdee et 
al., 1999). 
 
In the case of cisplatin damage, intrastrand cisplatin lesions that have not yet 
been repaired by NER can be present in the DNA during replication. Several 
scenarios can then present themselves. One scenario is that the DNA lesion 
will be subject to replication bypass and post-replication repair (Gibbons et al., 
1991; Mamenta et al., 1994). Replication bypass is a mechanism that allows 
the continuation of replication when a bulky lesion, such as a platinum adduct, 
blocks the progress of polymerase and stalls replication. In order to continue 
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replication and avoid replication fork crashing, lesions can be bypassed in a 
process known as damage tolerance, through translesion synthesis (Klarer 
and McGregor, 2011). Low-fidelity polymerases, such as pol β, pol ζ, pol κ 
and pol η (Yamada et al., 1997) have no proof-reading abilities and are poor 
at identifying mismatches ((Sale et al., 2012)). These polymerases are, 
therefore, capable of bypassing lesions and inserting a mispairing base, 
usually an adenine (A) or thymine, opposite the platinum lesion, creating a 
compound lesion (Chaney et al., 2004; Fourrier et al., 2003; Vaisman and 
Chaney, 2000). Polymerase ζ is required for cisplatin-resistance-driving 
replication bypass in the absence of functional MMR, indicating that MMR 
functions to promote cisplatin-induced cell death by preventing pol ζ-
dependent replication bypass (Lin et al., 2006; Wu et al., 2004). 
 
MMR proteins High Mobility Group Box 1 (HMGB1), MSH2 and MMR complex 
MutSα, which is a heterodimer of MSH2 and MSH6, are capable of 
recognising platinum lesions opposite a mispaired base (Duckett et al., 1996; 
Fink et al., 1996; Mello et al., 1996; Yamada et al., 1997; Yuan et al., 2004). 
MutSα then recruits the MutLα complex, a heterodimer of MLH1 and 
postmeiotic segregation increased 2 (PMS2), to these cisplatin lesions. The 
result of MMR protein binding at these regions is unclear but there are several 
hypotheses as to the role of MMR in the cytotoxicity and resistance 
mechanisms of platinum treatment. 
 
 70 
1.19 Futile cycle hypothesis 
The first hypothesis of MMR’s role is the “futile cycle” hypothesis. This 
hypothesis assumes that MutSα and MutLα binding to compound platinum 
lesions results in the removal of the mispaired base from the newly 
synthesised DNA strand and the persistence of the platinum adduct on the 
template strand. Multiple rounds of replication bypass and mismatch repair 
binding would result in futile cycles of repair, eventually resulting in multiple 
strand breaks and/or signaling cascades leading to cell cycle arrest and 
apoptosis (Anthoney et al., 1996; Duckett et al., 1996; Fink et al., 1996; Mello 
et al., 1996; van Boom et al., 1996; Yamada et al., 1997). In agreement with 
this hypothesis, studies using alkylating agents to induce O6-methylguanine 
lesions have shown evidence of iterative cycles of failed repair when the 
lesion is on the template DNA strand (York and Modrich, 2006). However, no 
such evidence has yet been produced in relation to cisplatin-induced DNA 
damage, and indeed several studies suggest differential MMR responses 
depending on the type of lesion present (Pani et al., 2007; Papouli et al., 
2004; Stojic et al., 2004). 
 
1.20 Direct signaling hypothesis 
It could, however, be argued that MutSα and MutLα binding alone could 
trigger damage signalling, cell cycle arrest and apoptosis responses in the 
absence of multiple futile cycles of repair. This is the “direct signalling” 
hypothesis of MMR’s role in the cytotoxicity and resistance mechanisms of 
platinum treatment (figure 1.9). In support of this hypothesis, studies have 
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shown MMR involvement in G2 arrest in response to other lesion-forming DNA 
damaging agents such as ionising radiation, the methylating agent N-methyl-
N'-nitro-N-nitrosoguanidine (MNNG) and the guanine base analogy 6-
thioguanine (6-TG) (Davis et al., 1998; Hawn et al., 1995). Cisplatin-induced 
G2/M phase arrest and slow S-phase transition has also been demonstrated 
to rely, to some extent, on MMR-proficiency in ovarian cancer cell line model 
A2780 and in human colon cancer cell line HCT116 (Pani et al., 2007). MMR 
signalling leading to cell cycle arrest and apoptosis relies on a variety of 
proteins, and Pani and colleagues have shown a difference in signalling and 
apoptosis between MMR-proficient A2780 cells and the cisplatin-resistant 
MMR-deficient derivative cell line CP70. Checkpoint pathways are equally 
triggered in both cell lines, however, differences are detected later, as the 
MMR-proficient line, at G2-arrest, undergoes checkpoint protein (BRCA1, 
BRCA2, FANCD2, RAD51) degradation followed by apoptosis, whereas the 
MMR-deficient line displays little to no degradation of these four proteins and 
these cells are able to progress through the cell cycle. These cell lines also 
differ in their apoptotic response, as key apoptosis signalling protein p53 is 
stabilised faster and cyclin-dependent kinase inhibitor p21 is induced only in 
MMR-proficient cells (Pani et al., 2007). These data highlight a role for MMR 
lesion-recognition in the cisplatin-induced apoptotic signal transduction, and a 
possible role for MMR directly or indirectly in cell cycle signalling. 
 
MMR-dependent apoptotic pathways have also been discovered, further 
indicating the potential for MMR-dependence and supporting the “direct 
signalling” hypothesis in the cisplatin-induced damage response. Lin and 
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Howell have shown that cells with a deficiency in p53 or MMR are resistant to 
cisplatin and that cells with combined loss of p53 and MMR activity are more 
resistant still (Lin and Howell, 2006; Lin et al., 2001). A MMR-dependent, p53-
independent, cell death pathway was later discovered, mediated by 
cytochrome C release into the cytoplasm and poly ADP ribose polymerase 
(PARP), capspase-3 and caspase-9 cleavage (Topping et al., 2009). An 
additional p53-independent MMR-dependent apoptotic response has also 
been demonstrated in HCT116 and mouse embryonic fibroblast cell lines 
(Gong et al., 1999). Gong and colleagues showed that cisplatin induces 
MLH1-dependent activation of the DNA damage-activated tyrosine kinase c-
ABL and that c-ABL then stabilises p73 to increase its half-life and trigger 
apoptosis in a p53-independent manner. Shimodaira et al. then showed that 
PMS2 binds to, and is also required for, the stabilisation of p73, leading to 
apoptosis in a c-ABL-dependent manner, and cisplatin was shown to increase 
PMS2-p73 interactions (Shimodaira et al., 2003). Given that MLH1 and PMS2 
are both required for the induction of p73-dependent apoptosis and that PMS2 
requires c-ABL for the stabilisation of p73, it is possible that the MLH1 and 
PMS2 complex MutLα is required for p73 stabilisation. Therefore, MutSα and 
MutLα binding to cisplatin lesions after translesion synthesis and replication 
bypass may induce cell cycle arrest and apoptosis via p73, in accordance with 
the direct signalling hypothesis. 
 
If the direct signalling hypothesis of MMR’s role in platinum response is 
correct, it is possible that loss of p53 function, a feature of many cancer cells, 
necessitates the MMR-dependent p73 apoptotic pathway for platinum 
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sensitivity. Loss of p53 and MMR would, therefore, result in the loss of two 
independent apoptotic pathways and a compound increase in cisplatin 
resistance. This is demonstrated in cisplatin-resistant cell line CP70, which 
has a dominant negative p53 mutation (Lu et al., 2001) and is deficient in 
MMR through the epigenetic silencing of MLH1 (Anthoney et al., 1996; Brown 
et al., 1993). Re-expression of MLH1 only partially re-sensitises these cells to 
cisplatin and it is perhaps the continued loss of p53 function that contributes 
to the remaining resistance of these cells (Plumb et al., 2000; Steele et al., 
2009).  
 
In total, the direct signaling hypothesis of MMR’s role in platinum damage 
response is supported by MMR involvement in post-damage signal 
transduction, the presence of MMR-dependent apoptotic pathways and the 
occurrence of cisplatin resistance in the absence of MMR proteins MLH1 or 
MSH2. In the absence of MMR, lesions could persist after translesion 
synthesis and a lack of MMR binding would prevent cell cycle arrest or 
apoptosis. This would result in damage tolerance and cells could continue to 
survive with accumulated platinum adducts. Although the role of MMR in 
platinum damage is still debated, direct signaling is currently thought to be the 
most likely mechanism for MMR involvement. 
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Figure 1.9 MMR-dependent signalling 
Schematic diagram showing the order of events resulting in platinum 
treatment leading to cell death. Platinum lesions that are present during 
replication are recognised by MMR proteins. MMR recognition triggers 
signalling responses including ATR and CHK1-mediated G2 checkpoint arrest 
and apoptosis. 
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1.21 Cisplatin interstrand crosslink - repair and resistance 
Until recently, the role of interstrand crosslinks in cisplatin’s cytotoxic 
mechanism has been overlooked, as intrastrand crosslinks were deemed to 
be the key modulators of cisplatin toxicity. However, more recent work has 
demonstrated key pathways in the ICL damage response that confer 
sensitivity to cisplatin when functional. Interestingly, the repair of ICLs 
requires coordination of proteins from several different repair pathways, and 
the Fanconi Anaemia (FA) and MMR pathways in particular have key roles in 
cisplatin ICL sensitivity (figure 1.10). 
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Figure 1.10 MMR and FA pathways in lesion bypass 
At replication forks stalled due to crosslinks, interaction between MMR protein 
MLH1 and FA protein FANCJ cause the displacement of MSH2, allowing the 
replication fork to restart and facilitating lesion bypass. In the absence of 
MLH1, or without the MLH1-FANCJ interaction, MSH2 is not displaced and 
therefore disrupts the ability for replication forks to restart, leading to HR 
DSBR at the damage site. Image taken from (Peng et al., 2014). 
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Recognition and repair of ICLs formed by cisplatin is generally triggered by 
stalled replication forks during S-phase (Niedernhofer et al., 2005), however 
mechanisms for replication-dependent and -independent ICL repair have 
been described. Replication-independent repair of cisplatin ICLs has been 
described by Enoiu and colleagues, who identified MMR- and DSBR-
independent transcription-coupled (TC) repair of ICLs relying on the NER TC-
specific protein CSB and downstream members of the NER pathway, as well 
as requiring pol ζ and REV1 for translesion synthesis (Enoiu et al., 2012). In 
replication-dependent ICL recognition, when replication forks encounter 
cisplatin interstrand crosslinks, RPA coats the single stranded DNA and this is 
recognised and bound by ATR-interacting protein (ATRIP) (Zou and Elledge, 
2003). ATRIP complexes with ATR, which is then activated, resulting in 
checkpoint kinase 1 (CHK1) phosphorylation, and FANCD2 is ubiquitylated, 
indicating a role for the FA pathway, a repair pathway activated by DNA 
damage-induced stalled replication forks, in transcription-dependent ICL 
repair (Räschle et al., 2008). MMR MutS complexes have been implicated in 
the recognition of ICLs, and they are required for the recruitment of the FA 
core complex (a complex of 16 FA proteins) to the damage site. MSH2, 
possibly in MutS complex, is required for the monoubiquitylation of FANCD2 
(Huang et al., 2011) and MLH1 binding to FANCJ is also essential for ICL 
repair (Peng et al., 2007) (figure 1.10). NER protein complex ERCC1-XPF is 
involved in the strand nicking, either 3’ or both 3’ and 5’, of the crosslink on 
one strand to facilitate its removal from the DNA through “unhooking”, and is 
recruited to the site of ICLs by interaction with SLX4 structure-specific 
endonuclease subunit (SLX4) and by localisation of ubiquitylated FANCD2 to 
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the ICL site and the surrounding DNA (Klein Douwel et al., 2014). BER and 
MMR have been shown to act epistatically in the prevention of transcription-
coupled ICL repair and, therefore, both BER and MMR are required for ICL-
induced cell death (Kothandapani et al., 2013). Cytosines flanking cisplatin 
ICLs are flipped out extrahelically and are subject to enhanced rates of 
deamination to uracil in this environment (Kothandapani et al., 2011; Lukin 
and de Los Santos, 2006). Kothandapani and colleagues have shown that 
BER of these flanking uracils leads to nucleotide incorporation by the low-
fidelity polymerase pol β. When the resulting incorporation leads to a 
mismatch, MMR proteins recognise and bind to these regions (figure 1.11). 
The presence of functional pol β, BER and MMR allows cisplatin sensitivity 
and increased ICL persistence in breast adenocarcinoma MDA-MB-231 and 
mouse embryonic fibroblast cell lines. Loss of uracil DNA glycosylase (UDG), 
inhibition of APE1 cleavage by methoxyamine (MX) or loss of pol β led to 
cisplatin resistance and increased ICL removal, indicated by corresponding 
decreases in ICLs and DSB-signalling γH2AX foci over time in cells deficient 
in UDG, pol β or treated with MX as the ICLs are repaired. These findings 
suggest that BER- and pol β-dependent replacement of adjacent ICL 
cytosines, followed by MMR binding, leads to the prevention of ICL repair, as 
BER is thought to compete with NER and HR repair events at ICL sites. As 
this work conflicts with data showing PARP inhibition, and therefore BER 
inhibition, to increase cisplatin sensitivity (Zhang et al., 2013), it is possible 
that PARP inhibition leads to additional effects outwith the context of ICLs, 
perhaps involving failure to resolve some intrastrand crosslinks, as PARP-1 
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has been shown to associate with members of the NER pathway (King et al., 
2012). 
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Figure 1.11 BER and MMR epistatic roles in ICL repair 
As cytosines flanking ICLs are extrahelically flipped out, they are processed 
by BER and Pol β is then able to incorporate both correct and incorrect bases 
at the abasic site. Incorporation of incorrect bases lead to mismatched that 
are recognised, bound and processed by MMR proteins. Repair by BER and 
MMR results in non-productive repair of cisplatin ICLs and results in 
persistence of the ICL lesions. The involvement of BER and MMR blocks 
productive ICL repair pathways and therefore contributes to cisplatin ICL 
sensitivity. Image taken from (Kothandapani et al., 2013) with permission from 
Oxford University Press. 
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Many interactions between members of the FA, MMR and HR pathways are 
found to be involved in the processing of platinum ICLs, demonstrating that, 
although loss of individual pathways may affect the response to platinum, no 
one pathway is solely responsible and crosstalk is essential. FANCJ 
interaction with BRCA1 is necessary for ICL repair through HR, and lack of 
this interaction leads to ICL replication bypass. Bypass occurs via an MLH1-
dependent mechanism whereby MLH1, in the MutLα complex, directly binds 
FANCJ to facilitate pol η-mediated ICL bypass (Peng et al., 2007; Xie et al., 
2010). Fanconi anaemia cells lacking the FANCJ-MLH1 interaction are hyper-
sensitive to ICL agents, as ICL bypass is prevented and cell cycle arrest and 
apoptosis occur (Peng et al., 2007). This sensitivity is reversed with the 
additional loss of MSH2, indicating that MSH2 plays a role in preventing ICL 
repair or bypass when the FA repair pathway is lost (Peng et al., 2014). This 
is possibly via MSH2 binding to mismatches and preventing error-prone 
recombination essential to ICL repair (Sharma and Canman, 2012) or through 
MSH2 binding to ICLs and preventing stalled replication forks from restarting. 
A possible mechanism for this would be MSH2 blocking FANCJ helicase 
activity that normally unwinds barrier DNA structures at stalled replication 
forks (Peng et al., 2014). Although the specific roles of individual proteins in 
the response to platinum ICLs are yet to be fully understood, the multiple 
interactions discovered thus far indicate that the roles of specific pathways in 
the response to platinum agents are intertwined, and indeed may conflict with 
each other when comparing the response(s) to intrastrand and interstrand 
crosslink lesions.  
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Interestingly, although it appears that both intrastrand crosslinks and ICLs 
contribute to cisplatin cytotoxicity, studies showing that the FANCJ-MLH1 
interaction is required for ICL tolerance have demonstrated that loss of MLH1 
contributes to increased ICL sensitivity, as these lesions then lead to 
replication fork crashes mediated by MSH2 binding (Peng et al., 2014).  
However, the fact that MLH1-loss leads to decreased intrastrand sensitivity, 
likely through loss of DNA damage signalling at compound intrastrand lesions, 
and MLH1-loss contributes to an overall net increase in resistance to cisplatin, 
this indicates that although both intrastrand crosslinks and ICLs contribute to 
cisplatin cytotoxicity, intrastrand crosslinks are the more toxic lesion in cells 
with full DNA repair capacity. Only when repair pathways are defective, as in 
FA or MMR-deficient HNPCC cells, do the dynamics of toxicity from the two 
categories of cisplatin lesions change. 
 
1.22 Epigenetics in platinum resistance 
Although platinum resistance can occur in any cell or tumour type, ovarian 
cancer is particularly affected by this occurrence. As ovarian cancer patients 
often present late due to the subtleness or absence of symptoms in early-
stage disease, the disease is often in the advanced stages at the time of 
diagnosis. 
 
1.23 Ovarian Cancer 
Ovarian cancer is the seventh most common cancer affecting women 
worldwide, with around 239,000 women being diagnosed with the disease in 
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2012 (Ferlay et al., 2015). Approximately 75 % of cases are in women over 
the age of 55, and the majority (80 %) of cases present with advanced 
disease (CRUK, 2015). Inherited mutations in HR DSBR genes BRCA1 and 
BRCA2 and in MMR genes MLH1, MSH2, MSH6 and PMS2 (Lynch 
syndrome) are associated with increased incidences of ovarian cancer. 
Women have an 39 % lifetime risk of developing ovarian cancer with a 
BRCA1 mutation, an 11-17 % lifetime risk with a BRCA2 mutation, and 
women with MMR mutations causing Lynch syndrome have a 9-12 % lifetime 
risk of developing ovarian cancer, compared to a lifetime risk of around 1.4 % 
for the average woman (Alliance, 2015; Antoniou et al., 2003). The ten year 
survival rate of women in the England and Wales with ovarian cancer is only 
around 35 % (CRUK, 2015). This relatively poor survival rate is partly 
attributed to a lack of early detection (Maringe et al., 2012) but is also affected 
by the incidence of chemotherapy resistance, sometimes initially and 
sometimes at relapse after a previous good response (Vaughan et al., 2011).  
 
First line chemotherapy for ovarian cancer is a combination of a DNA 
damaging platinum agent, either cisplatin or carboplatin, and a microtubule-
binding taxane, such as docetaxel. Although complete response to 
chemotherapy is between 40-60 % initially, most of these patients relapse 
with resistant disease within approximately 18 months (Greenlee et al., 2001; 
Neijt et al., 2000; Sandercock et al., 2002). Resistant disease is thought to be 
responsible for up to 90 % of the deaths of metastatic ovarian cancer patients, 
making it one of the most important factors to understand and overcome in 
the treatment of this disease (Vaughan et al., 2011).  
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As described previously, the incidence of platinum resistance is closely linked 
to the DNA repair capacity of cells; loss of MMR often drives increased 
resistance whereas loss of NER yields higher sensitivity. However, another 
major resistance mechanism is thought to be epigenetic changes in the cell 
(Brown and Glasspool, 2007). 
 
Numerous proteins, including tumour suppressors, DNA repair proteins and 
mediators of stress response and apoptosis are deregulated by epigenetic 
mechanisms in ovarian cancer platinum-resistant cells (Balch et al., 2004). 
FANCF, a gene involved in the FA-BRCA repair pathway, is silenced in some 
ovarian cancer cells through promoter CGI methylation, and is demethylated 
in platinum-resistant cells. The demethylation and subsequent re-expression 
of FANCF results in increased damage tolerance, likely to ICLs, and therefore 
contributes to the platinum resistance phenotype of these cells (Taniguchi et 
al., 2003). MLH1 is frequently suppressed through promoter CGI methylation 
in platinum-resistant ovarian cancer cells (Brown et al., 1997; Gifford et al., 
2004; Strathdee et al., 1999), and re-expression has been shown to partially 
re-sensitise cells, in vitro and in tumour xenografts, to platinum treatment, 
indicating a direct role for MLH1 in the resistance mechanism (Ding et al., 
2009; Papouli et al., 2004; Plumb et al., 2000; Steele et al., 2009). 
Methylation-Controlled protein J (MCJ) is a protein involved in mitochondrial 
protein importation (Schusdziarra et al., 2013). Aberrant expression of MCJ 
through loss of promoter methylation is common in ovarian cancer, and 
methylation of this gene correlates with cisplatin resistance and poor clinical 
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outcome (Strathdee et al., 2005). It is possible that loss of MCJ function 
causes platinum resistance through changes to mitochondrial function and 
loss of mitochondrial apoptotic pathways or signaling (Schusdziarra et al., 
2013). Furthermore, studies using array analysis of RNA expression (Chang 
et al., 2010) and CpG methylation (Yu et al., 2011; Zeller et al., 2012) have 
identified consistent differences in the methylation and expression of genes 
between platinum-sensitive and -resistant cell lines, and Zeller et al. went on 
to show that demethylation using the DNMT inhibitor 2-deoxy-5′-azacytidine 
(decitabine) and/or the HDAC inhibitor Belinostat caused the re-expression of 
key resistance-driver genes and re-sensitised cells to platinum treatment. 
 
Although it is clear that epigenetic mechanisms are involved in the 
development of platinum resistance, the process(es) leading to these changes 
are less well understood. Given that platinum resistance involves altered 
protection from, or response to, DNA damage it is possible that there is also 
an important interaction between DNA damage and or/repair and aberrant 
methylation contributing to platinum resistance. 
 
1.24 DNA damage and epigenetics 
There are several links between DNA damage and repair and DNA 
methylation in a number of studies, supporting the above hypothesis (figure 
1.12). In vitro studies have found an association between DNA 
methyltransferase inhibition and genome instability in mouse and human cells 
(Chen et al., 1998), showing the importance of methylation in maintaining 
viable DNA structure. DNMT1 is known to form a complex with PCNA, an 
 87 
important processivity factor for DNA synthesis and repair, and its interaction 
is mediated through p21 binding, indicating a possible role for p21 in cell cycle 
regulation of methylation (Chuang et al., 1997). DNMT1 has been shown to 
specifically bind DSB sites, recruited by its interaction with PCNA 
(Mortusewicz et al., 2005), and DNMT1-associated protein DMAP1 has been 
shown to stimulate both global and local DSB-associated DNA methylation 
(Lee et al., 2010), indicating a role for both DNMT1 and DMAP1 in DNA repair 
pathways. Additionally, work demonstrating DNA methylation changes relating 
to increased cancer risk in blood, particularly when comparing smokers vs. 
non-smokers, demonstrates a likely link between environmental DNA 
damaging agents and methylation changes and indicates that blood may be a 
suitable sample tissue for measuring the epigenetic effects of DNA damage 
(Brennan and Flanagan, 2012; Shenker et al., 2013b). 
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Figure 1.12 DNA methylation and DNA repair 
At a site of DNA repair where DNA synthesis occurs, there is the opportunity 
for gain or loss of DNA methylation through the removal of methylated DNA 
during repair and through the recruitment of DNMTs at sites of synthesis 
allowing methylation to be gained. (A-B) The substrate preference for DNMT1 
is hemi-methylated CpGs at newly synthesized DNA. DNMT1 is recruited to 
the replication fork, and associates with proteins such as UHRF and PCNA to 
facilitate its function. (C-D) MBD4 interacts with DNMT1 and MLH1 and these 
three proteins can co-localise at DNA damage sites post-replication and may 
be involved in activating apoptosis. MBD4 also recruits Fas-associated death 
domain protein (FADD), linking death receptors with initiator caspases. (E) 
Several models of active DNA demethylation have been suggested. MBD4 is 
reported to have its own DNA demethylating role. TDG (Thymine DNA 
glycosylase) can interact with DNMT3A and DNMT3B to facilitate 5meC 
glycosylase activity on hemi-methylated DNA. Proteins AID, MBD4 and 
GADD45a may cooperate and trigger demethylation. TDG and MBD4 may 
deaminate 5meC via mismatch repair. (F) TET1 produces 5hmC in 
methylated and hemi-methylated DNA, and 5hmC may also be involved in 
signaling pathways associated with epigenome turnover and maintenance. 
Image taken from (Meng et al., 2011). 
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1.25 Ionising radiation 
Ionising radiation (IR) has been used in multiple studies to demonstrate an 
aberrant methylation response to IR-induced DNA damage. Early work by 
Kalinich et al. and Tawa et al. showed that single exposure of high-dose γ and 
X-ray radiation resulted in decreased levels of methylation in cultured cell 
lines and in mouse tissues (Kalinich et al., 1989; Tawa et al., 1998). Research 
from Pogribny and Kovalchuk then showed genomic hypomethylation in lung, 
liver and spleen of mice exposed to acute and chronic low- and high-dose X-
ray radiation (Kovalchuk et al., 2004; Pogribny et al., 2004; Raiche et al., 
2004). As this work demonstrated a correlation between DNA damage sites 
and degree of hypomethylation, they propose a mechanism for DNA 
hypomethylation caused by the repair of IR lesions through synthesis 
pathways, such as recombination or long-patch base excision repair, where 
cytosines would be incorporated, and in some cases replace methylcytosines 
(Pogribny et al., 2004). The role of IR-induced hypomethylation in genomic 
instability and carcinogenesis was further probed by this group when they 
demonstrated the persistence of hypomethylation in IR-target thymus tissue in 
mice (Koturbash et al., 2005). The group then demonstrated that fractionated 
low-dose IR caused accumulation of strand break damage, loss of H4K20 
trimethylation, loss of DNA methylation and downregulation of DNMT1, 
DNMT3A, DNMT3B and methyl-binding proteins MeCP2 and MBD2 in mouse 
thymus (Pogribny et al., 2005). Kaup et al. went on to show DNA hypo- and 
hypermethylation in human keratinocytes irradiated in vitro, indicating possible 
mechanisms for bi-directional methylation changes in response to radiation-
induced DNA damage (Kaup et al., 2006). More recently, Antwih et al. have 
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used the genome-wide Illumina Infinium HumanMethylation450 BeadChip 
array to assess the methylation levels at approximately 480,000 CpG sites in 
MDA-MB-231 cells and demonstrated IR-induced bi-directional methylation 
changes at a range of sites with prevalence in genes of gene-ontology 
damage-response pathways that include cell cycle, apoptosis and DNA repair 
(Antwih et al., 2013). They propose a possible radiation-response epigenetic 
mechanism that regulates damage-response pathways in a non-random way. 
Following this, Bae and colleagues have used the same genome-wide 
Illumina array in colorectal HCT116 cells and demonstrated IR-induced 
hypomethylation of gene-specific CpG sites correlating with increased 
expression, and decreased levels of DNMT1 and DNMT3B at promoter sites 
(Bae et al., 2015). This research also identified multiple hypermethylated CpG 
sites but these were not discussed. Given the large body of evidence 
supporting the notion that radiation-induced DNA damage causes epigenetic 
changes to DNA methylation, research into the methylation response of 
specific types of DNA damage has become more prevalent. 
 
1.26 Induced double strand breaks 
In 2007 Cuozzo and colleagues used an exogenous inducible double strand 
break construct to stimulate HR DSBR in human and mouse cells in vitro 
(Cuozzo et al., 2007). Their work showed that HR created hypermethylated 
and hypomethylated repaired gene products in a roughly 1:1 ratio, and that 
the methylation changes were confined to the approximately 300 bp of 
homologous DNA shared between the damaged and template cassette 
regions (Cuozzo et al., 2007). This was confirmed in later studies with the 
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same construct (Cuozzo et al., 2007; Lee et al., 2012). They further showed 
that hypermethylation of HR-repaired DNA was associated with DNMT1 
activity, as DNMT1-null cells produced only hypomethylated product, and 
DNMT1 bound the DSB site. Therefore, they suggest that DNMT1 may have a 
de novo methylating role in a DNA repair context, particularly as template 
methylation did not appear to influence the methylation of the repaired region. 
This was further supported by later work showing DNMT1-associated protein 
DMAP1 is required for the recruitment of DNMT1 to these sites of DSBR and 
that DMAP1 absence results in hypomethylation of all HR products (Lee et al., 
2010). DNMT1 was further shown to be recruited rapidly and transiently to 
sites of DSB, relying on ATR signaling and interactions between PCNA and 
CHK1 for its recruitment (Ha et al., 2011). A non-methylating role for DNMT1 
was proposed in this paper, such as in signaling or chromatin remodeling, 
given its early recruitment. Cuozzo et al. proposed a model of damage-
induced aberrant DNA methylation where HR repair of a DSB yields one 
methylated and one unmethylated strand of repaired DNA, and that upon 
replication and cell division, double stranded methylated or unmethylated 
products would be present in the daughter cells in a 1:1 ratio (Cuozzo et al., 
2007). Interestingly, GADD45α is recruited to sites of DSBs and has been 
shown to inhibit DNMT1 methylating activity at these loci (Lee et al., 2012; 
Morano et al., 2014). The authors suggest that GADD45α inhibits DNMT1 
from methylating one of the two strands repaired during HR DSBR, resulting 
in the hemimethylated repair products described above. 
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O’Hagan et al used a different exogenous promoter construct, of the E-
Cadherin promoter CGI, to demonstrate silencing mechanisms in a small 
number of cells after an induced DSB in human breast cancer cell line model 
MDA-MB-231 (O'Hagan et al., 2008). They found DNA methylation, initially 
within a 200-300 bp region local to the break site, along with chromatin 
silencing marks such as H3K9me2 and me3, H4K16 hypoacetylation and 
H3K27me3. Transcriptional repression proteins SIRT1, EZH2, DNMT1 and 
DNMT3B were recruited to the damaged region, and SIRT1, which is known 
to interact with DNMT1 (Espada et al., 2007), was required for the recruitment 
of DNMT1 to the site. The location of methylation at the repaired region was 
found to expand over multiple generations of cell division, and the group 
identified DNMT3B as having the initial “priming” methylation role early in the 
repair process. They hypothesise that DNMT1 carries out a de novo 
methylating maintenance role to spread the methylation during subsequent 
cell divisions. 
 
1.27 Oxidative damage 
O’Hagan and colleagues later went on to demonstrate in cell lines that 
increased reactive oxygen species (ROS)-induced oxidative damage via 
treatment with hydrogen peroxide induces damage-specific recruitment of a 
complex or complexes containing DNMT1, SIRT1, DNMT3B, and members of 
the PRC4 complex including EZH2 and that this recruitment is mediated either 
through 8-oxo-2′deoxyguanosine (8-oxodG) base damage or the BER 
pathway (O'Hagan et al., 2011). These proteins were found to translocate 
from repressed genes to damage sites, causing histone modifications and 
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reduced transcripts in active genes and hypermethylation of promoter CGIs in 
low-expressing genes. As increased ROS production from metabolic 
dysregulation and inflammatory responses has been shown to cause an 
increase in cancer susceptibility risk (Federico et al., 2007), and increases in 
ROS are demonstrated during tumourigenesis (Storz, 2005), they propose 
that epigenetic changes through the recruitment of these proteins may 
contribute to the epigenetic dysregulation seen in cancer cells. In this study 
they also showed similar protein recruitment and epigenetic changes in 
mouse models of colitis inflammation, further supporting their hypothesis that 
inflammation causes aberrant DNA methylation through an oxidative damage 
mechanism. Additionally, they hypothesise that translocation of the 
aforementioned proteins DNMT1, SIRT1, DNMT3B and EZH2 from repressed 
genes to sites of damage may lead to the hypomethylation of repressed 
genes and hypermethylation of active, and damaged, genes reflecting the 
occurrence of global hypomethylation and localised hypermethylation seen in 
cancer cells (Jones and Baylin, 2007). 
 
Given that there are so many links between DNA damage, DNA repair and 
DNA methylation, it is likely there are specific mechanisms involved in these 
relationships and that these mechanisms are potential areas of interest for 
exploiting in cancer therapies. It is also possible that the epigenetic 
component of platinum drug resistance is linked to the DNA damage response 
to the drug itself, and therefore that the relationship between DNA damage 
and epigenetics could be a focus for combination therapies to re-sensitise 
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cells to platinum drugs or to prevent the emergence of resistance in the first 
instance. 
 
1.28 Hypothesis and Aims 
Although DNA damage has been linked to changes in DNA methylation, no 
research has been conducted into the epigenetic effects of platinum drug 
treatment, in cell lines or in patient samples. The hypothesis of this thesis is 
that platinum-induced DNA damage and repair causes aberrant DNA 
methylation that has the potential to be selected for, leading to platinum 
resistance. A further hypothesis is that this epigenetic response to platinum-
induced damage and repair is dependent on the MMR pathway, as MLH1 is 
frequently silenced in platinum-resistant cells and MLH1 re-expression in 
MLH1-silenced cells has been shown to confer partial re-sensitisation to 
platinum drugs (Plumb et al., 2000; Steele et al., 2009). Given that 
environmental exposure to DNA damaging agents in cigarette smoke has 
been linked to altered DNA methylation in blood (Shenker et al., 2013b), it is 
also hypothesised that platinum-induced aberrant DNA methylation will be 
present and detectable in the blood of patients treated with platinum agents. 
 
The aims of this thesis are: 
1) To determine whether platinum treatment, at levels not selective for 
platinum resistance, induces changes to DNA methylation in ovarian cancer 
cell lines models. 
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2) To determine whether any DNA methylation response to platinum is 
dependent on the MMR pathway. 
 
3) To determine whether platinum treatment of ovarian cancer patients results 
in changes to DNA methylation in peripheral blood mononucleocytes 
(PBMCs). 
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Chapter 2: 
Materials and Methods 
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Chemical/reagent Supplier Storage 
Aprotinin Calbiochem 4 °C 
Cisplatin (1mg/ml in saline) Hammersmith Hospital Pharmacy Room temperature  
 
Crystal violet  Merck Room temperature 
 
DTT Invitrogen 4 °C 
Ethanol Fisher Scientific Room temperature 
 
Foetal calf serum Sigma Frozen at -80 °C until use, then at 4 °C as part of complete media 
Isopropanol Fisher Scientific Room temperature 
 
L-Glutamine Sigma Frozen at -20 °C until use, then at 4 °C as part of complete media. 
Leupeptin Calbiochem Frozen at -20 °C and then stored at 4 °C for up to 1 week when in use. 
Methanol Fisher Scientific Room temperature 
 
Na3VO4 Sigma Room temperature 
 
NaAz Sigma Room temperature 
 
NaCl Sigma Room temperature 
 
NaF Sigma Room temperature 
 
Nuclease-free water Qiagen Room temperature 
 
PBS IRDB stores 4 °C 
Penicillin-streptomycin Sigma Frozen at -20 °C until use and then at 4 °C as part of complete media.  
PMSF Sigma 4 °C 
RIPA buffer Thermo Scientific Pierce 4 °C 
RPMI media Sigma 4 °C 
Tris Sigma Room temperature 
 
Trypsin Sigma 4 °C 
Tween20 Sigma Room temperature 
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Table 2.1 Chemicals and reagents 
Table lists chemicals and reagents used in the lab and their respective 
suppliers and storage conditions.  
 
2.1 Cell lines 
Cell lines A2780, CP70, CP70/MLH1+ and CP70/MLH1- were obtained from 
internal lab stocks (Durant et al., 1999). Cell lines CP70/MLH1+ and 
CP70/MLH1- will be referred to as MLH1+ and MLH1- respectively. All cells 
were maintained in RPMI media supplemented with 10 % (v/v) foetal calf 
serum (Sigma), 1 % (w/v) penicillin-streptomycin (Sigma) and 2 mM L-
Glutamine (Sigma) and were grown at 37 °C in a humidified 5 % CO2 
atmosphere. Cells were regularly tested for mycoplasma infection using the 
MycoAlert® kit (Lonza) and consistently tested negative. 
 
2.2 STR profiling 
All cell lines were sent for authentication to Genetica DNA Laboratories Inc. 
for STR profiling using the PowerPlex® 16 kit. 
 
2.3 RNA extraction and reverse transcription 
In order to analyse the expression status of MLH1 in all cell lines, RNA was 
extracted and reverse transcribed to cDNA from cells prior to drug-treatment 
using CellsDirect SuperScript III RNA extraction kit (Invitrogen) according to 
manufacturer’s instructions. cDNA samples were chilled on ice before 
proceeding to PCR. Unused cDNA was stored at -20 ˚C. 
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2.4 Western Blotting 
Cells were lysed by pipetting and vortexing with 250 µl of lysis buffer (RIPA 
buffer (Thermo Scientific Pierce), 55.5 mM NaF, 0.1 mM Na3VO4, 2 mM DTT, 
1 mM PMSF in isopropanol, 0.1 % (v/v) aprotinin (Calbiochem, Darmstadt, 
Germany) and 0.1 % (v/v) leupeptin (Calbiochem, Darmstadt, Germany)), 
followed by 30 min incubation on ice. Samples were then centrifuged for 15 
min at full speed to remove membranes and unsolublised proteins. Protein 
concentrations were determined using the BioRad Protein Assay kit according 
to manufacturing instructions. Twenty µg of each protein sample, diluted to 10 
µl in 1 x NuPAGE® LDS Sample Buffer (Invitrogen) and 1 x NuPAGE® 
Reducing agent (500 mM dithiothreitol (DTT), Invitrogen), were heated for 5 
min at 100 °C, cooled on ice for 1 min, vortexed and then centrifuged at full 
speed for 30 sec. Samples were then loaded into the wells of a 10 % 
NuPAGE® Bis-Tris gel (Invitrogen) in a gel tank filled with 1 x NuPAGE® 
MOPS SDS running buffer (Invitrogen), ensuring all wells were filled. One well 
was loaded with full-range rainbow ladder (Amersham). Gels were run for 1 hr 
at 100 V. Protein was then transferred from the gel to a PVDF nitrocellulose 
transfer membrane (GE Healthcare) using an iBlot Dry Transfer System 
(LifeTechnologies). The membrane was blocked with blocking buffer (5 % 
Bovine Serum Albumin (Sigma), Tris buffer saline/Tween 20 (TBST) (50 mM 
Tris, 150 mM NaCl, 0.05 % Tween20, pH 7.6), 0.02 % (w/v) NaAz) for 20 min 
at room temperature with gentle agitation. The membrane was then incubated 
in blocking buffer with primary antibody (MLH1 - 1/1,000 diluted (Abcam, 
ab14206), β-actin - 1/10,000 diluted (Abcam, ab1791)) overnight at 4 °C with 
gentle agitation. The membrane was then washed 3 times for 5 min in TBST 
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before incubating in Marvel (5 % w/v), TBST with 1/15,000 diluted goat anti-
mouse Igg HRP secondary antibody (Santa Cruz Biotechnology, sc-2005) for 
2 hr at room temperature with gentle agitation. The membrane was then 
washed 5 times for 10 min in TBST. Detection of the secondary antibody was 
carried out using detection reagent (Thermo Scientific) in accordance with the 
manufacturing instructions. The membrane was exposed to High Performance 
Chemiluminescence film (GE Healthcare) for a range of time intervals to 
ensure correct exposure. The film was then developed in an automatic 
developer. 
 
2.5 MTT assay 
Cisplatin concentration-response curves were generated from 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays using 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) 
according to manufacturer’s instructions. Briefly, cells were seeded at 104 
cells per well of a 96 well plate in 150 µl growth medium 24 hr prior to cisplatin 
treatment. Cells at 70-90 % confluence were then treated with cisplatin (liquid 
form, dissolved in saline and stored at room temperature, supplied by 
Pharmacy, Hammersmith Hospital) in triplicate at the following concentrations: 
0 µM, 5 µM, 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, 60 µM, 70 µM, 80 µM, 90 
µM and 100 µM. Growth media was replaced to remove drug after 24 hr and 
cells were grown until 72 hr. CellTiter 96 Aqueous One Solution (20 µl) was 
added to each well and cells were incubated at 37 °C in a CO2 incubator for 2 
hr. Absorbance was measured at 490 nm in a 96-well plate reader (BD 
Bioscience). Percentage cell survival was measured in comparison to 
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untreated control cells.  
 
2.6 Cisplatin clonogenic assay and creation of clones 
Cells were seeded at 104 cells per well of a 96 well plate in 150 µl growth 
medium 24 hr prior to cisplatin treatment. Cells at 70-90 % confluence were 
then treated with cisplatin (supplied by Pharmacy, Hammersmith Hospital) in 
replicates of 12 (to allow for a suitable number of surviving cells) at the 
following concentrations: 0 µM, 0.1 µM, 0.5 µM, 1 µM, 2.5 µM, 5 µM and 10 
µM for 72 hr. In order to grow out clonal populations of treated cells, cisplatin-
containing media was removed at 72 hr, cells were washed in phosphate 
buffer saline (PBS) and were detached from the wells by the addition of 50 µl 
Trypsin (Sigma). Cells from the 12 replicates were pooled, counted and re-
plated at 103 cells per 10 cm dish in triplicate and were left to grow for 18 
days. 
 
In order to establish a concentration-response curve for cisplatin treatment, 
media was removed from the 10 cm dishes, cells were washed in PBS and 
then washed twice in 100 % methanol (Fisher Scientific) for 5 min. Dishes 
were then stained with 5 ml 1 % crystal violet (w/v) (MERCK) for 5 min before 
being washed with water. A click counter was used to count the number of 
colonies per plate. 
 
In order to grow out clones of cisplatin- or mock-treated cells, individual 
colonies were picked and added to a well of a 6 well plate containing 4 ml of 
growth medium. Colonies were grown in 6 well plates for approximately 2 
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weeks, or until cells were over 50 % confluent. Cells were then removed by 
500 µl Trypsin and transferred to a T25 flask. When flasks were confluent 
cells were removed using 1 ml Trypsin and split into three T25 flasks that 
were maintained for approximately 1-2 weeks until cells were again confluent. 
Cells from each flask were then removed using 1 ml Trypsin and harvested for 
DNA extraction, RNA extraction and freezing for storage in liquid nitrogen 
respectively. 
 
2.7 DNA extraction 
Cells were trypsinised, washed in PBS and centrifuged at 1500 x g for 5 min 
prior to genomic DNA extraction. Extractions were carried out using QIA 
Amp® DNA mini kit (Qiagen) according to manufacturer’s instructions. DNA 
concentrations were quantified using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific). 
 
2.8 Bisulphite treatment 
In order to convert unmethylated cytosine bases to uracil to allow for 
distinction between methylated and unmethylated cytosines, 500 ng of 
genomic DNA extracted from each clone or SCOTROC1 sample was 
bisulphite converted in duplicate with EZ-96 DNA-methylation Gold kit (Zymo 
research, CA) according to manufacturer’s instructions. Samples were eluted 
in 30 µl of Nuclease-Free water (Qiagen) for use in pyrosequencing, or 10 µl 
of Nuclease-Free water for Illumina Infinium HumanMethylation450 BeadChip 
array experiments. SCOTROC1 samples validated with pyrosequencing by 
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Chail Koo were converted using the EZ-96 DNA-methylation kit (Zymo 
research, CA) according to manufacturer’s instructions using the alternative 
cycling conditions detailed for bisulphite conversion optimisation. 
 
2.9 Polymerase chain reaction (PCR) 
PCR was conducted on samples to detect LINE-1 methylation, to detect 
MLH1 RNA or to analyse array CpG sites for array validation using 
pyrosequencing. Primer sequences relating to LINE-1, MLH1 and validation 
CpG sites from the clonal and SCOTROC1 array experiments and annealing 
temperatures of these primers are detailed in table 2.2. Primers are named 
either by the CpG site being analysed by that assay or by the gene in which 
the CpG site of interest resides. LINE-1 and MLH1 PCRs were carried out in 
50 µl reactions containing 1 µl DNA, 1 x PCR buffer (Roche Applied Science), 
2 µM MgCl2 (Roche Applied Science), 0.2 µM dNTPs (Applied Biosystems), 
0.5 µM of each primer and 2.5 U FastStart Taq DNA polymerase (Roche 
Applied Science). PCR cycling conditions were 95 °C for 5 min followed by 45 
cycles of 95 °C for 45 sec, 53-60 °C (primer-dependent) for 45 sec, 72 °C for 
2 min and a final extension of 72 °C for 5 min. Clone validation PCR reactions 
were carried out in two steps as primers were not biotinylated. Step one 
contained validation site forward and reverse primers (one of which is biotin-
tagged) in 10 µl reactions using 0.5 µl DNA with reagent concentrations and 
cycling times as above. Step two contained the non-biotin tagged primer and 
the universal biotin primer in 45 µl reactions using 2 µl of 1/10-diluted round 
one product with reagent concentrations and cycling times as above. PCR 
products were run on 1 % (w/v) agarose gels (Fisher Scientific) alongside 100 
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bp ladder (Invitrogen) to determine product sizes. SCOTROC1 sample 
validation PCR reactions were carried out by Chail Koo as part of his MSc 
project and were conducted in one reaction as primers were biotinylated. 
Reactions were carried out in 45 µl with the reagent concentrations detailed 
above. Cycling conditions were 95 °C for 10 min, 10 touchdown cycles 
running from 60 °C to 50 °C (or 65 °C to 50 °C for LPHN1 primers) followed 
by 30 cycles of 95 °C for 20 sec, 50 °C for 20 sec and 72 °C for 20 sec and 
then a final extension of 72 °C for 5 min. 
 
 106  
Primer name Sequence Annealing temp. (°C) Biotinylated
(y/n) 
Biotin tagged 
(y/n) 
Universal Biotin Primer Biotin-GGGACACCGCTGATCGTTTA  N/A Y N 
MLH1 Fwd TTCGTGGCAGGGGTTATTCG  56 N N 
MLH1 Rev GCCTCCCTCTTTAACAATCACTT  56 N N 
LINE-1 Fwd GGATTTTTTGAGTTAGGTGTGGG  53 N N 
LINE-1 Rev CAAAAATCAAAAAATTCCCTTTCC  53 Y N 
cg20674248 Fwd AGTTATTGAGTAGAGTAGGATTAGTTT 56 N N 
cg20674248 Rev GACGGGACACCGCTGATCGTTTAATATCCATCTAAAAATCCCCATCTC 56 N Y 
cg12879242 Fwd TGGGTAGAGATTATTTAGTTTAAGTTATTA 55 N N 
cg12879242 Rev GACGGGACACCGCTGATCGTTTAATACCAAATCCTAACTACAAC 55 N Y 
cg16115688 Fwd GACGGGACACCGCTGATCGTTTAATGGGTGGTGAGTTTGGATTTTAAGAAG 60 N Y 
cg16115688 Rev AACTTCCCTCCTAAAAAACCCTACAACAAC 60 N N 
cg20634127 Fwd GATTTGGAAATAGAGGTTGTTTGTATA 56 N N 
cg20634127 Rev GACGGGACACCGCTGATCGTTTAATAAAAACCCCCCAAAACTAATAACCTAA 56 N Y 
cg21625271 Fwd AGATAGTAAGTATATGATAAATGGTTAATG 57 N N 
cg21625271 Rev GACGGGACACCGCTGATCGTTTAATACAACTTCAAACCCCACAAAAATA 57 N Y 
 
MAN2A2 Fwd AGGGATATAAGTGTAGATAGTGTTGA  Touchdown 60-50 
Annealing cycle 50  
N N 
MAN2A2 Rev TTCAAATCACACCCCATTCATC  Touchdown 60-50 
Annealing cycle 50  
Y N 
LPHN1_1 Fwd TTGTGGTTAGAGGATTAGGGAGATG  Touchdown 65-50 
Annealing cycle 50  
Y N 
LPHN1_1 Rev CCCCTCAACAACAACACCT  Touchdown 65-50 
Annealing cycle 50  
N N 
CRIM1 Fwd TTGTGAATTGGTATGGTTTTTAGT  Touchdown 60-50 
Annealing cycle 50  
N N 
CRIM1 Rev CACAAACCCAAATAAAAACTCACT  Touchdown 60-50 
Annealing cycle 50  
Y N 
CDK6_3 Fwd ATGTTTTTGAGATAGTAGTAGGGTATT  Touchdown 60-50 
Annealing cycle 50  
Y N 
CDK6_3 Rev AATAACCAATCTAAACCCCATTTACTC  Touchdown 60-50 
Annealing cycle 50  
N N 
HOXB3_1 Fwd TTTTTGGGAGGAAGTATATATAGGG  Touchdown 60-50 
Annealing cycle 50   
N N 
HOXB3_1 Rev TTCCACCATACAAACCTTCTATCCTA Touchdown 60-50 
Annealing cycle 50  
Y N 
XRCC3_2_2 Fwd GGGTTGTATAGTTATGGGGATAT  Touchdown 60-50 
Annealing cycle 50  
N N 
XRCC3_2_2 Rev ACTTCCTTTCCTAAATCCAATCTA  Touchdown 60-50 
Annealing cycle 50  
Y N 
DUSP6 Fwd GGGTAGGTTGTATATATGGGTATAG  Touchdown 60-50 
Annealing cycle 50  
N N 
CG27 Fwd TTGTGGGTGATAGTAGGTAGTGTT  Touchdown 60-50 
Annealing cycle 50  
N N 
CG27 Rev TATTCCATATCACTACTCCTCTCTATT  Touchdown 60-50 
Annealing cycle 50  
Y N 
RBMS1 Fwd AGGAGTGGAGGAATAAATAAATAAGA  Touchdown 60-50 
Annealing cycle 50  
N N 
RBMS1 Rev AAAACCCTACTCTACAACACC  Touchdown 60-50 
Annealing cycle 50  
Y N 
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Table 2.2 PCR primer details 
Table showing PCR primer names, sequences (with biotin tag sequence in 
bold), annealing temperatures and whether sequences are biotin-tagged or 
biotinylated. 
 
2.10 Pyrosequencing 
PyroQ software was used to design the pyrosequencing assays. Sequencing 
primers used are detailed in table 2.3. PyroQ CpG software (Biotage, 
Uppsala, Sweden) determined the percentage methylation of each CpG in the 
assay and overall methylation values were determined as the average of all 
CpG sites within the assay. In each assay, 10-20 µl of bisulphite-converted 
PCR product was used, depending on the PCR yield as determined by band 
brightness on agarose gels. Fully methylated genomic DNA (Zymo Research) 
and whole genome amplified genomic DNA (Genomiphi, GE Healthcare) were 
used as 100 % methylated and unmethylated controls respectively. Sample 
data was removed if samples were flagged as “check” or “fail” by the inbuilt 
PyroQ quality assurance measures, which detect any samples where the 
sequence of ddNTP incorporation deviates from the expected sequence or 
where extremely low or no levels of sequencing product are made. Overall 
methylation values were determined as the average of three replicate 
sequencing runs. 
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Table 2.3 Pyrosequencing primers 
Table showing pyrosequencing primer names and sequences 
 
 
 
 
 
 
Primer name Sequence 
LINE-1 Seq AGGTGTGGGATATAGT  
cg20674248 Seq AGTTTTTGTTTTTTAGTTATTTGTT 
cg12879242 Seq AAGTTATTATTTTTAATTTTTTTG 
cg16115688 Seq AACCCTACAACAACC 
cg20634127 Seq GTAGAGTAAAAGAAAATTTTGT 
cg21625271 Seq AAGTATATGATAAATGGTTAATGAA 
MAN2A2 Seq TGTTGATTTTTTTAGGAGTTTAT  
LPHN1_1 Seq TCCCCAAACTATACCCC  
CRIM1 Seq AATAAGGTTTTTTAATATAATGTTG  
CDK6_3 Seq CCCACTTAAAAACCTTC  
HOXB3_1 Seq ATAGGGTGTTATAGTATTTTAT  
XRCC3_2_2 Seq GGGAGTAGGAATTATTTTAGAG  
DUSP6 Seq AAATTTTTTTGTTAGTATTAATTA  
CG27 Seq AGTATTTAGGAGTTTTTTTTAGT  
RBMS1 Seq GGTTTTTTTAAGAATTGGAG  
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2.11 Methylation profiling 
Illumina Infinium HumanMethylation450 BeadChips are methylation array 
chips that allow for the interrogation of over 480,000 CpG sites across the 
genome at single base pair resolution. Each chip holds up to 12 samples and 
multiple chips can be run in batches for the same experiment.  
Clones from each of the four cell line test groups (mock- and cisplatin-treated 
MLH1+ and MLH1- cells), were selected at random for cell line methylation 
array profiling (n=5 per group for the first experiment and n=6 per group for 
the expanded test set experiment). SCOTROC1 samples were selected 
based on there being enough DNA (500 ng) to complete a single bisulphite 
conversion reaction prior to methylation analysis for matched presentation 
and relapse samples (n=59 per group). Successful bisulphite-conversion was 
confirmed using the LINE-1 PCR and pyrosequencing assay before samples 
were sent for analysis. Six µl of bisulphite-converted DNA from each sample 
were then sent to the University College London (UCL) Genomics Microarray 
and High Throughput Sequencing Facility for DNA methylation profiling using 
Infinium HumanMethylation450 BeadChips (Illumina). Raw data was provided 
by the UCL facility with methylation levels presented as β values, which 
represent the ratio of methylated probe intensity to total probe intensity (the 
sum of methylated and unmethylated probe intensities). Before the data could 
be analysed, a series of pre-processing and quality control measures were 
carried out. 
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2.12 Normalisation and background correction 
The reasoning for and approach taken to normalisation, quality control and 
correction methods is explained in detail in chapter 3, however the methods 
are detailed briefly here. 
 
Data was first normalised and background corrected to ensure that 
differences in channel intensities, and therefore β values, were due to 
differential methylation rather than errors in sample hybridisation to the 
BeadChips, or due to artifacts in the scanning of the BeadChips. The UCL 
genomics facility provided normalisation and background correction as part of 
the array service and they utilise internal control normalisation and negative 
control background correction methods built into the Genomestudio software 
package. 
 
2.13 Quality control 
Once normalisation and background correction were carried out on the array 
data, several quality control measures were undertaken. Quality control was 
carried out using software-programming tool R v2.15.1, versions Toasted 
Marshmallow and Frisbee Sailing. Analysis coding produced individual plots 
for each set of control probes and all BeadChips. Quality control was carried 
out using sample-independent controls testing for the efficiency of the 
fluorescent staining step, the extension efficiency of each nucleotide, the 
efficiency of post-extension reaction stripping of the DNA and the efficiency of 
hybridisation. Sample-dependent controls tested the efficiency of the 
bisulphite conversion of sample DNA, the specificity of methylation state 
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detection, the array background and the overall performance of the array 
assay.  
 
2.14 Detection p-value screening 
After confirming all samples passed the primary quality control checks, 
detection p-values were screened for all probes and all samples. Any sample 
with a non-significant detection p-value at a given CpG site had the data 
replaced with “NA” (non-applicable). Data from probes that had more than 20 
% non-significant detection p-values across all samples were removed and 
data from samples that had more than 20 % non-significant detection p-values 
across all probes were also removed. 
 
2.15 Imputation 
As the presence of multiple NAs in the BeadChip data presented difficulties in 
later processing and analysis, a function called K-nearest neighbour (knn) 
Impute was used to fill NAs with β values.  
 
2.16 Batch effect correction 
The next stage in the pre-processing of data was to correct for batch effect, 
due to samples being distributed across multiple BeadChips. ComBat is a 
batch effect correction method that uses an empirical bayes procedure to 
adjust for batch (Johnson et al., 2007). ComBat was run on M values and 
plots detailing the density of probes across β values for each BeadChip pre- 
and post-ComBat were created. 
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2.17 Probe type correction 
As the Infinium HumanMethylation 450 BeadChip arrays use two probe types, 
there are probe type biases that need to be corrected for. Peak-based 
correction is a method created to counter these probe type biases by 
normalising type II probe data and returning it in a state more comparable to 
type I data (Dedeurwaerder et al., 2011). 
 
2.18 Statistical Analyses 
To assess the differences in DNA methylation between test groups, 2-tailed 
Student’s t-tests were conducted on M values, or Wilcoxon rank sum tests 
were conducted on β values of samples across all probes. Volcano plots were 
created to visualise the methylation differences between groups, plotting         
-log10 t-test p-values against the percentage methylation difference when 
subtracting mean methylation of mock-treated or untreated samples at a given 
probe from that of treated samples. This subtraction means probes displaying 
negative values for the difference in methylation are less methylated in treated 
samples, and probes with positive values are more methylated in treated 
samples. 
 
Biases, for example in directional change of methylation, genomic regions or 
chromatin states were determined using odds ratio and chi-squared test 
functions in the epitools package of R, comparing numbers of significant 
probes with the numbers of non-significant probes. 
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2.19 Bonferonni correction 
As Infinium HumanMethylation 450 BeadChip arrays allow the measurement 
of methylation at over 480,000 CpG sites, significant changes detected 
between test groups across all of these sites may be wrongly detected due to 
the false discovery rate (FDR) of multiple hypothesis testing, or multiplicity. 
This is due to the fact that testing a high number of variables on a relatively 
low number of samples (for example ~470,000 variables and 6 vs. 6 samples) 
results in an increased likelihood of detecting a rare event that disproves the 
null hypothesis (for example that MLH1 status or platinum treatment does not 
result in differences or changes to DNA methylation). A form of correction for 
false discovery called the Bonferroni correction method was used to 
determine the number of probes significantly differentially methylated between 
groups, accounting for this false discovery risk. This is a conservative method 
of correction that works on the basis that if n number of hypotheses are 
tested, then a significance level of 1/n times that of a single hypothesis test 
will correct for multiplicity. In this case, the significance value for a given test 
would be no more than 0.05, and the number of hypotheses to be tested is 
approximately 470,000, therefore the Bonferroni corrected significance level is 
0.05/470,000, which is approximately 1E-7. 
 
2.20 Correlation matrix 
Correlation between the two sets of data was measured using the Pearson 
product-moment correlation coefficient, or R value. This value measures both 
the strength and direction of a linear relationship between two sets of data 
and is defined by the sample covariance of the data divided by the product of 
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their sample standard deviations. This linear correlation value lies between -1 
and 1, with -1 indicating a perfect inverse correlation, with all data points lying 
on a line where Y increases as X decreases, 0 indicating no correlation 
between data points, and 1 indicating a perfect correlation with all data points 
lying on a line where Y increases as X increases. 
 
2.21 Heatmaps 
Heatmaps were created to detect patterns in cisplatin-induced aberrant 
methylation. All samples were subject to unsupervised clustering of selected 
test probes using the “heatmap.2” function of the gplots package in R v2.15.1. 
This function clusters samples according to their similarity in β values for a 
given set of probes, and produces a dendrogram depicting clusters and 
sample relationships 
 
2.22 Consensus sequence analysis 
To create consensus sequence logos, the source sequence for each of the 
500 most significantly differentially methylated probes were entered into 
WebLogo version 2.8.2 (Crooks et al., 2004a; Crooks et al., 2004b), an online 
consensus logo programme. This programme produces graphic 
representations of nucleic acid multiple sequence alignment, showing stacked 
bases at each position along the sequence length. Overall stack heights 
represent the level of conservation at a given position, and individual base 
heights represent the frequency of that base at a given position. 
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2.23 Chromatin banding analysis 
To assess the relationship between aberrant DNA methylation and chromatin 
state, chromatin banding categories of g-positive heterochromatin (dark) or g-
negative euchromatin (light) were assigned to all probes. Banding was 
assigned based on the G-staining profile of each probe region of the human 
genome (version Feb. 2009 GRCh37/hg18) on the UCSC genome browser 
(http://genome.ucsc.edu) (Cheung et al., 2001; Furey and Haussler, 2003; 
Kent et al., 2002). Odds ratio and chi-squared tests were conducted on 
samples to determine whether significant hypo- and hypermethylation events 
were occurring preferentially in g-positive- or g-negative-associated probes 
when comparing test groups. 
 
2.24 Conditional logistic regression of SCOTROC1 data 
Conditional logistic regression was carried out using the Survival statistics 
package in R v2.15.1. 
 
2.25 Survival analysis 
Illumina 450k data was pre-processed using the minfi package and functional 
normalisation (Fortin et al., 2014). CpG sites most significantly differentially 
methylated were selected based on the Student’s t-test on M-values as 
performed previously, selecting all probes with FDR p<0.1 (FDR of 10 %) 
which resulted in n=333 CpG sites. Methylation beta values of these 333 CpG 
sites were used as a continuous value in a univariate Cox proportional 
hazards model for time to death (time from relapse to death) for each of the 
333 CpG sites, correcting for multiple testing using FDR. CpG sites that were 
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significant (FDR< 10%) were then used in consensus clustering to identify the 
number of sample clusters using the ConsensusClusteringPlus package 
(Monti et al., 2003). All multivariable Cox regression models for the 
association between methylation classes and survival were adjusted for FIGO 
stage, age at relapse, bulk of residual disease, ECOG performance status 
and histological type to ensure independence from these known prognostic 
factors. Kaplan Meier curves and Cox regression analyses were conducted 
using the “survival” package. All data analysis was conducted in R version 
3.0.1. This survival analysis was conducted by Dr James Flanagan. 
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Chapter 3: 
The establishment and LINE-1 
methylation analysis of mock- and 
cisplatin-treated A2780/CP70 clonal cell 
lines 
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3.1 Introduction 
The main aim of the work described in the chapter was to address the 
hypothesis that short-term (72 hour) treatment of ovarian cancer cell lines with 
cisplatin results in changes to DNA methylation, without selection for drug 
resistance. The first hypothesis being addressed is that cisplatin crosslinks 
cause changes to DNA methylation in cells. Secondly, this work aimed to 
address a further hypothesis that cisplatin-induced aberrant DNA methylation 
is dependent on the MLH1 status, and MMR capacity, of the cells in question. 
Mechanisms that could give rise to MLH1-dependent induced methylation 
changes would be replication stalling, translesion synthesis or DNA repair 
events causing increased DNA methylation. 
 
Although the mechanism(s) contributing to platinum resistance in cancer are 
not yet clearly defined, one hypothesis is that platinum resistance in cancer 
cells is driven by epigenetic mechanisms, causing epimutations that can be 
selected for (Zeller et al., 2012). Due to the building evidence that various 
forms of DNA damage lead to bi-directional aberrant DNA methylation (Bae et 
al., 2015; Cuozzo et al., 2007; Koturbash et al., 2005; Lee et al., 2010; 
O'Hagan et al., 2008; O'Hagan et al., 2011; Pogribny et al., 2005; Pogribny et 
al., 2004), it is hypothesised that platinum treatment leads to DNA damage 
and repair-induced bi-directional aberrant DNA methylation. Further, given 
that loss of MMR protein MLH1 through epigenetic silencing occurs in a 
variety of tumour types, including in approximately 35 % of ovarian cancer 
patients post-platinum treatment, conferring resistance to cisplatin in vitro and 
in vivo, and that re-expression of MLH1 partially re-sensitises cells to platinum 
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(Ding et al., 2009; Papouli et al., 2004; Plumb et al., 2000; Steele et al., 2009; 
Strathdee et al., 1999), it is hypothesised that MLH1 plays an important role in 
the emergence of platinum resistance. 
 
As MLH1 is involved in the binding and recognition of compound intrastrand 
platinum lesions (Duckett et al., 1996; Fink et al., 1996; Mello et al., 1996; 
Yamada et al., 1997; Yuan et al., 2004) and is required for damage signaling 
and checkpoint activation via CHK1, CHK2 and ATR at ICLs (Wu and 
Vasquez, 2008), MLH1 may contribute to changes in DNA methylation 
through these pathways. For example, DNA methylation may be lost when 
cytosines opposite or flanking a platinum lesion are removed upon MMR 
recognition and repair, and methylation may be gained when ICLs are 
repaired, as CHK1 and ATR have been shown to recruit DNMT1 to sites of 
DNA damage (Ha et al., 2011).  
 
In order to examine the changes in DNA methylation caused following 
cisplatin-induced DNA damage and to investigate the role of MLH1 in this 
response, cisplatin damage was induced in paired isogenic cell lines 
CP70/MLH1+ and CP70/MLH1-, which differ in their MLH1 expression and, 
therefore, in their MMR capacity. Cell line A2780 is a well-characterised 
cisplatin-sensitive ovarian cancer cell line, obtained from an untreated patient, 
in which MLH1 is expressed. In the 1980s, this cell line was subject to various 
extended periods of selection in high concentrations of cisplatin in order to 
derive multiple clonal cisplatin-resistant cell lines (Behrens et al., 1987). Cell 
line CP70 was created from this selection method after intermittent exposure 
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of A2780 to increasing concentrations of cisplatin, reaching a peak 
concentration of 70 µM on three separate occasions for three days (Yao et al., 
1995). The CP70 cell line was found to be 28-fold more resistant to cisplatin 
than A2780, contains a dominant negative p53 mutation (Lu et al., 2001) and, 
importantly, it lacks MLH1 expression due to bi-allelic MLH1 promoter 
methylation (Strathdee et al., 1999). Although the A2780 and CP70 cell lines 
could be regarded as an ideal matched pair with differential MLH1 expression, 
the potential effects of long-term cisplatin selection on gene expression are 
such that these lines could not be classed as isogenic. Therefore, a pair of 
clonal cell lines was chosen, derived from CP70 in the absence of cisplatin 
treatment selection. Fragments of chromosome 3 containing the MLH1 gene 
were re-inserted into the CP70 line through microcell-mediated chromosomal 
transfer and MLH1-expressing and -non-expressing clones were 
subsequently created (Durant et al., 1999). Cell lines CP70/MLH1+ and 
CP70/MLH1- are two resultant clones in which a single copy of the 
chromosomal fragment is present (Robert Brown, personal communication, 
2015), and in which a copy of MLH1 is expressed in the former and is not 
expressed in the latter (Hewish et al., 2013). Although the chromosome 
fragments contained a dominant selectable marker (neomycin), these 
transfections were stable (Robert Brown, personal communication, 2015). 
Therefore, these cells were grown under non-selected conditions in this study, 
and MLH1-espression was checked to ensure non-selection had not resulted 
in loss of the chromosomal fragments. These cell lines will henceforth be 
referred to as MLH1+ and MLH1- (figure 3.1).  
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Figure 3.1 Schematic representation of MLH1+ and MLH1- cell line 
derivation  
Cell line A2780 was subject to repeat cisplatin treatment to derive the cisplatin 
resistant cell line CP70 (Yao et al., 1995). Fragments of chromosome 3 were 
then introduced into CP70 cells and clones were grown out (Durant et al., 
1999). Two of these clonal lines were used for the experiments detailed in this 
thesis, one of which expresses MLH1 (MLH1+) and the other does not 
(MLH1-). 
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Once these cell lines were validated and characterised for their respective 
cisplatin sensitivities, clonal cell lines were created following mock- or 
cisplatin-treatment. A concentration of cisplatin that corresponded to an 
approximate IC95 for both cell lines was used with the aim of inducing high 
levels of DNA damage, similar to the damage levels of cells in a clinical 
setting, while avoiding selection for resistant cells that may occur at higher 
concentrations. Although the IC95 concentration differed between the two cell 
lines due to their difference in cisplatin sensitivity, a single concentration of 
cisplatin was used to treat both lines in order to standardise the platinum load, 
and thus the number of platinum lesions, as much as possible. Cells were 
treated for 72 hours prior to cloning out as this allowed enough time for at 
least two cell doublings (usually around 26 hours for A2780/CP70 cells (Zhen 
et al., 1992)), ensuring time for transcription and replication events to occur 
leading to potential strand breaks and repair. The clonogenic approach was 
taken to improve the sensitivity of aberrant methylation detection in all further 
experiments, as stochastic variation in DNA methylation could result in high 
background levels of methylation variance when comparing treatment groups 
in bulk culture and this could mask cisplatin-induced changes in methylation. 
Growing clonal colonies out over a period of weeks also allowed for the 
detection of DNA methylation changes that persisted after DNA repair through 
multiple generations, while not being diluted out by bulk culture variation, 
rather than only detecting immediate methylation changes at 72 hours that 
may not have persisted. 
To initially address the question of cisplatin-induced aberrant DNA 
methylation, global methylation was determined in clones after mock- or 
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cisplatin-treatment. Long Interspersed Elements, or LINE-1, are repetetive 
elements that make up approximately 17 % of the human genome (Lander et 
al., 2001). LINE-1 methylation was measured as a surrogate for global 
methylation as these elements are dispersed throughout the genome and 
undergo CpG methylation, and their methylation levels have historically been 
used for genome-wide methylation estimation (Ostertag and Kazazian, 2001). 
 
3.2 Aims 
The aims of this chapter were to authenticate and characterise the cisplatin 
sensitivities of cell lines MLH1+ and MLH1-, to create clones after mock- and 
cisplatin-treatment of these cell lines and to initially measure the global DNA 
methylation response to cisplatin in these clones using LINE-1 methylation as 
a surogate. 
  
3.3 Results 
 
3.3.1 STR profiling authenticates cell lines 
Cell line stocks were initially authenticated to ensure all future experiements 
were conducted on the cells intended, and that stocks were not contaminated 
with other cell lines. To authenticate cell line stocks, microsatellite (STR) 
profiling was carried out using the PowerPlex16 kit. STR profiling is used in 
cell line authentication as the number of tandem repeats is highly variable 
between alleles at a given loci and between loci in a given sample, due to 
these regions being homologous recombination hotspots where replication 
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slippage often leads to duplications of repeats (Klintschar et al., 2004; Wahls 
et al., 1990). This allows for the identification of cell lines as two samples of 
the same cell line should possess the same number of repeats at each loci 
tested, whereas unrelated samples would differ in repeat length at some or all 
loci. A minimum of 8 loci are required to uniquely identify a cell line, however 
the PowerPlex16 kit was designed as a platform for single amplification STR 
detection and measures the repeat sizes of 16 STR loci, the same as those 
used on the criminal justice DNA database CODIS (Combined DNA Index 
System) (Krenke et al., 2002). As there was no pre-existing STR profile for the 
parental cell line A2780 available on the online resource American Type 
Culture Collection (ATCC), the cell lines could not be unequivocally 
authenticated. However, as all CP70 lines were derived from line A2780 they 
were expected to, and indeed did, have very similar STR profiles, more than 
would be expected by chance for unrelated cell lines (table 3.1). Several 
discrepancies were found between these cell lines, particularly in the 
multiplicity of certain STRs (eg. D5S818), however this is likely due to the 
known microsatelite instability phenotype (a marker of MMR deficiency) of the 
CP70 cell line (Anthoney et al., 1996).  
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Table 3.1 STR profiles of cell lines show high degree of similarity across 
related cell lines 
Left column indicates name and chromosomal location of individual STR loci. 
Numbers indicate the number of repeats at each loci for each allele of a given 
cell line. More than 2 values for a given loci indicates a mutation, gene or 
allele duplication at that region. Single values indicate loss of 
heterozygosity/loss of allele at that loci. Decimal values indicate a repeat 
sequence followed by an incomplete repeat, for example sample MLH1+ at 
loci D7S820 has a repeat length of 10.3, indicating 10 repeats followed by 3 
bases. 
  
!
STR name and location A2780 CP70 MLH1+ MLH1- 
TPOX 2p23-2pter 8, 10 8, 10 8, 10 8, 10 
D3S1358 3p 14, 16 14, 16 14, 16 14, 16, 17 
FGA 4q28 19, 24 19, 24 19, 24 19, 24 
D5S818 5q21-31 11, 12 11, 12, 13 11, 12 10, 11, 12 
CSF1PO 5q33.3-34 10, 11 11, 12 10, 11 10, 11 
D7S820 7q 10 10 9, 10.3 9, 11, 12 
D8S1179 8 15, 17 15, 17 15, 17 15, 17 
THO1 11p15.5 6 6 6 6 
vWA 12p12-pter 15, 16 16 15, 16 15, 16 
D13S317 13q22-31 12, 13 13, 14 13 12 
D16S539 16q24-qter 11, 12, 13, 14 11, 14, 15, 16 11, 14 11, 14 
D18S51 18q21.3 16, 18 15, 16 16, 18 15, 16, 18 
D21S11 21q11.2-q21 28 28, 29 28 28 
Amelogenin X:p22.1-22.3 Y:p11.2 X X X X 
PENTA D 21q22.3 8, 9 8, 9 8, 9 8, 9 
PENTA E 15q26.2 10, 13 9, 13 10, 13 10, 12 
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3.3.2 Validation of MLH1 expression in parental cell lines 
To confirm MLH1 expression status in cell lines A2780, CP70, MLH1+ and 
MLH1-, RNA extraction and reverse transcription was carried out to obtain 
cDNA from the four cell lines and PCR was used to amplify a 156 bp fragment 
of MLH1 . Primers were designed to amplify a segment of cDNA spanning the 
boundary of the first intron (forward primer binds in the first exon and reverse 
primer in second exon) to ensure that amplified product comes only from 
cDNA and not from genomic DNA. Using gel electrophoresis, a 159 bp band 
was detected for cell llines A2780 and MLH1+, and no band was detected for 
cell lines CP70 and MLH1- (figure 3.2 A). Protein was then extracted from 
each of the four cell lines and Western blotting was carried out using an 
hMLH1-specific antibody. Bands corresponding to hMLH1 protein were 
detected in the A2780 and MLH1+ cell lines and these bands were absent in 
the CP70 and MLH1- cell lines (figure 3.2 B). These data confirm that the cell 
lines reported to be MLH1-proficient did indeed express MLH1 RNA and 
protein and the cell lines reported to be MLH1-deficient did not. Therefore, 
these lines were as expected and mycoplasma-free stocks were frozen and 
used in all subsequent experiments. 
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Figure 3.2 RT-PCR screen and Western blot shows MLH1 expression in 
A2780 and MLH1+ cell lines 
(A) Agarose gel showing RT-PCR product of MLH1, using primers amplifying 
159 bp of MLH1 from cDNA. A 159 bp band is present for cell lines A2780 
and MLH1+, but not for cell lines CP70 and MLH1- or for the RT-negative 
control. (B) Cell line protein extracts were analysed by Western blot using an 
hMLH1 monoclonal antibody. Beta-actin was measured as a loading control. 
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3.3.3 Validation of increased cisplatin sensitivity with MLH1 expression  
In addition to the CP70 cell line being more resistant to cisplatin than the 
A2780 line, it has been shown previously that the re-expression of MLH1, 
through treatment with the cytosine analogue DNMT inhibitor 2-deoxy-5-
azacytidine alone or in combination with HDAC inhibitor Belinostat, to reverse 
promoter methylation, or through the reintroduction of a functioning copy of 
the MLH1 gene in a cisplatin-resistant and MLH1-deficient cell line conveys 
partial recovery of platinum sensitivity (Papouli et al., 2004; Plumb et al., 
2000; Steele et al., 2009). It, therefore, follows that cell lines A2780 and 
MLH1+ should be more sensitive to cisplatin than their MLH1-deficient 
counterparts. Cell viability assays using MTT were used to establish the 
cisplatin sensitivities of each of the four cell lines (figure 3.3). These results 
show that the MLH1-expressing lines were more sensitive to cisplatin with a 
50 % inhibitory concentration (IC50) of 3.49 µM (A2780) compared to 22.8 µM 
(CP70) and an IC50 9.615 µM (MLH1+) compared to 17.39 µM (MLH1-). (IC50 
of A2780 is an extrapolated calculation as it was lower than the lowest 
concentration used in this experiment.) 
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Figure 3.3 Cisplatin MTT concentration-responses 
Cell survival values represent the average survival as a percentage of 
baseline (mock-treated) cells from triplicate MTT assays. Error bars show 
standard error of the mean (SEM).  
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3.3.4 Cisplatin clonogenic assays determine 5 µM as a standardised 
concentration for cell lines MLH1+ and MLH1- 
To establish the epigenetic effects of cisplatin treatment in the MLH1+ and 
MLH1- cell lines, cells were to be exposed to a single dose of cisplatin before 
measuring epigenetic changes. Previous unpublished studies have shown 
that a single exposure to cisplatin, even at relatively high concenration, will 
not select for drug resistance, but rather multiple drug exposures are required 
(Robert Brown, pers. comm.). The aim was to identify an approximate IC95 
after 72 hours of treatment with a single exposure to cisplatin, resulting in a 
high level of DNA damage while avoiding the selection of resistant clones that 
could occur after multiple treatments with drug concentrations of IC99 or over. 
A single drug concentration for both cell lines was also preferred to the use of 
two separate IC95 concentrations in order to standardise the platinum load, 
and thus the potential DNA damage, across the two cell lines. Cisplatin 
clonogenic assays were carried out on MLH1+ and MLH1- cells with a range 
of drug concentrations and a treatment time of 72 hours to determine the 
concentration of cisplatin that corresponded to an approximate IC95 in the two 
cell lines. The clonogenic assay further supported the MTT assay data 
showing MLH1+ to be more sensitive to cisplatin than MLH1-, and a drug 
concentration of 5 µM was found to be suitable for future experiments (figure 
3.4).  
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Figure 3.4 Cisplatin clonogenic concentration-responses 
Values represent the number of colonies counted as a percentage of baseline 
(mock-treated) colonies and are the average of triplicate plates from a single 
experiment. Error bars represent the SEM. 
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3.3.5 Creation of multiple mock- and cisplatin-treated MLH1+ and MLH1- 
clones 
As cisplatin-induced methylation changes could be masked in cell lines due to 
the stochastic variation of methylation in mixed cell populations, multiple 
independent clonal cell lines were derived from mock-treated (media only) 
and 5 µM cisplatin-treated MLH1+ and MLH1- cell lines. In order to create 
these clonal cell lines, cells were treated with media (mock) or 5 µM cisplatin 
for 72 hours in flasks and were then plated out on to 10 cm dishes at a density 
of 1000 cells per dish. This density allowed for the growth of individual cell 
colonies over the course of approximately 2.5 weeks in a sparse enough form 
to allow single colony collection. Colonies were then expanded in 6 well 
plates, T25 flasks and finally in T75 flasks over the course of several weeks to 
a few months (figure 3.5 A). Once clonal cell lines were established they were 
split into batches for cell freezing and DNA harvesting. Clones were 
generated in three batches of 10-15 week treatment and cell expansion cycles 
(~8 clones per treatment group, per batch) to reach ~20 clones per treatment 
group (figure 3.5 B).  
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Figure 3.5 Clonogenic assay and colony creation with timeline 
(A) Schematic representation of methodology for creating and growing 
cisplatin- and mock-treated clones. (B) Timeline indicating approximate 
duration of one cycle of clonal creation; multiple cycles were conducted to 
create a full compliment of clones (~20) for each test group. 
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3.3.6 Short-term cisplatin treatment did not change the cisplatin 
sensitivity of clonal cell lines 
To ensure that any methylation changes detected were not due to the 
selection of resistant clones post-cisplatin treatment, the cisplatin-sensitivities 
of randomly selected mock- and cisplatin-treated clones (n=5 for each group) 
were measured via the MTT assay. No significant difference in cisplatin-
sensitivity was detected between mock- and cisplatin-treated clones from 
either MLH1+ or MLH1- cell lines (figure 3.6 A and B) (Student’s t-test 
p>0.05).  
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Figure 3.6 Cisplatin treatment did not affect survival curves of MLH1+ or 
MLH1- clones  
Values represent log10 of the average percentage survival of five clones each 
of mock- and cisplatin-treated MLH1+ (A) and MLH1- (B) cells and are the 
average of three experimental replicates. Error bars represent the standard 
deviation across the five clones. Significant difference between the two 
survival curves at each drug concentration was measured using the two-tailed 
Student’s t-test. Significance was determined as p<0.05. 
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3.3.7 Short-term cisplatin treatment increases LINE-1 methylation in 
MLH1-proficient cells 
 To determine the effect of short-term high-concentration cisplatin treatment 
on genome-wide methylation, DNA was extracted from the clonally-derived 
mock- and cisplatin-treated MLH1+ and MLH1- cell lines desribed previously. 
The DNA was bisulphite treated and a region of LINE-1 was amplified via 
PCR. LINE-1 methylation levels were then measured using pyrosequencing. 
LINE-1 methylation was significantly lower in MLH1+ mock-treated clones 
(47.95 %) compared to their MLH1-deficient mock-treated counterparts (55.84 
%), (p=1.93E-10). Cisplatin significantly increased LINE-1 methylation in 
MLH1+ clones (52.9 %) (p=4.087E-5) but no significant change was detected 
after cisplatin treatment in MLH1- clones (56.3 %, p=0.632) (figure 3.7).  
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Figure 3.7 Cisplatin treatment increases LINE-1 methylation in MLH1+ 
clones 
Percentage methylation of LINE-1 for mock- and 5 µM cisplatin-treated 
MLH1+ and MLH1- clones. Methylation values are the mean of three 
independent replicates. Two-tailed Student’s t-tests showed LINE-1 
methylation to be significantly higher in mock-treated MLH1- clones compared 
to mock-treated MLH1+ clones (p=1.93E-10), and found 5 µM cisplatin 
treatment to significantly increase LINE-1 methylation of MLH1+ clones 
(p=4.087E-5). Error bars represent SEM. 
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3.4 Discussion 
The overall aims of the work in this chapter were to determine the epigenetic 
effects of short-term cisplatin treatment on DNA methylation, with the 
additional aim of determining the role of MLH1 in the cisplatin-induced 
epigenetic response.  
 
Mock- and cisplatin-treated clones were derived from the MLH1+ and MLH1- 
cell lines via a protocol of treatment, colony selection and cell culture 
expansion. A final complement of clones was created, comprising 25 clones 
for mock-treated MLH1+, mock-treated MLH1- and cisplatin-treated MLH1- 
cells and 21 clones for cisplatin-treated MLH1+ cells.  
 
Although MTT assays were informative of relative cisplatin sensitivities in 
MLH1+ and MLH1- cells pre- and post-cloning, the data presented here 
indicated that cells post-cloning were more resistant than pre-cloning (see 
figures 3.3 and 3.6). As the MTT experiments were conducted on cells with a 
relatively high confluency and cisplatin treatment time was around three cell 
doublings at 72 hours, cells are likely to have reached confluency early in the 
experiment time frame and this may, therefore, have affected the data on 
cisplatin concentration sensitivity. In hindsight it would have been better to 
conduct this experiement on cells of a much lower confluency to allow 
exponential growth during the cisplatin treatment period, to eliminate 
confluence and resultant cellular stress as conflounders in the MTT data. 
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Clonogenic assays used to determine the cisplatin sensitivities of the MLH1+ 
and MLH1- cell lines indicated a lesser difference between the two groups 
than the MTT assay, although the difference was still statistically significant. 
This is possibly due to the low number of colonies present at higher 
concentrations of cisplatin, leading to large error bars in the data at these 
concentrations. It is also possible that the reduced difference is due to the 
wider concentration range used in the clonogenic assay compared to the MTT 
assay and that a narrower range of concentrations, and a larger number of 
cells plated at higher concentrations, may have improved the sensitiity of this 
assay. The clonogenic assay also demonstrated a lower concentration of 
cisplatin required to inhibit cell growth. As this is not a phenomena 
documented in the literature comparing MTT and clonogenic assays, it is 
possible that the high confluency of cells prior to cisplatin treatment in both 
the MTT and the clonogenic assays may be affecting the reliability of the data, 
particularly as confluence-associated cellular stress may be increasing cell 
death at lower concentrations.  
 
Analysis of LINE-1 methylation as a surrogate for global DNA methylation was 
carried out on all clones to establish a picture of genome-wide methylation 
pre- and post-cisplatin treatment, prior to more detailed locus-specific 
analysis. LINE-1 was significantly hypermethylated in mock-treated MLH1- 
clones compared to mock-treated MLH1+ clones. This difference could be 
due to clonal variation between the two parental cell lines MLH1+ and MLH1-, 
however it is notable that later analysis of methylation at specific CpG sites 
throughout the genome also demonstrates significant differences in 
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methylation between clones in these two groups. Clonal difference, caused by 
genetic drift, could be tested by comparing LINE-1 methylation in CP70 cells 
to the data presented here, as if CP70 LINE-1 methylation is vastly different to 
that of the MLH1+ and MLH1- lines it would be likely that genetic drift, or the 
cloning process, contributed to some of the methylation differences detected 
here. It is also possible that these differences are a result of the differential 
MMR capacity of these two cell lines.  
 
Given that in this study cisplatin treatment significantly increased LINE-1 
methylation only in the MMR-competent MLH1+ clones, there are several 
hypotheses regarding potential mechanisms. Mismatch repair and/or MLH1 
may be required for abberrent methylation to occur after cisplatin-induced 
DNA damage. As it is unclear whether this and other DNA damage-induced 
aberrent methylation is a result of damage signalling or damage repair it is 
possible that in the absence of MLH1 or other MMR  proteins, some cisplatin-
induced DNA damage is not being recognised, preventing signals that lead to 
changes in DNA methylation, or else these cells may not be capable of 
repairing some of the damage and, therefore, do not undergo repair-related 
methylation changes. These hypotheses would conclude that MLH1 and/or 
mismatch repair is at least involved in, and possibly necessary and/or 
sufficient, for cisplatin-induced aberrent methylation. A further hypothesis is 
that clones deficient in MLH1 have already undegone significant DNA 
damage-induced methylation changes through the loss of the MMR pathway, 
and these clones have reached a maximum capacity or threshold for damage-
induced aberrent methylation. In this scenario it could be the case that further 
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DNA damage induced by cisplatin is unable to trigger an additional 
methylation response due to the genome already being saturated with 
damage-induced methylation changes. This hypothesis would also suggest 
that MLH1 is not required for at least some forms of damage-related aberrent 
DNA methylation, as these cell lines have undergone extensive damage-
induced methylation changes in its absence. It is also possible that the results 
presented here are due to a combination of these hypotheses, whereby 
clones lacking in MLH1 have higher LINE-1 methylation due to an inherent 
endogenous DNA damage phenotype caused by the lack of MMR and further 
methylation changes are not detected after cisplatin treatment in these clones 
because MLH1 and/or MMR is required to mediate cisplatin-specific aberrent 
methylation. 
 
3.5 Summary 
In summary, this chapter has shown that clones derived from MLH1-proficient 
and MLH1-deficient cell lines have differential LINE-1 methylation, and 
cisplatin treatment results in hypermethylation of LINE-1 only in MLH1-
proficient clones. 
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Chapter 4: 
Infinium methylation array analysis of 
mock- and cisplatin-treated MLH1+ and 
MLH1- clones 
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4.1 Introduction 
In Chapter 3, analysis of DNA methylation at the repetitive element LINE-1 
indicated that cisplatin-induced DNA damage causes hypermethylation at a 
global-genome level in ovarian cancer cell line models and that this increase 
was dependent on MLH1 expression. Additionally, LINE-1 methylation was 
lower in MLH1-proficient than MLH1-deficient cells, indicating a possible role 
for MLH1 in the preservation of epigenetic signatures, either by actively 
preventing hypermethylation of genomic regions or by passively preventing 
aberrant methylation through its role in maintaining genomic stability, 
regulating DNA damage rates. Based on this data, it was hypothesised that 
cisplatin treatment would result in the hypermethylation of multiple CpG sites 
throughout the genome in an MLH1-dependent manner. To test this 
hypothesis, Illumina Infinium HumanMethylation450 BeadChip whole genome 
methylation arrays were used to interrogate over 480,000 CpG sites at single 
base pair resolution, allowing the comparison of methylation in mock- and 
cisplatin-treated clones proficient and deficient in MLH1. 
 
Given the hypothesis that cisplatin binding to DNA results in changes to DNA 
methylation, it was also important to consider whether specific regions of the 
genome, or specific genomic states were differentially affected by the 
platinum-induced methylation response, perhaps indicating a different 
propensity for platinum to bind in certain regions. Cisplatin is already known to 
have DNA binding site preferences, binding to GpG and ApG sites while not 
to GpA (Fichtinger-Schepman et al., 1985). It is, therefore, possible that 
cisplatin also has preferences for the wider structure of the DNA or chromatin 
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at a given binding site, or for the presence or absence of DNA-binding 
proteins. For example, it may be that cisplatin more readily binds DNA in 
open, euchromatic regions or in CpG islands due to improved access to the 
DNA, or binds DNA of specific structure(s) more readily and, therefore, there 
may be sequence motifs that are highly associated with aberrant methylation.  
 
4.2 Aims 
The aims of this chapter were to determine whether cisplatin treatment results 
in DNA methylation changes at individual CpG loci and to determine whether 
an epigenetic response to cisplatin is dependent on MLH1-proficiency. Further 
aims were to establish whether cisplatin-induced epigenetic changes 
preferentially occur in specific regions of the genome, sequence motifs or 
chromatin environments. 
 
4.3 Results 
 
4.3.1 Bisulphite conversion quality control  
Genome-wide methylation profiling was conducted on 5 clones, selected at 
random, from each of the four experimental test groups (mock- and cisplatin-
treated MLH1+ and MLH1- CP70 cells). DNA was extracted from these clones 
and 500 ng of each sample were bisulphite converted. Successful bisulphite-
conversion was then confirmed using the LINE-1 PCR and pyrosequencing. 
The LINE-1 pyrosequencing assay was designed to contain a bisulphite 
conversion check at the beginning of the assay. As all unmethylated cytosines 
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should be converted to uracils in a successful bisulphite conversion, the assay 
is designed to check for unconverted cytosines that are not part of a CpG site 
(ie. cytosines that cannot be methylated and, therefore, should always be 
converted to uracil, and then to thymine during PCR) by adding cytosine 
(indicating an unconverted cytosine) followed by thymine (indicating an 
unmethylated, successfully converted, cytosine) at the conversion test point. 
Successful bisulphite conversion is automatically determined by the 
pyrosequencing software based on the ratio of cytosine to thymine peaks 
detected, with no cytosine peak indicating complete bisulphite conversion. All 
samples passed the bisulphite conversion check and the standard inbuilt 
quality assurance checks (see chapter 2) and, therefore, were sent for 
analysis on the Infinium arrays by the UCL Genomics Microarray and High 
Throughput Sequencing Facility.  
 
4.3.2 Normalisation and background correction of array data 
Illumina Infinium HumanMethylation 450 BeadChips are methylation array 
chips that allow for the interrogation of over 480,000 CpG sites across the 
genome at single base pair resolution (Bibikova et al., 2011). Each chip holds 
up to 12 samples and multiple chips can be run in batches for the same 
experiment. The Infinium BeadChip platform is a two-colour assay and uses 
two types of probe technology to detect methylation, type I and type II. Type I 
probes use two bead types per CpG locus, one for the methylated and one for 
the unmethylated state. A red or green signal will be detected depending on 
which bead type is bound and extended, which in turn will depend on the 
methylation state of the queried locus. Type II probes use only one bead type 
 147 
per CpG locus and the colour of signal detected will depend on which base 
extends the probe. This again is dependent on the methylation state of the 
locus being queried. Red and green signals are detected when the base 
extension of each probe incorporates a dinitrophenol (DNP)- or biotin-labelled 
ddNTP. These are then stained with a fluorescent reagent called Superior 
Two-Color Master Mix and this staining results in fluorescent colour intensities 
being picked up by either the red or green detection channel. 
 
Raw data was provided by the UCL facility with methylation levels presented 
as β values, which represent the ratio of methylated probe intensity to total 
probe intensity (the sum of methylated and unmethylated probe intensities). 
These values lie between 0 and 1 and can be multiplied by 100 to be 
interpreted as methylation percentages. Before the data could be analysed, a 
series of pre-processing and quality control measures had to be carried out.  
 
Data was first normalised and background corrected to ensure that 
differences in channel intensities, and therefore β values, were due to 
differential methylation rather than errors in sample hybridisation to the 
BeadChips, or due to artifacts in the scanning of the BeadChips. The UCL 
genomics facility provided normalisation and background correction as part of 
the array service and they utilise internal control normalisation and negative 
control background correction methods built into the Genomestudio software 
package. The internal control normalisation method uses the first array 
sample as a reference and removes background noise, technical and 
systematic variation caused by the array technology. This is carried out for 
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both between-array and within-array normalisation, to ensure that samples on 
the same array and samples across different arrays are normalised. The 
negative control background correction method uses an estimate of 
background intensities via the median intensity of the 600+ negative control 
probes present on the chip. A median intensity value is calculated separately 
for the red and green colour channels. This correction helps to remove non-
specific signal from the total signal and it additionally corrects for between-
array artifacts relating to the array chemistry. 
 
4.3.3 Quality control checks on array data 
Once normalisation and background correction were carried out on the array 
data, several quality control measures were undertaken. Quality control was 
carried out using software-programming tool R, versions Toasted 
Marshmallow and Frisbee Sailing. Analysis coding produced individual plots 
for each set of control probes and all BeadChips and samples passed this 
quality control process.   
 
There are multiple control probes present on the BeadChips that can be 
checked for both red and green detection channels to assess the quality of 
samples and the performance of the assay. The sample-independent controls 
consider the efficiency of various steps in the assay, and the sample-
dependent controls consider the quality and efficiency of each sample 
individually. Sample-independent controls test the efficiency of the fluorescent 
staining step in both the red and green channels (figure 4.1 A and B), the 
extension efficiency of each nucleotide with a hairpin probe, which should 
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result in high signal from perfect matches and low signal from mismatches 
(figure 4.1 C and D), the efficiency of post-extension reaction stripping of the 
DNA (figure 4.1 E and F) and finally the efficiency of hybridisation (indicating 
the overall performance of the assay) using synthetic targets in place of 
amplified DNA (figure 4.1 G and H). 
 
Sample-dependent controls test the efficiency of the bisulphite conversion of 
sample DNA by testing bisulphite-induced C/T polymorphisms at non-CpG 
sites (figure 4.2 A and B), the specificity of methylation state detection through 
G/T mismatch controls for non-specific detection of methylation signal over 
unmethylated background (figure 4.2 C and D), the array background through 
the use of randomly permutated negative probe sequences that should not 
hybridise DNA (figure 4.2 E and F), and overall performance of the array 
assay from amplification to detection by querying a single nonpolymorphic 
base in a non-variable region of the bisulphite genome (figure 4.2 G and H). 
Sample signal intensities vary across the array due to differences in sample 
position on the beadchips, therefore sample spots tend to be distributed in 
increasing waves of signal intensity when looking across samples (and 
beadchips) from left to right. Samples are defined as failed if they differ more 
than 3 standard deviations from the rest of the samples, therefore spots on 
the following plots that are notably outliers would likely be failed samples. No 
samples failed these controls in this set of experiments.  
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Figure 4.1 All samples pass sample-independent quality controls 
Plots of red and green channel signal intensities per sample, with each 
sample represented by a spot, across BeadChips for: staining control probes 
(A and B), with spots marking high (turquoise) or background (blue) DNP 
signal and high (red) or background (green) biotin signal; extension control 
probes (C and D), with spots marking signal correlating to the extension of T 
(turquoise), A (red), G (blue) and C (green); target removal control probes (E 
and F), with spots indicating the signal after target removal of type I (green) 
and type II (red) probes; and hybridisation control probes (G and H), with 
spots indicating signal intensity for low (blue), medium (green) and high (red) 
hybridisation.  
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Figure 4.2 All samples pass sample-dependent quality controls 
Plots of red and green channel signal intensities per sample, with each 
sample represented by a spot, across BeadChips for; bisulphite conversion 
control probes (A and B) with spots indicating unconverted control for type I 
(blue) and type II (turquoise) probes and converted control for type I (red) and 
type II (green) probes; specificity control probes (C and D) with spots 
indicating type I perfectly matched (PM) (green) and mismatched (MM) 
(turquoise) probes and type II PM (red) and MM (blue) probes; negative 
control probes (E and F) with spots representing signal across different 
negative probes; and non-polymorphic control probes (G and H) with spots 
indicating signal intensity for A (red), C (green), G (blue), and T (turquoise) 
bases.  
 
4.3.4 Removal and imputation of probes with poor data 
After confirming all samples passed the primary quality control checks, 
detection p-values were screened for all probes and all samples. Detection p-
values are 1 minus the p-value calculated from the background model and 
these values are used to characterise the chance that signal for a given probe 
was distinguishable from negative controls. These values reflect the strength 
of DNA hybridisation over the background by comparing the intensity of CpG 
detection to that of negative control probes. When the detection p-value is not 
significant, i.e. is >0.05, this indicates problems with either bad probe design, 
poor hybridisation of the DNA or sample chromosomal abnormalities at the 
probe locus. For every probe with a detection p-value of >0.05 for any given 
sample, the methylation data related to that probe and sample was replaced 
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with an “NA”, as the methylation data is not deemed reliable. Probes that had 
more than 20 % non-significant detection p-values across all samples were 
removed, as this is an indicator that something is wrong with that probe or 
DNA region across samples. Similarly, samples that had more than 20 % non-
significant detection p-values across all probes were also removed as this 
indicates the sample is unreliable, possibly due to poor DNA hybridisation or 
quality. In this instance 13,509 probes (2.8 %) were removed due to poor 
detection p-values, leaving 472,068 probes to analyse. 
 
As the presence of multiple NAs presented difficulties in later processing and 
analysis, a function called Impute was used to fill NAs with β values. For a 
given probe with a β value of NA, impute uses contextual data from 
surrounding probes to predict a likely β value for that probe. As this method is 
an unreliable source of β value estimation, all probes deemed to be significant 
in later analyses were checked to ensure they were not subject to imputation 
at this stage. No imputed probes were carried forward as significant in further 
analysis, therefore this method only served to facilitate the successful running 
of analysis code, rather than to provide prediction-based data.  
 
4.3.5 Batch effect correction 
The next stage in the pre-processing of data was to correct for batch effect, 
due to the 20 samples being distributed across two BeadChips. Arrays are 
susceptible to batch effects through differences in experimental and 
laboratory conditions, experiment time and chip loading. As batch effect is a 
significant confounding factor in array data it was taken into consideration in 
 155 
the study design phase. Samples from all four experimental test groups were 
distributed across each BeadChip to ensure there was no batch effect-driven 
bias for one or two study arm(s). ComBat is a batch effect correction method 
that uses an empirical bayes procedure to adjust for batch. Methylation data is 
not normally distributed as it is constrained by upper and lower limits of 0 and 
1 in relation to complete lack or presence of methylation. As the ComBat 
method relies on the assumption of normal data distribution, the data first had 
to be transformed from a bi-modal distribution (common to β values due to the 
prevalence of readings at the extreme ends of the distribution relating to 
complete presence or absence of methylation) to a normalised distribution by 
converting β values to M values, through the following equation: 
 
 
 
ComBat was then run on M values and plots detailing the density of probes 
across β values for each BeadChip pre- and post-ComBat were created 
(figure 4.3). 
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Figure 4.3 Correction of batch effect using ComBat 
Distribution of probes by β value for chip 1 (red) and chip 2 (green) before (A) 
and after (B) ComBat batch correction. 
 
4.3.6 Probe type correction 
As the Infinium HumanMethylation 450 BeadChip arrays use two probe types, 
there are probe type biases that need to be corrected for. Type II probes have 
a lower dynamic range, that is, they are able to accurately detect a smaller 
range of methylation compared to type I probes, and they provide data that is 
typically less reproducible. These factors result in raw data exhibiting different 
distributions depending on which probe methylation values relate to 
(Dedeurwaerder et al., 2011). Peak-based correction is a method created to 
counter these probe type biases by normalizing type II probe data and 
returning it in a state more comparable to type I data (Dedeurwaerder et al., 
2011). Plots were created showing probe densities across the β value 
distribution for type I and type II probes pre- and post-peak base correction 
and type II probe distributions are seen to normalise to type I (figure 4.4). 
Following pre-processing and quality control of samples and probes, all 
samples passed QC across 472,068 CpG sites. 
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Figure 4.4 Correction of probe type bias through peak-based correction 
Distribution of probes by β value for type I (red) and type II (green) probes 
before (A) and after (B) peak-based correction. 
 
4.3.7 Confirmation of MLH1 methylation in clones  
To ensure cisplatin treatment or the cloning process had not altered the 
methylation, and therefore expression, of MLH1, probes relating to the MLH1 
gene were selected and methylation values were plotted across the gene. As 
expected, clones created from mock and cisplatin-treated MLH1-deficient 
cells were completely methylated across the MLH1 gene and transcription 
start site. Clones created from mock and cisplatin-treated MLH1-proficient 
cells displayed approximately 30 % to 60 % methylation across the start and 
middle of the gene, due to the presence of two methylated endogenous and 
one unmethylated exogenous copy of the gene (figure 4.5). These data 
confirmed that cisplatin treatment had not affected the methylation of MLH1 
as mock and cisplatin-treated clones from both cell lines displayed highly 
similar methylation levels across the gene.  
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Figure 4.5 Methylation across MLH1 gene 
β values across all MLH1-related probes plotted from 1035 bp downstream of 
transcription start site (indicated with arrow) to 57370 bp upstream, for 5 
mock- (red) and 5 cisplatin- (pink) treated MLH1+ clones and for 5 mock- 
(grey) and 5 cisplatin- (black) treated MLH1- clones.  
 
4.3.8 Differential MLH1 expression results in genome-wide methylation 
differences 
Significant differences were observed in the methylation of the parental cell 
lines, comparing mock-treated MLH1-proficient and MLH1-deficient clones 
(Figure 4.6). The volcano plot shows numerous significant bi-directional 
differentially methylated CpG sites between the two test groups, with 5.1 % 
(1.2 % hypermethylated, 3.9 % hypomethylated) of all CpG sites significantly 
different in MLH1-proficient compared to -deficient clones (Student’s t-test 
p<0.01). Of those CpG sites, there is a skewing of the distribution towards 
hypomethylated CpGs in MLH1-proficient clones; significantly differentially 
methylated CpGs were more than twice as likely (2.26 times as likely) to be 
hypomethylated than hypermethylated in MLH1-proficient clones (chi-squared 
p-value <2.2E-16, odds ratio: 2.262, 95 % confidence interval: 2.194 - 2.332) 
(table 4.1). 
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Figure 4.6 DNA methylation is highly divergent between MLH1-proficient 
and -deficient clones 
Each point represents the -log10 Student’s t-test p-value on the Y-axis and 
delta mean methylation as a percentage on the X-axis for 5 MLH1+ vs. 5 
MLH1- mock-treated clones for 472068 probes. Probes with a Student’s t-test 
p-value <0.01 are coloured blue (57,294 probes), probes with a Student’s t-
test p-value <0.01 and an absolute delta mean methylation of ≥20 % are 
coloured green (35,474 probes), and probes with a Student’s t-test p-value of 
<0.05 after Bonferroni correction for multiple testing are coloured red (175 
probes). 
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4.3.9 Short-term cisplatin treatment significantly alters gene-specific 
DNA methylation bi-directionally 
To assess the DNA methylation response to cisplatin treatment, mock treated 
clones were compared to cisplatin treated clones for both MLH1+ and MLH1- 
cell lines. Bi-directional changes in methylation were found in both MLH1-
deficient (0.44 % all probes significantly hypomethylated; 0.25 % all probes 
significantly hypermethylated) and MLH1-proficient clones (0.23 % of all 
probes significantly hypomethylated; 0.57 % of all probes significantly 
hypermethylated) (Student’s t-test p-value <0.01) (figures 4.7 and 4.8). 
Interestingly, cisplatin causes the distribution of significantly differentially 
methylated probes to be skewed towards hypermethylation in MLH1-proficient 
clones, with probes significantly aberrantly methylated being approximately 75 
% more likely to be hypermethylated than hypomethylated after treatment (chi 
squared p-value <2.2E-16, odds ratio: 1.768, 95 % confidence interval; 1.648 - 
1.899). Conversely, probes are skewed towards hypomethylation in MLH1-
deficient clones, with probes approximately 80 % more likely to be 
hypomethylated than hypermethylated after treatment (chi squared p-value 
<2.2E-16, odds ratio: 1.802, 95 % confidence interval; 1.678 - 1.936) (table 
4.1).  
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Figure 4.7 Cisplatin causes bi-directional methylation changes with a 
bias towards hypomethylation in MLH1-deficient clones 
Each point represents the -log10 Student’s t-test p-value on the Y-axis and 
delta mean methylation as a percentage on the X-axis for 5 mock- vs. 5 
cisplatin-treated MLH1-deficient clones for 472068 probes. Probes with a 
Student’s t-test p-value <0.05 are coloured blue (19,160 probes), probes with 
a Student’s t-test p-value <0.05 and an absolute delta methylation of ≥20 % 
are coloured green (2,947 probes), and probes with a Student’s t-test p-value 
of <0.05 after Bonferroni FDR correction for multiple testing are coloured red 
(5 probes). 
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Figure 4.8 Cisplatin causes bi-directional methylation changes with a 
bias towards hypermethylation in MLH1-proficient clones 
Each point represents the -log10 Student’s t-test p-value on the Y-axis and 
delta mean methylation as a percentage on the X-axis for 5 mock- vs. 5 
cisplatin-treated MLH1-proficient clones for 472068 probes. Probes with a 
Student’s t-test p-value <0.05 are coloured blue (20,913 probes), probes with 
a Student’s t-test p-value <0.05 and an absolute delta methylation of ≥20 % 
are coloured green (9,388 probes), and probes with a Student’s t-test p-value 
of <0.05 after Bonferroni FDR correction for multiple testing are coloured red 
(5 probes). 
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Table 4.1 Bias in methylation changes by test group 
Table showing direction, p-value, odds ratio and 95 % confidence intervals of 
bias in methylation changes between different test group. 
 
4.3.10 No gene or CpG island region biases were detected in MLH1-
related and cisplatin-induced methylation differences 
As methylation is highly variable, and has specific roles, in different regions of 
genes and of the genome, it was important to determine whether the 
methylation changes related to MLH1 expression or detected after cisplatin 
treatment were preferentially occurring in some of these regions. For 
example, methylation in an active gene is typically very low in the promoter 
region and then higher and/or more variable throughout the gene body (Ball et 
al., 2009; Jjingo et al., 2012; Lister et al., 2009) and methylation is also lower 
in CpG islands compared to CpG island shores (2kb up and downstream of 
CpG islands) and shelves (2-4kb up and downstream of CpG islands) (Deaton 
and Bird, 2011; Irizarry et al., 2008). If methylation changes were 
preferentially occurring in specific regions of genes or of the genome, this may 
indicate the mechanism(s) involved in the aberrant methylation response to 
platinum and may also elucidate possible epigenetic mechanisms leading to 
treatment resistance. 
 
Test group Direction of bias Chi-squared p-value Odds ratio 95 % Confidence intervals 
MLH1+ mock vs. MLH1- mock hypomethylation <1E-220 2.26215 2.194045 - 2.332598 
MLH1- mock vs. cisplatin hypomethylation 2.731473E-60 1.802431 1.678415 - 1.936462 
MLH1+ mock vs. cisplatin hypermethylation 2.423656E-57 1.963986 1.834561 - 2.103784 
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Average β values across clones of each test group were plotted for all CpG 
sites grouped into their gene-centric regions (figure 4.9 A-G) and CpG island 
regions (figure 4.10 A-F) of the genome, as annotated by the Illumina 450 
array. Significant differences in methylation due to MLH1 expression and 
cisplatin treatment were detected in all 11 regions analysed (Wilcoxon rank 
sum test p-value <0.05). This data suggest that the methylation changes are 
randomly distributed across the genome and are not biased towards any 
particular gene or CpG island-specific region(s).   
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Figure 4.9 part 2 
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Figure 4.9 Differences in MLH1 expression and cisplatin treatment cause 
significant changes in DNA methylation across all gene regions 
Boxplots of average methylation values (%) across all clones (n=5) of each 
test group for genome regions: TSS1500 (1500 bp upstream of the 
transcription start site (TSS)) (A), TSS200 (200 bp upstream of the TSS) (B), 
the 5’ untranslated region (UTR) (C), the 1st exon (D), the gene body (E) and 
the 3’ UTR (F). Significant differences are indicated with respective p-values 
from Wilcoxon rank sum tests. Significance was determined as p<0.05. Box 
and whisker plots represent the median (black line), the 25th-75th interquartile 
range (lower and upper segments of box, respectively), the minimum and 
maximum values (within set parameters - up to a maximum/minimum of 1.5 * 
length of the box) (whiskers) and outliers as points. The structure of gene 
regions running 5’ to 3’ is depicted in schematic diagram (G), image taken 
from MethHC online database of DNA Methylation and gene expression in 
human cancer (ISBLab, 2014).  
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Figure 4.10 Differences in MLH1 expression and cisplatin treatment 
cause significant changes in DNA methylation across all CpG island 
regions 
Boxplots of average methylation values (%) across all clones (n=5) of each 
test group for CpG island regions: north shelves (4kb-2kb upstream of CGI) 
(A), north shore (2kb upstream of CGI) (B), the CGI (C), south shore (2kb 
downstream of CGI) (D) and south shelves (2kb-4kb downstream of CGI) (E). 
Significant differences are indicated with respective p-values from Wilcoxon 
rank sum tests. Significance was determined as p<0.05. The structure of CGI 
regions running 5’ to 3’ is depicted in schematic diagram (F), image taken 
from MethHC online database of DNA Methylation and gene expression in 
human cancer (ISBLab, 2014). 
 
4.3.11 Bisulphite pyrosequencing validated four out of five significantly 
differentially methylated CpG sites 
As Infinium HumanMethylation 450 BeadChip arrays allow the measurement 
of methylation at over 480,000 CpG sites, significant changes detected 
between test groups across all of these sites may be wrongly detected due to 
the false discovery rate (FDR) of multiple hypothesis testing, or multiplicity. 
This is due to the fact that testing a high number of variables on a relatively 
low number of samples (for example ~470,000 variables and 5 vs. 5 samples) 
results in an increased likelihood of detecting a rare event that disproves the 
null hypothesis (for example that MLH1 status or platinum treatment does not 
result in differences or changes to DNA methylation). For this reason, it was 
important to validate the array data using a different methodology. Bisulphite 
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pyrosequencing is the gold standard for DNA methylation detection as it 
accurately and quantitatively detects differences in DNA methylation in mixed 
DNA samples in a manner that is more cost-effective and contains less biases 
than previously used bisulphite-PCR cloning and sequencing methods (Reed 
et al., 2010). Bisulphite pyrosequencing was, therefore, used as an alternative 
method to validate the array data. For this, ten CpG sites were selected based 
on having significant differential DNA methylation (p<0.001) and greater than 
20 % methylation difference between mock- and cisplatin-treated MLH1-
proficient clones in the array data (delta β >0.2). Of these ten CpG sites, five 
assays were successfully created, as 3 failed in primer design and two failed 
to produce PCR product, even after extensive troubleshooting. DNA samples 
from all clones were analysed by pyrosequencing at these five CpG sites. For 
validation, DNA samples from between 16-20 independent clones for each 
test group were used that were not assayed on the Infinium 
HumanMethylation450 BeadChip array. Boxplots were created depicting 
methylation values for each CpG site across the validation samples for all test 
groups. Array and pyrosequencing data from DNA samples of clones that 
were on the array were used to create correlation matrix plots comparing 
pyrosequencing and array data. BeadChip methylation values and bisulphite 
pyrosequencing methylation values of the array clones were highly correlated 
(R≥0.85) for four of the five CpG site assays (figure 4.11 A-D). The significant 
differences in methylation between mock-treated MLH1-deficient and MLH1-
proficient clones, and between MLH1-proficient mock- and cisplatin-treated 
clones detected by the BeadChips were also validated for these four sites 
(p<0.05).  
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Additional to the validation of these probes, a pattern was detected whereby 
cisplatin-treated MLH1-proficient clones adopted a methylation signature at 
each probe that closely resembled that of the MLH1-deficient mock- and 
cisplatin-treated clones. This was true for all probes, whether the cisplatin-
induced change was increasing (figure 4.11 B & D) or decreasing methylation 
(figure 4.11 A & C). 
 
One of the five validation CpG sites had a poorer correlation between Infinium 
HumanMethylation450 BeadChip methylation values and pyrosequencing 
methylation values (R=0.66) (figure 4.12) and also did not reach statistical 
significance to validate the difference between mock- and cisplatin-treated 
MLH1-proficient clones (p=0.0575), however there remained a trend towards 
decreasing methylation in MLH1-proficient cells after cisplatin treatment. 
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Figure 4.11 Bisulphite pyrosequencing validates four CpG sites  
Significant differential methylation of CpG sites cg12879242 (A), cg21625271  
(B), cg20634127 (C) and cg16115688 (D) were validated by bisulphite 
pyrosequencing. For each CpG site this figure shows a boxplot of % 
methylation for the 20 clones from the Infinium HumanMethylation450 
BeadChip experiment (left panel), the linear model and correlation (including 
R correlation value) between BeadChip methylation % and pyrosequencing 
methylation % values for the same 20 clones (middle panel), and a boxplot of 
the pyrosequencing methylation values for the validation clones for each test 
group (MLH1- mock-treated n=19, MLH1- cisplatin-treated n=19, MLH1+ 
mock-treated n=20, MLH1+ cisplatin-treated n=16) (right panel). P-values 
were calculated using the Wilcoxon rank sum test. Significance was 
determined as p<0.05. 
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Figure 4.12 Bisulphite pyrosequencing failed to validate one CpG site  
Significant differential methylation of CpG site cg20674248 was not validated 
by bisulphite pyrosequencing. This figure shows a boxplot of methylation 
values for the 20 clones from the Infinium HumanMethylation450 BeadChip 
experiment (left panel), the linear model and correlation (including R 
correlation value) between BeadChip methylation values and pyrosequencing 
methylation values for the same 20 clones (middle panel), and a boxplot of 
the pyrosequencing methylation values for the validation clones for each test 
group (MLH1- mock-treated n=19, MLH1- cisplatin-treated n=19, MLH1+ 
mock-treated n=20, MLH1+ cisplatin-treated n=16) (right panel). P-values 
were calculated using the Wilcoxon rank sum test. Significance was 
determined as p<0.05. 
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4.3.12 Expanded test set to increase statistical power  
Given that the findings from both the preliminary LINE-1 methylation analysis 
and the small test set of Infinium HumanMethylation450 BeadChip analysis on 
groups of five clones demonstrated that DNA methylation is significantly 
altered in cell lines after cisplatin-induced DNA damage, and differential MLH1 
expression may also contribute to differential DNA methylation, the Infinium 
HumanMethylation450 BeadChip test set was expanded to increase the 
power of detection of statistical differences between test groups. DNA 
samples from a further six clones for each test group were prepared and sent 
to the UCL genomics unit for analysis. Data from this second experiment were 
subject to the same quality control and pre-processing protocols as described 
for the first experiment, (supplementary figures 1-4) and then the data for both 
experiments were combined to address the same question of cisplatin-
induced effects on DNA methylation. All samples from the second batch 
passed QC, and 7.9 % of probes were removed due to having > 20 % fail 
rate, leaving 447,199 probes from this batch. Once the original and expanded 
data sets were combined, non-overlapping probes were also removed, 
leaving 446,681 probes to analyse. 
 
4.3.13 Differential MLH1 expression results in bi-directional differential 
methylation patterns in expanded test set clones 
Having combined the data from the first and second Infinium 
HumanMethylation 450 BeadChip experiments, the combined data was 
analysed using the two-tailed Student’s t-test to determine whether there were 
significant differences in DNA methylation between mock-treated MLH1-
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expressing and -non-expressing clones. Volcano plots were created 
displaying the -log p-value from the Student’s t-test for each probe against the 
mean difference in methylation between clones of the two test groups (figure 
4.13). Over 12 % of probes were significantly differentially methylated 
between these two test groups, with 60 % of those probes hypermethylated in 
MLH1-deficient CP70 clones compared to MLH1-proficient clones. This bias 
toward hypermethylation was statistically significant (odds ratio 1.34, 95 % 
C.I.s 1.31-1.36, chi-squared p-value of 3.4E-219) (table 4.2).  
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Figure 4.13 MLH1-expressing clones have significantly more 
hypomethylated probes than MLH1-non-expressing clones 
Each point represents the -log10 Student’s t-test p-value on the Y-axis and 
delta mean methylation as a percentage on the X-axis of 11 MLH1-proficient 
vs. 11 MLH1-deficient mock-treated clones for 446681 probes. Probes with a 
Student’s t-test p-value <0.01 are coloured blue (54,942 probes), probes with 
a Student’s t-test p-value <0.01 and an absolute delta mean methylation of 
≥20 % are coloured green (40,001 probes), and probes with a Student’s t-test 
p-value of <0.01 after Bonferroni FDR correction for multiple testing are 
coloured red (3,305 probes). 
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4.3.14 Cisplatin treatment causes significant bi-directional methylation 
changes in MLH1-proficient and -deficient clones with a bias towards 
hypermethylation 
The combined data was analysed to determine the effect of cisplatin 
treatment on DNA methylation for MLH1-deficient and MLH1-proficient CP70 
clones. Both sets of clones exhibited significant bi-directional changes in DNA 
methylation after cisplatin treatment, and in both sets of clones there was a 
statistically significant bias towards hypermethylation, with significantly 
differentially methylated probes in cisplatin-treated MLH1-deficient clones 
approximately two thirds (66 %) more likely, and in cisplatin-treated MLH1-
proficient clones approximately twice (102 %) as likely, to be hypermethylated 
than hypomethylated (MLH1- odds ratio 1.66, 95 % C.I.s 1.58-1.76, chi-
squared p-value=6.2E-77, MLH1+ odds ratio 2.02, 95 % C.I.s 1.92-2.13, chi-
squared p-value=2.2E-165) (figures 4.14 and 4.15, table 4.2). The difference in 
odds ratio between cisplatin-treated MLH1-deficient and -proficient clones is 
also statistically significant, with MLH1-proficient clones approximately a 
quarter (24 %) more likely to undergo hypermethylation of a given probe 
compared to MLH1-deficient clones (odds ratio 1.24, C.I.s 1.19-1.29, chi-
squared p-value 2.2E-25).  
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Figure 4.14 Cisplatin causes bi-directional methylation changes with a 
bias towards hypermethylation in MLH1-deficient clones 
Each point represents the -log10 Student’s t-test p-value on the Y-axis and 
delta methylation as a percentage on the X-axis for 11 mock- vs. 11 cisplatin-
treated MLH1-deficient clones for 446681 probes. Probes with a Student’s t-
test p-value <0.05 are coloured blue (32,826 probes), probes with a Student’s 
t-test p-value <0.05 and an absolute delta mean methylation of ≥20 % are 
coloured green (6,572 probes), and probes with a Student’s t-test p-value of 
<0.05 after Bonferroni FDR correction for multiple testing are coloured red (0 
probes). 
  
-lo
g1
0 
p-
va
lu
e 
0 
1 
2 
4 
   
   
   
 
-40           0 40 
Difference in methylation (%) 
p<=0.01 
Δ methylation >= 20% increase Δ methylation >= 20% decrease 
-20 20 
5 
3 
 184 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Cisplatin causes bi-directional methylation changes with a 
bias towards hypermethylation in MLH1-proficient clones 
Each point represents the -log10 Student’s t-test p-value on the Y-axis and 
delta mean methylation as a percentage on the X-axis for 11 mock- vs. 11 
cisplatin-treated MLH1-proficient clones for 446681 probes. Probes with a 
Student’s t-test p-value <0.05 are coloured blue (26,538 probes), probes with 
a Student’s t-test p-value <0.05 and an absolute delta methylation of ≥20 % 
are coloured green (8,577 probes), and probes with a Student’s t-test p-value 
of <0.05 after Bonferroni FDR correction for multiple testing are coloured red 
(1 clone). 
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Table 4.2 Bias in methylation changes by test group 
Table showing direction, p-value, odds ratio and 95 % confidence intervals of 
bias in methylation changes between different test group. 
 
4.3.15 Cisplatin-induced methylation changes in MLH1-proficient cell 
lines mimic the MLH1-deficiency phenotype 
As MLH1-expressing clones displayed a higher number of significant 
hypermethylation changes after cisplatin treatment than MLH1-deficient 
clones and the pattern of methylation changes detected in the validation 
mimicked MLH1-deficient clone methylation levels, this analysis was 
expanded to include all highly significant probes. Using unsupervised 
clustering of probes that were significantly hypermethylated (p<0.001) (figure 
4.16 A) or significantly hypomethylated (p<0.001) (figure 4.16 B) in MLH1-
proficient cisplatin- vs. mock-treated clones, the MLH1-deficient mock- and 
cisplatin-treated clones were clustered together in non-discrete groups, i.e. 
the mock- and cisplatin-treatment arms did not separate into two clusters, 
while MLH1-proficient mock treated clones clustered together in a single 
discrete group. For hypermethylated probes, the majority (7/11) of MLH1-
proficient cisplatin-treated clones clustered as a discrete group in the middle 
of the MLH1-deficient mock- and cisplatin-treated clone clusters and were 
grouped in the MLH1-deficient arm of the dendrogram (figure 4.16 A). For 
Test group Direction of bias Chi-squared p-value Odds ratio 95 % Confidence intervals 
MLH1+ mock vs. MLH1- mock hypomethylation 3.4E-219 1.339762 1.315607 - 1.364383 
MLH1- mock vs. cisplatin hypermethylation 6.2E-77 1.66482 1.576965 - 1.758252 
MLH1+ mock vs. cisplatin hypermethylation 2.2E-165 2.020585 1.919838 - 2.172728 
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hypomethylated probes, the majority (8/11) of MLH1-proficient cisplatin-
treated clones clustered in a discrete group between the MLH1-proficient 
mock-treated clone cluster and the MLH1-deficient mock- and cisplatin-
treated clone clusters, again as part of the MLH1-deficient arm of the 
dendrogram (figure 4.16 B). This analysis shows that cisplatin-treatment 
caused MLH1-proficient clones to adopt MLH1-deficient-like methylation 
phenotypes across the most significantly hyper- and hypomethylated probes.  
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Figure 4.16 Cisplatin causes MLH1-proficient clones to adopt MLH1-
deficient-like methylation phenotypes 
Heatmaps with Y-axis showing hierarchical clustering dendrogram of probes 
significantly differentially hypermethylated (p<0.001) (A) (n=831) and 
hypomethylated (B) (n=384) between MLH1-proficient mock- and cisplatin-
treated clones. X-axis shows hierarchical clustering dendrogram of each clone 
(n=11 for each test group) based on their Infinium HumanMethylation450 
BeadChip β-values for each probe. Blue indicates low levels of methylation 
and pink indicates high levels of methylation. Sample key: MLH1+ mock-
treated = green, MLH1+ cisplatin-treated = blue, MLH1- mock-treated = black, 
MLH1- cisplatin-treated = red. 
 
4.3.16 Absence of sequence specificity in cisplatin-induced aberrant 
methylation 
To determine whether certain DNA sequence motifs were preferentially 
undergoing methylation changes subsequent to cisplatin treatment, probe 
sequences were analysed using WebLogo, an online tool that creates 
consensus logos displaying bases at different sizes based on the frequency of 
that base at a given position in a batch of analysed sequences (Crooks et al., 
2004a; Crooks et al., 2004b). Consensus logos were created for the 500 most 
significantly differentially methylated probes in MLH1-deficient (figure 4.17 A & 
B) and MLH1-proficient (figure 4.17 C & D) clones after cisplatin treatment. 
The source sequence for each probe was used in creating the logos, as these 
sequences cover 60 bases up- and down-stream of the probe CpG site, 
allowing the detection of sequence conservation relating to CpG methylation 
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changes on either site of the CpG site. In both cases, the only sequence 
conservation detected was the CpG site itself, located in the middle of all 
probe sequences (figure 4.17 A & C). The CpG sites were then removed from 
the sequences to detect any less-conserved sequence(s) possibly being 
masked by the 100 % conservation of the CpG site. In both cases, no 
significant consensus sequence could be detected when using the default Y-
axis scale, and although localised consensus sequences of C and G bases 
were detected when limiting the Y-axis scale to 0.1 bits, with a predominance 
of a C one base before the CpG site and a G one base after (CCGG motif), 
this level of resolution indicated that these sequences were not highly 
conserved (figure 4.17 B & D).  
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Figure 4.17 Consensus logos indicate limited sequence bias in 
differentially methylated CpG regions 
Consensus logos indicate sequence conservation (height of base stacks) and 
frequency of bases (height of base in stack) in bits on the Y-axis for bases 
across probe source sequences that were the 500 most significantly 
differentially methylated in MLH1-deficient clones (A and B) and MLH1-
proficient clones (C and D) after cisplatin treatment (n=11 for each test group). 
Logos A and C represent consensus sequences with the probe CpG site 
present; logos B and D represent consensus sequences with the probe CpG 
site masked and Y-axis constrained to a maximum of 0.1 bits.  
 
4.3.17 Cisplatin-induced methylation changes in euchromatin versus 
heterochromatin  
Chromatin state is directly linked to DNA methylation, with highly methylated 
regions of DNA typically more condensed in heterochromatin to promote gene 
repression and less methylated regions typically less condensed in 
euchromatin form (Urnov and Wolffe, 2001; Wolffe and Matzke, 1999). As 
cisplatin was found to induce bi-directional methylation changes with a bias 
toward hypermethylation, analysis was carried out to determine whether these 
damage-induced methylation changes were occurring at regions with 
particular chromatin states. Data was retrieved from the University of 
California, Santa Cruz (UCSC) genome browser containing the approximate 
chromatin structure of each region of the genome through the giemsa staining 
patterns of that genomic region, known as G-banding. Giemsa stain is used to 
highlight chromosome banding, as it is a stain with an affinity to adenine-
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thymine bonding. Chromatin regions with higher densities of A-T bases are 
typically more condensed regions of heterochromatin, where G-banding is 
darkest. Less condensed euchromatin typically has a higher density of C-G 
pairs and a lower density of A-T pairs resulting in lighter G-banding. All array 
probes were annotated according to their UCSC G-banding profile and were 
then grouped into G-positive (heterochromatic) or G-negative (euchromatic) 
probes. Comparisons were drawn between the number of probes that were 
unaltered and those that were significantly hypomethylated, and between 
those that were unaltered and those that were significantly hypermethylated 
between MLH1-proficient and MLH1-deficient mock-treated clones, MLH1-
deficient mock- and cisplatin-treated clones and MLH1-proficient mock- and 
cisplatin treated clones.  
 
In the comparison of mock-treated MLH1-proficient and -deficient clones, 
MLH1-deficiency preferentially caused increased methylation in 
heterochromatin and decreased methylation in euchromatin (p<1e-10). 
Cisplatin was found to preferentially increase methylation in heterochromatin 
(p<0.001) in MLH1-proficient cells. In contrast, in the MLH1-deficient cells, 
cisplatin preferentially decreased methylation in heterochromatin and 
increased it in euchromatin (p<1e-10) (figure 4.18). These biases in 
methylation changes are summarised in a schematic diagram of chromatin 
(figure 4.18 D). 
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A 
B 
C 
D 
MLH1+ mock vs. MLH1- mock G-stain Odds ratio Confidence intervals Chi Squared p-value 
Hypomethylation 
Heterochromatin 1.25 1.227 - 1.274 2.98E-120 
Euchromatin 1   NA   NA 
Hypermethylation 
Heterochromatin 1 NA NA 
Euchromatin 1.08   1.06 - 1.11   1.07E-11 
MLH1- mock vs. cisplatin G-stain Odds ratio Confidence intervals Chi Squared p-value 
Hypomethylation 
Heterochromatin 1.16 1.12 - 1.21 5.36E-13 
Euchromatin 1 NA NA 
Hypermethylation 
Heterochromatin 1 NA NA 
Euchromatin 1.11 1.07 - 1.14 3.41E-12 
MLH1+ mock vs. cisplatin G-stain Odds ratio Confidence intervals Chi Squared p-value 
Hypomethylation 
Heterochromatin 1.04 0.99 - 1.09 0.103 
Euchromatin 1 NA NA 
Hypermethylation 
Heterochromatin 1.05 1.02 - 1.09 0.00078 
Euchromatin 1 NA NA 
MLH1- MLH1+ 
+ cisplatin 
MLH1- 
+ cisplatin 
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Figure 4.18 Chromatin bias data tables and schematic diagram 
Tables showing the odds ratios, 95 % confidence intervals and chi-squared p-
values of the methylation bias in heterochromatin and euchromatin for mock-
treated MLH1-proficient vs. -deficient clones (A), mock- vs. cisplatin-treated 
MLH1-proficient clones (B) and mock- vs. cisplatin-treated MLH1-deficient 
clones (C) (n=11 for each test group). Schematic representation of chromatin 
bias of methylation changes (D) depicts heterochromatin as dark bands and 
euchromatin as light bands. Arrows pointing up represent hypermethylation 
and arrows pointing down represent hypomethylation. Red or green coloured 
arrows represent significant (p<0.05) bias, black arrows represent non-
significant bias. 
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4.4 Discussion 
The work in this chapter has shown that cisplatin induces bi-directional DNA 
methylation changes in both MLH1-proficient and -deficient cell lines. 
Significantly more methylation changes occurred in MLH1-proficient cells 
post-cisplatin treatment, and although cisplatin-induced changes occurred bi-
directionally in all clones, there was a significant bias toward hypermethylation 
in both cell types. The prevalence of bi-directional methylation changes is in 
agreement with other studies that show that DNA damage induced by double 
strand breaks (DSBs), oxidative stress and IR can result in both 
hypomethylation and hypermethylation of the DNA local to the damage site(s) 
(Antwih et al., 2013; Cuozzo et al., 2007; Kaup et al., 2006; Lee et al., 2012; 
O'Hagan et al., 2011). 
 
Significant methylation differences were observed between the mock-treated 
MLH1-proficient and -deficient cells with a bias towards hypermethylation in 
the absence of MLH1. These methylation changes were validated using 
bisulphite pyrosequencing, and they were found to be sufficient to differentiate 
these two groups when using unsupervised clustering. These differences in 
methylation replicate the effect observed with the analysis of the genome-
wide repetitive element LINE-1 (see chapter 3). As described in the previous 
chapter, although it is possible that these difference are simply due to clonal 
variation in the derivation of these lines, a concept eluded to in the genetic 
heterogeneity of clonal cultures (Chess, 2012; Gimelbrant et al., 2007; 
Neildez-Nguyen et al., 2008; Tanasijevic et al., 2009), it would therefore be 
expected that a similar level of methylation variability would be detected 
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between any two clones within a subgroup in this experiment. As none of 
these differences have been demonstrated between clones within a treatment 
group, it is more plausible that the difference in MLH1 expression is causing 
the methylation variability detected between these lines. Of particular interest 
was the observation that cisplatin treatment in MLH1-proficient cells 
repeatedly resulted in methylation patterns that more closely resembled 
MLH1-deficient cells. Given that the aberrant methylation patterning of 
cisplatin-treated MLH1-proficient clones is due to cisplatin treatment, and 
therefore DNA damage and/or repair, it follows that the observed methylation 
pattern of mock-treated MLH1-deficient clones may also be due to DNA 
damage and/or repair, due to a loss of mismatch repair that is sufficient to 
create a build up of endogenous DNA damage over time in culture. This loss 
could lead to accumulation of oxidative damage (Glaab et al., 2001; Piao et 
al., 2013; Russo et al., 2007; Shockley et al., 2013) or mismatches leading to 
replication fork stalling and strand breaks, which then undergo different forms 
of DNA repair such as BER, DSBR or non-homologous end joining (NHEJ) 
(Iraqui et al., 2012; Lambert et al., 2005). This may cause changes to DNA 
methylation (Cuozzo et al., 2007; O'Hagan et al., 2008; O'Hagan et al., 2011) 
resulting in the methylation phenotype observed. The striking similarity 
between cisplatin-treated MLH1-proficient clones and mock-treated MLH1-
deficient clones could suggest a general DNA damage and/or repair 
methylation phenotype. As clones deficient in MLH1 already display this 
methylation phenotype, additional damage induced through cisplatin 
treatment is perhaps harder to detect due to the genome already displaying a 
DNA damage methylation signature. This could also potentially explain the 
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lower number of methylation changes occurring in cisplatin-treated MLH1-
deficient clones, as some changes may be masked by the original methylation 
pattern or there may be less areas of undamaged genome able to display new 
cisplatin-induced changes. In summary, these data suggest that cisplatin-
induced methylation changes replicate the MMR-deficient epigenetic 
phenotype. 
 
There is an alternative, and not mutually exclusive, hypothesis explaining the 
presence, but reduced numbers, of cisplatin-induced methylation changes in 
MLH1-deficient clones - that all cisplatin lesions that are repaired have the 
potential to result in methylation changes and MLH1 is required for/involved in 
the repair of some, but not all, cisplatin lesions. Indeed, MLH1 has a different 
role in damage repair and signaling for intrastrand crosslinks and ICLs, and it 
is therefore possible that some lesions are processed in the absence of 
MLH1, resulting in methylation changes, while others requires MLH1 for repair 
(Peng et al., 2007; Peng et al., 2014; Xie et al., 2010). NER of intrastrand 
adducts may contribute to the cisplatin-induced methylation response in 
MMR-deficient cells, perhaps leading to passive loss of methylation through 
excision and re-synthesis of the surrounding 24-34 nucleotides (de Laat et al., 
1999) and gains of methylation during synthesis repair through the 
recruitment of DNMTs to the damage sites, possibly via PCNA interactions 
(Chuang et al., 1997; Ha et al., 2011; Mortusewicz et al., 2005; Overmeer et 
al., 2010). Similarly, ICLs have been shown to require MLH1 for switching 
from recombination repair to lesion bypass (Xie et al., 2010), therefore the 
absence of MLH1 may result in increased recombination repair of ICLs and 
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DSB-induced aberrant methylation (Cuozzo et al., 2007; Lee et al., 2010). 
Lesions requiring MLH1 for binding or signaling to mediate repair, such as 
compound intrastrand crosslinks present at S phase, may not result in 
aberrant methylation as these lesions are bypassed rather than repaired 
(Anthoney et al., 1996; Duckett et al., 1996; Fink et al., 1996; Mello et al., 
1996; van Boom et al., 1996; Yamada et al., 1997) (figures 4.19 and 4.20). 
Therefore, the collective number of lesions repaired by non-MMR pathways 
and those repaired differently due to loss of MMR should equate to the 
number of aberrant methylation events in MMR-deficient cells, and MMR-
proficient cells would be expected to have an increased number of aberrant 
methylation events as MMR-dependent repair of lesions likely outnumber 
those repaired due to loss of MMR (e.g. recombination ICL repair) (Eastman, 
1987; Gelasco and Lippard, 1998; Huang et al., 1995; Takahara et al., 1995). 
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Figure 4.19 Mechanism for cisplatin-induced methylation changes in 
MLH1-deficient cells 
Diagram showing proposed types of platinum damage repair that can lead to 
gain, loss or no change in DNA methylation in the absence of MLH1. 
Intrastrand crosslinks in the absence of MMR do not cause replication stalling. 
Lesion bypass allows lesion persistence and no change in DNA methylation. 
NER of intrastrand crosslinks could lead to loss of methylation if methylated 
CpGs are removed along with the crosslink, and could lead to gains of 
methylation if DNMTs are recruited at the DNA synthesis step. ICL repair in 
the absence of MLH1 leads to replication stalling and double strand break 
formation. This can then be resolved by HR DSBR, which in turn could lead to 
gains in DNA methylation when DNMTs are recruited at the DNA synthesis 
step.  
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Figure 4.20 Mechanism for cisplatin-induced methylation changes in 
MLH1-proficient cells 
Diagram showing proposed types of platinum damage repair that can lead to 
gain, loss or no change in DNA methylation in MLH1-proficient cells. 
Intrastrand crosslinks are recognised by MLH1/MMR leading to replication 
stalling and double strand break formation. This can then be resolved by HR 
DSBR, which in turn could lead to gains in DNA methylation when DNMTs are 
recruited at the DNA synthesis step. NER of intrastrand crosslinks could lead 
to loss of methylation if methylated CpGs are removed along with the 
crosslink, and could lead to gains of methylation if DNMTs are recruited at the 
DNA synthesis step. ICL repair in the presence of MLH1 leads to lesion 
bypass mediated by polymerase η and methylation would not be altered. 
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Given that the MLH1+ and MLH1- cell lines were derived from cell line CP70, 
which lacks MLH1 expression, the difference in DNA methylation between the 
MLH1+ and MLH1- cells could also be viewed as hypomethylation occurring 
as the result of the reintroduction of MLH1. The use of another isogenic pair of 
cell lines differentially expressing MLH1, such as HCT116, to measure MLH1-
related DNA methylation differences may be useful in clarifying whether the 
differences detected in this study relate specifically to MLH1 expression or are 
possibly a result of the chromosomal transfer technique used to derive the 
MLH1+ and MLH1- lines. A further explanation for the differences in 
methylation in these two lines could be that the cisplatin selection process 
used to create the CP70 cell line from A2780 resulted in the upregulation of 
DNMT protein expression in the CP70 cell line. Expression data comparing 
A2780 and CP70 was available from Zeller et al., 2012 and was analysed by 
Erick Loomis using GEO2R (Zeller et al., 2012). This data showed no 
significant change in expression of DNMT1, DNMT3A, DNMT3B or DNMTL, 
therefore, the upregulation of a DNMT protein is not influencing the 
methylation of the CP70 cell line (Erick Loomis, personal communication, 
2015). 
 
It is interesting to note that the bias in methylation changes in MLH1- clones 
caused by cisplatin treatment changes from hypomethylation in the first batch 
of clonal data to hypermethylation when the first set of data and the expanded 
test set data is combined. It is possible that the first test set used was too 
small a number of samples to get a true reflection of the incidence and bias of 
cisplatin-induced DNA methylation changes and that the expanded data set 
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better captures the number of cisplatin-induced changes. It is also possible 
that the original set of clones tested possessed a higher number of 
hypomethylated CpG sites purely by chance and that this bias was diluted out 
when further clones were included. Conducting the array experiments on all 
clones created from mock- and cisplatin-treatment would have provided the 
best possible understanding of the number and directional bias of cisplatin-
induced methylation changes, however financial constraints prevented this 
from being a viable option at the time of research. 
 
Methylation differences between MLH1+ and MLH1- clones, and those 
induced by cisplatin treatment occurred across all regions of the genome 
when stratified according to gene or CGI region. Importantly, averaging of 
DNA methylation across these regions demonstrated methylation levels in 
agreement with the literature, where areas around CGIs and the promoter of 
genes are typically less methylated than gene bodies or CGI-distal regions, 
and where more distal genomic regions possess intermediate levels of DNA 
methylation (Jabbari and Bernardi, 2004; Stadler et al., 2011). 
 
Mock-treated MLH1-deficient clones and cisplatin-treated MLH1-proficient 
clones appeared to preferentially undergo hypermethylation at 
heterochromatic regions of the genome, whereas cisplatin-treated MLH1-
deficient clones appeared to preferentially undergo hypermethylation at 
euchromatic regions. The MLH1-deficiency-induced and MLH1-proficient 
cisplatin-induced methylation bias is surprising, given that there is an 
increased susceptibility of unmethylated regions to DNA damage (Falk et al., 
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2008) and an improved proficiency of repair in these regions (Lorat et al., 
2012). Biases in both hyper- and hypomethylation would, therefore, be 
expected in euchromatic regions. Interestingly, this bias in hypermethylation in 
heterochromatin also contradicts what has been previously shown in cell 
lines, where hypomethylation occurs in epigenetically suppressed genes and 
hypermethylation at low expression genes upon oxidative damage induction 
(O'Hagan et al., 2011). The authors suggest this effect is due to migration of 
methylating proteins away from suppressed regions, leading to a passive loss 
of methylation at repressed sites. This hypothesis could apply to the situation 
detailed here for MLH1-deficient cisplatin-treated cells, but disagrees with the 
rest of the clone data. Alternatively, the data may be simply explained by the 
limitations of this work. Although statistically significant, the biases in 
chromatin regions were not calculated based on chromatin profiling of the 
clones used in these experiments, but rather they were based on the 
chromatin mapping of reference genomes detailed on the UCSC genome 
browser. It is, therefore, possible that the data does not reflect the true 
situation within these cells, and the assumption that cells differing in MLH1-
status have the same giemsa banding may also be incorrect. Further, the 
biases shown here are small, ranging from 5-25 %, and therefore may reflect 
only subtle changes in DNA repair and/or methylation protein dynamics and/or 
localisation. 
 
Finally, cisplatin is known to bind to non-DNA nucleophiles including proteins 
(Barnes and Lippard, 2004; Reedijk, 2003). It is, therefore, possible that 
cisplatin is binding to and interfering with proteins involved in DNA damage 
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signaling, DNA damage repair and/or DNA methylation and that this leads to 
the DNA methylation changes described in this thesis. Immunoprecipitation 
experiments to pull down cisplatin and proteins it is bound to, followed by 
mass spectrometry, could be used in an attempt to identify which, if any, 
proteins cisplatin binds to in order to assess the likely involvement of 
cisplatin:protein interactions in the methylation response to cisplatin. 
 
4.5 Future work 
At this stage, the role of MLH1 in the epigenetic response to cisplatin-induced 
DNA damage and repair remains unclear. There are significant differences in 
the magnitude of methylation response between MLH1-proficient and -
deficient clones, however this difference cannot be unequivocally linked to the 
role of MLH1 or MMR in the cisplatin epigenetic response. It is quite possible 
that the difference in number of methylation changes is due to the fact that 
some of those changes require MLH1 or MMR either in a binding, signaling or 
repair pathway role, however it is also viable that these differences are linked 
to the differences in DNA methylation between the MLH1+ and MLH1- cell 
lines detailed previously. The difficulty in resolving these hypotheses is that 
any deficiency in a DNA repair pathway could be linked to increases in 
endogenous DNA damage, therefore specifying the exact role of a given 
protein or repair pathway in an epigenetic response to damage will always be 
confounded by this. An experimental design utilising an inducible repair 
protein construct, such as the HEK293T Lα cell line (a human embryonic 
kidney cell line, normally epigenetically silencing MLH1, containing an MLH1 
expression cassette connected to a tetracycline-inducible system for switching 
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MLH1-expression off (Cejka et al., 2003)) would be one possible method to 
confirm the direct involvement of MLH1 in the mechanism of damage-induced 
methylation changes. A range of short- and long-term experiments altering the 
temporal expression of MLH1 in the presence or absence of cisplatin 
treatment would be required to assess the effect of loss of MLH1 on both 
endogenous DNA methylation changes and on cisplatin-induced methylation 
changes. This would allow a better understanding of the role of MLH1 and/or 
MMR in the damage response mechanism. Due to the role of MLH1 in 
cisplatin lesion recognition through the BRCA-FA pathway (Peng et al., 2007; 
Peng et al., 2014; Xie et al., 2010), possibly in the absence of MMR, it is of 
additional importance to repeat similar experiments using cells differentially 
expressing alternative mismatch repair genes, such as using MSH6 or PMS2-
proficient and deficient cells or indeed multiply deficient cells, to further 
separate the role of MLH1 and the role of MMR in this process. 
 
Experimentation using different drugs to invoke lesions specifically repaired 
by other DNA repair pathways, such as the use of UV or 4-Nitroquinoline 1-
oxide (4NQO) to induce lesions repaired by NER and the use of gemcitabine 
or mitomycin C to induce damage repaired by HRR could also help to 
determine the roles of the various repair pathways in damage-induced DNA 
methylation changes. The use of these drugs or treatments on the MLH1+ 
and MLH1- cell lines may also help in establishing the 
involvement/requirement of MMR for the damage-induced methylation 
response related to the NER and HRR pathways.  
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4.6 Summary 
In summary, this chapter explored the epigenetic consequences of cisplatin-
induced DNA damage in a preliminary and an expanded test set of MLH1+ 
and MLH1- CP70 clones using high-throughput Infinium 
HumanMethylation450 BeadChip arrays. Bi-directional cisplatin-induced 
differences in methylation were detected in MLH1-expressing and -non-
expressing clones, with more cisplatin induced methylation changes detected 
in MLH1-expressing cells. Methylation changes were biased towards 
hypermethylation and occurred across all regions of the genome. Methylation 
changes displayed differential biases in chromatin structure for MLH1-
expressing and -non-expressing clones. Significant differences in methylation 
were also detected between mock-treated MLH1-expressing and -non-
expressing clones. These differences were biased towards hypermethylation 
in the MLH1-deficient clones, and these changes occurred in all regions of the 
genome. The methylation changes in these clones showed the same 
chromatin bias as cisplatin-treated MLH1-expressing clones. Finally, cisplatin-
induced methylation patterning in MLH1-expressing cells displayed strong 
similarity to the methylation patterns of mock-treated MLH1-deficient clones. 
These findings provide support for the hypothesis that cisplatin as a 
chemotherapy agent induces aberrant methylation in tumours that may lead to 
acquired cisplatin resistance (Zeller et al., 2012).  
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Chapter 5: 
Infinium methylation array analysis on 
presentation and relapse SCOTROC1 
blood PBMC DNA samples 
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5.1 Introduction 
Having found in the MLH1-proficient and -deficient CP70 cancer cell line 
models that a short-term 72 hour IC95 concentration of cisplatin confers 
significant changes to DNA methylation, it was important to investigate the 
epigenetic effects of DNA damage induced by platinum in a clinical setting. 
Ovarian cancer is a disease where the first line chemotherapeutic treatment 
regimen consists of a combined therapy of a platinum-based drug, 
carboplatin, and a taxane, paclitaxel. Carboplatin is a platinum-based DNA 
damaging agent with a similar structure to that of cisplatin and, like cisplatin, 
induces DNA damage through hydrolysis, resulting in binding to two adjacent 
guanine bases in DNA (Reedijk, 1987). 
 
Paclitaxel was the first member of the taxane family of drugs (compounds 
derived from trees of the taxus (yew) genus) to be discovered through the 
National Cancer Institute’s plant screening programme, where thousands of 
plants were assessed for anti-cancer properties (Wani et al., 1971). The 
mechanism of action for paclitaxel is related to its ability to bind the beta-
tubulin subunit of microtubules, which causes them to polymerise and form 
highly stable non-functional structures (Manfredi et al., 1982; Schiff et al., 
1979). As microtubules, and their ability to dissociate from one another, are a 
key component of functional cell division, paclitaxel-binding prevents cell 
division and results in apoptosis. Docetaxel is a more recent taxane, and an 
analogue of paclitaxel, that was found to be of use in treating advanced and 
paclitaxel-resistant ovarian cancer (Kaye et al., 1997; Rose et al., 2003). A 
prospective, randomised phase III clinical trial called the Scottish Randomised 
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Trial in Ovarian Cancer (SCOTROC) 1 was organised in 1998 to compare the 
progression-free survival, toxic effects, overall survival and quality of life of 
patients undergoing one of two treatment regimens using either paclitaxel and 
carboplatin or docetaxel and carboplatin. Patients enrolled on this study were 
recruited at 83 study centres between 1998 and 2000 and were over 18 years 
of age with epithelial ovarian carcinoma or ovarian-type peritoneal 
carcinomatosis, an International Federation of Gynaecological Oncology 
(FIGO) stage (a measure of how the tumour has spread) of Ic-IV, an Eastern 
Cooperative Oncology Group (ECOG) performance status (a measure of a 
cancer patient’s well-being and ability to carry out activities in daily life) of 0-2, 
no previous chemo- or radiotherapy and suitable levels of renal, hepatic and 
bone marrow functions. Patients were then randomly assigned a treatment 
arm and underwent six cycles of chemotherapy with three-week intervals 
between cycles. No significant differences in efficacy, progression-free or 
overall-survival were found between the two treatment arms of this study 
(Vasey et al., 2004), however clinical samples collected throughout this study 
have led to various important research findings, including the discovery that 
variations in DNA methylation of stratifin (SFN) and oestrogen receptor 1 
(ESR1) genes in the PBMCs of patients associate with progression-free 
survival in the paclitaxel arm (Flanagan et al., 2013), that methylation of MLH1 
in plasma samples of relapse patients correlated with increased microsatellite 
instability and a poorer progression-free survival outcome (Gifford et al., 
2004), and that PBMC DNA methylation of three individual loci associated 
with either progression-free survival or cancer antigen (CA) 125 response 
(CA125 is a protein found in the blood and is a surface antigen expressed by 
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some cancer cells and, therefore, is used as a marker for tumour response to 
treatment) (Wilhelm-Benartzi et al., unpublished data). 
 
To test the hypothesis that platinum-induced DNA damage leads to bi-
directional aberrant epigenetic changes in patient samples, PBMC DNA 
collected during the SCOTROC1 study was used to measure DNA 
methylation before and after chemotherapy, at the time of relapse of the 
patients’ tumours. Blood samples were taken from patients on enrollment, 
prior to chemotherapy, and then again at relapse and DNA was extracted 
from these samples at the Beatson Cancer Research Laboratories, Glasgow 
(Gifford et al., 2004). As presentation samples from chemo-naïve patients and 
matched relapse samples from patients after platinum treatment differed in 
platinum exposure, this provided a clinical model for studying the effects of 
platinum-induced DNA damage in vivo. Fifty-five pairs of matched 
presentation and relapse DNA samples were hybridised to Infinium 
HumanMethylation 450 BeadChip arrays to allow the testing of multiple loci 
for treatment-induced methylation changes.  
 
5.2 Aims 
The main aim of this chapter was to establish whether platinum treatment 
induces methylation changes in the DNA of peripheral blood mononuclear 
cells of ovarian cancer patients from the SCOTROC1 clinical trial. Further 
aims were to determine whether methylation changes occurred in specific 
genomic regions, and whether DNA methylation at relapse associates with 
clinical outcomes. 
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5.3 Results 
5.3.1 Sample clinical data 
As there were a limited number of matched presentation and relapse 
SCOTROC1 patient samples, samples were selected for analysis on the basis 
that matched presentation and relapse samples had enough DNA available 
for a single bisulphite conversion reaction. Clinical data for the final 51 
samples analysed is presented in table 5.1. 
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SCOTROC1  Patients N=51 N (%) or Mean (SD)
Study Arm Paclitaxel/Carboplatin 14 (27.5%)
Docetaxel/Carboplatin 37 (72.5%)
Deceased Status Deceased 44 (86.3%)
 (as at 2010) Alive 7 (13.7%)
Progression Free Survival Status Progressed 51 (100%)
Did Not Progress 0 (0%)
Overall survival Mean OStime years (SD) 2.36 (2.09)
Progression free survival Mean PFStime years (SD) 1.0 (0.6)
Age Mean (SD) 59.2 (9.3)
Residual Disease None or Microscopic 7 (13.7%)
Macroscopic <= 2 cm 23 (45.1%)
Macroscopic > 2 cm 21 (41.2%)
FIGO Stage stage 1c 0 (0%)
stage 2 1 (2%)
stage 3 41 (80.4%)
stage 4 9 (17.6%)
New histology Adenocarcinoma 5 (9.8%)
Serous cystadenocarcinoma 12 (23.5%)
Clear cell carcinoma 3 (5.9%)
Endometrioid carcinoma 8 (15.7%)
Papillary adenocarcinoma 10 (19.6%)
Other/Unknown 13 (25.5%)
ECOG performance status 0 15 (29.4%)
1 28 (54.9%)
2 8 (15.7%)
RECIST response Complete 10 (19.6%)
Partial 10 (19.6%)
Stable 14 (27.5%)
Progressive 1 (2%)
No data 16 (31.4%)
CA125 Response No response 14 (27.4%)
Response 33 (64.7%)
NA 4 (7.8%)
Serious Haem toxicity No 42 (82.4%)
Yes 9 (17.6%)
Grade 3/4 GI toxicity 0 2 (3.9%)
1 13 (25.5%)
2 26 (51%)
3 10 (19.6%)
4 0 (0%)
Grade 2/3/4 neuropathy 0 15 (29.4%)
1 26 (51%)
2 8 (15.7%)
3 2 (3.9%)
4 0 (0%)
*Differences in numbers within categories and total numbers are due to missing
unknown/unevaluable data for these variables.
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Table 5.1 Clinical data 
Clinical data by category (first column) and sub-category (second column) 
presented in numbers and percentage of samples (third column). 
 
5.3.2 LINE-1 methylation is unchanged in relapse samples 
DNA methylation was measured using a bisulphite pyrosequencing assay to 
assess the success of bisulphite conversion for all presentation and relapse 
samples prior to sending for Infinium HumanMethylation 450 BeadChip 
analysis. As LINE-1 has been used previously as a surrogate for global DNA 
methylation, this assay was selected for bisulphite conversion analysis as it 
also had the potential to give insight into the methylation differences between 
presentation and relapse samples. All samples displayed sufficient bisulphite 
conversion, determined by the conversion control present in the assay as 
described in chapter 3, however, LINE-1 methylation was not significantly 
different between presentation and relapse samples (Student’s t-test p=0.55) 
(figure 5.1). 
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Figure 5.1 LINE-1 methylation is unchanged in relapse samples 
Boxplot of percentage methylation of LINE-1 for matched presentation and 
relapse PBMC DNA samples. Methylation values are the mean across all 55 
samples. Two-tailed Student’s t-tests showed LINE-1 methylation is not 
significantly different between the two groups (p=0.55). 
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5.3.3 Quality control 
Data was normalised and background corrected by the UCL genomics facility 
as described previously. Sample-dependent and -independent quality control 
measures were then carried out for each detection channel using R, as 
described previously. Presentation samples 252 and 194 and relapse sample 
307 failed the bisulphite conversion control, and presentation sample 784 
failed the specificity and non-polymorphic controls. All failed samples and their 
matched counterparts were removed from the data, leaving 51 matched 
presentation and relapse samples to analyse. After primary quality control 
checks, detection p-values were screened for all probes and all samples. In 
this instance 2370 probes were removed due to poor detection p-values, 
leaving 483,207 probes to analyse. Impute was then carried out before batch 
and probe effects were corrected using ComBat and peak-based correction, 
as described previously. QC images are presented in supplementary figures 
5-8. 
 
5.3.4 Presentation and relapse sample matching confirmed with SNP 
analysis 
Although presentation and relapse samples were labeled with patient IDs to 
allow matched samples to be identified, sample matching was confirmed 
using the BeadChip data. As the BeadChips carry 65 known single nucleotide 
polymorphism (SNP) probes it was possible to use these DNA markers to 
confirm that paired samples were from the same individual. Samples were 
subjected to unsupervised hierarchical clustering using the heatmaps.2 
function of the gplots package in R. A heatmap of methylation across all SNP 
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probes (n=56 due to probe removal in pre-processing) was created and 
patient samples were clustered in a dendrogram. All presentation samples 
were found to match relapse samples of corresponding patient IDs (figure 
5.2).  
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Figure 5.2 SNP analysis confirms presentation and relapse sample 
matches 
Heatmap with Y-axis showing hierarchical clustering dendrogram of SNP 
probes. Top X-axis shows hierarchical clustering dendrogram for each 
sample, with predicted presentation (n=51) and relapse (n=51) matched pairs 
coloured individually. Bottom X-axis shows patient sample IDs, with “R” 
indicating relapse samples, and magnified patient IDs presented below. 
Samples cluster based on their Infinium HumanMethylation450 BeadChip β-
values across all SNP probe. Blue indicates low levels of methylation and pink 
indicates high levels of methylation. All predicted presentation and relapse 
matched samples are found to match with SNP data. 
 
5.3.5 Platinum treatment causes significant bi-directional methylation 
changes in PBMC DNA with a bias towards hypermethylation 
The BeadChip data was analysed to determine the effect of platinum 
treatment on DNA methylation of PBMCs for SCOTROC1 ovarian cancer 
patients. Post-treatment relapse samples exhibited significant bi-directional 
changes in DNA methylation, and there was a statistically significant bias 
towards hypermethylation, with significantly differentially methylated probes in 
relapse samples around 45 % more likely to be hypermethylated than 
hypomethylated (odds ratio 1.45, 95 % C.I.s 1.397-1.505, chi-squared p-
value=1.04E-85). A volcano plot was created plotting the -log10 Student’s t-test 
p-value for each probe against the mean difference in methylation in percent 
between presentation and relapse samples (figure 5.3). 
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Due to the various confounding factors present in clinical sample data, a 
conditional logistic regression was used to test whether treatment resulted in 
significant DNA methylation changes after correcting for batch effect and 
accounting for differences between individuals. Logistic regression is used to 
measure the relationship between a dependent categorical variable, in this 
case presentation or relapse, and one or more additional independent 
variable(s), usually continuous, in this case methylation and batch number. 
The logistic regression model assigns probability scores as the predicted 
values of the dependent variable, and then tests these scores against the 
data. The model predicts the odds of a sample being a relapse sample based 
on the independent variable, in this case methylation, by dividing the 
probability that a sample is a presentation sample by the probability that the 
sample is a relapse sample. As there are many variables across patients that 
could affect the outcome of platinum treatment on DNA methylation, 
conditional rather than non-conditional logistic regression was used. 
Conditional logistic regression specifies all matched pairs and then looks at 
whether treatment influences methylation within each pair, rather than across 
all pairs. This accounts for differences in age, ethnicity, environmental 
exposure, additional health conditions and many other variables that could be 
different between individuals. A volcano plot was created from the conditional 
logistic regression model, plotting the -log10 p-value against the 
exponentiated conditional logistic regression estimate, which becomes an 
odds ratio, for all probes across samples. The odds ratios plotted here can be 
interpreted as the odds that a given sample is a relapse sample for every 0.1 
% increase in methylation of that probe. For example, a probe with a Y-axis -
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log10 p-value of 2 and a conditional logistic regression estimate of 1.4 is 
statistically significantly (p<0.01) associated with relapse status, and a sample 
is 40 % more likely to be a relapse sample for every 0.1 % increase in 
methylation of that probe. Probes found to be significantly differentially 
methylated (p<0.05) between presentation and relapse samples after 
accounting for batch effect and between-patient variables after multiple testing 
correction using the Bonferroni method were coloured red (figure 5.4). 
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Figure 5.3 Relapse samples display bi-directional methylation changes 
with a bias towards hypermethylation 
Each point represents the -log10 Student’s t-test p-value on the Y-axis and 
delta methylation as a percentage on the X-axis of 51 presentation vs. 51 
relapse PBMC DNA samples. Probes with a Student’s t-test p-value <0.01 are 
coloured blue and probes with a Student’s t-test p-value of <0.05 after 
Bonferroni correction for multiple testing are coloured red. 
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Figure 5.4 Bi-directional methylation changes associate with relapse 
status after accounting for inter-patient variability and batch number 
Each point represents the -log10 conditional logistic regression p-value on the 
Y-axis and the exponentiated conditional logistic regression estimate (odds 
ratio) on the X-axis of 51 presentation vs. 51 relapse PBMC DNA samples. 
Probes with a p-value <0.01 are coloured blue and probes with a p-value of 
<0.00005 are coloured red. 
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5.3.6 Methylation profiles of blood DNA at time of ovarian cancer relapse 
predict overall survival 
To determine whether blood DNA methylation profiles can be used to predict 
survival outcomes for ovarian cancer patients, univariate analysis using Cox 
proportional hazards modelling was used on the 333 most significant CpG 
sites differentially methylated between presentation and relapse blood 
samples (FDR<10%). Eight CpG sites were identified that were associated 
with survival in this analysis with FDR<10%. Univariate analysis is a simple 
analysis asking whether a single variable, in this case the methylation level of 
a single CpG site, is associated with something, in this case overall survival. 
The Cox proportional hazard model predicts what the hazard of death from 
time of relapse is for every 1 % change (increase or decrease) in DNA 
methylation at a given CpG site. Using this method, eight CpG sites were 
identified that associated with overall survival. 
 
To determine the number of survival groups defined by these eight CpG sites, 
consensus clustering was carried out on all 51 subjects using the 
ConsensusClustering Plus package in R version 3.0.1. Consensus clustering 
quantitatively determines the number of possible clusters using K-means 
clustering (k is the number of clusters tested in the method and for this 
analysis k=2-6), and identifies the samples belonging to those clusters, within 
in a given set of data. This method indicated that there were two clusters, or 
groups, defined by the methylation of the eight probes, as shown in the 
correlation matrix heatmap in figure 5.5 A. A Kaplan Meier curve was then 
created using the 51 relapse samples to show the overall survival in years of 
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patients in the two identified groups. This curve shows poorer survival for 
group 1 compared to group 2, with group 1’s hazard of death 4.2 times higher 
than that of group 2 (HR=4.2, 95 % C.I. 2.1- 8.4, Wilcoxon rank sum p=4.4e-5) 
after adjusting for age, grade, stage and ECOG performance status in a 
multivariable Cox proportional hazards model (figure 5.5 B). The average time 
from relapse to death is 0.62 years (7.4 months) for group 1 compared to 2.2 
years (2 years and 2.4 months) for group 2.  
 
The combined methylation change across all eight probes is a decrease in 
methylation in group 1 (poorer survival) relapse compared to presentation 
samples (Wilcoxon rank sum p=6.15e-8) and an increase in methylation in 
group 2 (better survival) relapse compared to presentation samples (Wilcoxon 
rank sum p=3.9e-4) (figure 5.6). These eight CpG sites did not separate 
patients into survival groups at presentation, therefore this data is related to 
the response to platinum, rather than the underlying epigenetic profile, of 
these patients. 
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Figure 5.5 Methylation profiles of blood DNA at time of ovarian cancer 
relapse predict overall survival. 
Univariate analysis using Cox proportional hazards model identified 8 CpG 
sites (out of 333, FDR<10%) associated with overall survival (time from 
relapse to death) at FDR<10%. (A) Plot of the correlation matrix heatmap, 
with the scale presented on the right ranging from white (low correlation) to 
blue (high correlation). (B) Kaplan Meier curve of overall survival for the two 
identified groups shows poorer survival for class 1 compared to class 2 
(HR=4.2 95 % C.I., 2.1 - 8.4, p=4.4e-5) adjusted for age, grade, stage and 
performance status in a multivariable cox proportional hazards model. This 
analysis was carried out by Dr. James Flanagan. 
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Figure 5.6 Relapse group 1 samples have lower methylation, and relapse 
group 2 samples have higher methylation than presentation samples 
across 8 CpG sites 
Mean percentage methylation of all eight survival-predicting CpG sites for 
matched presentation samples (n=51) and relapse samples by methylation 
group (group 1 n=19, group 2 n=32). Wilcoxon rank-sum test showed 
methylation is significantly different between presentation and relapse group 1 
(p= 6.145e-08), presentation and relapse group 2 (p=3.9e-4), and relapse 
group 1 and relapse group 2 (p=8.318e-15). This analysis was carried out by 
Dr. James Flanagan. 
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5.3.7 Global methylation is increased in relapse samples and is 
associated with improved gastrointestinal toxicity scores 
The overall effect of platinum treatment on DNA methylation across the 
genome was measured by taking the mean methylation across all CpG sites 
for presentation and relapse samples. Global methylation was significantly 
increased in relapse samples compared to presentation samples (Student’s t-
test p=0.02538) (figure 5.7). However, when looking at global methylation 
changes in individual samples, two patients had no significant change in 
methylation between presentation and relapse, 32 of the remaining 49 
samples displayed a global methylation increase, and 17 of the 49 displayed a 
global methylation decrease. When comparing the clinical data available 
between patients with global methylation increases and those with global 
methylation decreases, there was no significant association between either 
methylation increase or decrease with progression-free survival status or time, 
overall survival time, age, residual disease, FIGO stage, histology, ECOG 
performance, RECIST response, CA125 response, haemoglobin toxicity or 
neurological toxicity (p>0.05), however the decrease group did associate with 
better “three/four” gastrointestinal (GI) toxicity scoring, meaning patients in 
this group were less likely to present with the two most severe scales (3 and 4 
from a 0-4 scale) of GI problems, predominantly related to nausea and 
vomiting. The difference in these groups equated to 1/17 patients with global 
methylation decrease experiencing thee/four GI toxicity, while 9/32 patients 
with global methylation increase experienced the same (5.88 % compared to 
28.12 %, Student’s t-test p=0.0308). 
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Figure 5.7 Relapse samples have higher global methylation than 
presentation samples 
Boxplot of mean percentage methylation of all probes for matched 
presentation (n=51) and relapse (n=51) PBMC DNA samples. Methylation 
values are the mean across all 51 samples. Wilcoxon rank-sum test showed 
methylation is significantly different between the two groups (p=0.02538). 
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5.3.8 Platinum-induced methylation increases occur outwith gene 
promoter regions 
To determine whether methylation changes related to platinum treatment 
were occurring only in certain regions of the genome, average β values 
across clones of presentation and relapse samples were plotted for all CpG 
sites grouped according to the gene-centric (figure 5.8 A-G) and CpG island 
regions (figure 5.9 A-F) of the genome. Increases in methylation in relapse 
samples were detected in all 11 regions analysed. Of these, all bar one gene 
centric region (TSS 200) displayed significant increases (p<0.05), while 3/6 
CpG island regions displayed significant increases (north shelf, south shelf 
and regions unrelated to CGIs). Interestingly, the regions that do not display 
significant increases in methylation - TSS 200, north shore, CpG island and 
south shore - are those regions that are closest together and are all located 
within gene promoters. Methylation values across these regions and 
respective p-values are summarised in tables 5.2 and 5.3. 
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Figure 5.8 Platinum treatment caused increased methylation across 
gene-centric regions 
Boxplots of average methylation values (%) across 51 presentation and 51 
relapse samples for genome regions: TSS1500 (1500 bp upstream of the 
TSS) (A), TSS200 (200 bp upstream of the TSS) (B), the 5’ UTR (C), the 1st 
exon (D), the gene body (E), the 3’ UTR (F) and regions outwith these gene 
locations (G). Significant differences are indicated with respective p-values, 
coloured red, from Wilcoxon rank sum tests. Significance was determined as 
p<0.05. The structure of gene regions running 5’ to 3’ is depicted in schematic 
diagram (H), image taken from MethHC online database of DNA Methylation 
and gene expression in human cancer (ISBLab, 2014).  
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Figure 5.9 Platinum treatment caused increased methylation across CpG 
island regions 
Boxplots of average methylation values (%) across 51 presentation and 51 
relapse samples for CpG island regions: north shelves (4kb-2kb upstream of 
CGI) (A), north shore (2kb upstream of CGI) (B), the CGI (C), south shore 
(2kb downstream of CGI) (D), south shelves (2kb-4kb downstream of CGI) (E) 
and regions unrelated to CGI (F). Significant differences are indicated with 
respective p-values, coloured red, from Wilcoxon rank sum tests. Significance 
was determined as p<0.05. The structure of CGI regions running 5’ to 3’ is 
depicted in schematic diagram (G), image taken from MethHC online 
database of DNA Methylation and gene expression in human cancer (ISBLab, 
2014).  
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Table 5.2 Gene-centric methylation levels 
Table showing average β-values across all probes of a named gene-centric 
region for presentation and relapse samples and Wilcoxon rank sum test p-
values of methylation difference between 51 presentation and 51 relapse 
matched samples.  
 Gene Loci  Presentation average beta-value 
 Relapse 
average beta-value  p-value 
TSS1500  0.3746706  0.3773904 0.02418 
TSS200  0.1789709  0.1805259 0.07725 
5'UTR  0.3762359  0.3792609 0.008557 
1st Exon  0.2342603  0.2360513 0.02477 
Gene Body  0.6682539  0.6708804  0.01984 
3'UTR  0.7698936  0.7744737  0.01749 
Unrelated  0.6258711  0.6286166 0.03702 
 237 
 
Table 5.3 CGI region methylation levels 
Table showing average β-values across all probes of a named GGI region for 
presentation and relapse samples and Wilcoxon rank sum test p-values of 
methylation difference between 51 presentation and 51 relapse matched 
samples. 
 
5.3.9 Bisulphite pyrosequencing validated nine significantly 
differentially methylated CpG sites 
Bisulphite pyrosequencing was again used as an alternative method to 
validate the array data. For this, ten CpG sites were selected by ranking the 
most significantly differential DNA methylation (p<0.001) followed by the 
greatest methylation difference between presentation and relapse samples. 
PCR and pyrosequencing assays were successfully created for nine of the ten 
Relation to CGI  Presentation  average beta-value 
Relapse 
average beta-value p-value 
North Shelf  0.7866927  0.7902943  0.02359 
North Shore  0.4838962  0.4860934  0.1019 
CpG Island  0.2113319  0.2127964  0.08714 
South Shore  0.4730055  0.4752671 0.0943 
South Shelf  0.7931499  0.7967008 0.02538 
Unrelated  0.7416864  0.7452808  0.0184 
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CpG sites. For validation, 45 unmatched independent pairs of presentation 
and relapse samples not assayed on the Infinium HumanMethylation450 
BeadChip array were analysed and boxplots were created depicting 
methylation values for each CpG site across the validation samples. The 
significant differences and direction of change in methylation between 
presentation and relapse samples detected by the BeadChips were validated 
for these nine sites (p<0.05) (figure 5.10). 
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Figure 5.10 Independent validation using bisulphite pyrosequencing in 
unmatched pairs. 
PBMC DNA samples of independent SCOTROC1 patients at presentation 
(n=45) were compared with those at relapse (n=45) and bisulphite 
pyrosequencing was conducted for 9 candidate CpG sites. Boxplots show all 
9 CpG sites (labelled by CG site number and associated gene, where 
relevant) validate significant differential DNA methylation and the expected 
direction of change at relapse compared to presentation. Delta (Δ) methylation 
(relapse minus presentation) and p-values from Wilcoxon rank sum tests are 
shown. This work was conducted by Chail Koo as part of his MSc project at 
Imperial College London. 
 
5.4 Discussion 
By comparing the DNA methylation of PBMCs from presentation and relapse 
samples of the SCOTROC1 clinical trial it was possible to assess the effect of 
platinum-induced DNA damage on epigenetic marks in vivo, as all patients on 
this trial were treated with carboplatin between presentation and relapse 
sampling. As samples were matched, true clinical platinum-induced epigenetic 
effects could be determined with minimal confounding factors, such as age, 
medical history, ethnicity and environmental exposure, influencing the data. 
Initial measurements using bisulphite pyrosequencing of LINE-1 indicated no 
significant difference in global methylation between presentation and relapse 
samples. However, using the Infinium HumanMethylation450 BeadChip array 
it was identified that significant methylation changes did indeed occur after 
 241 
platinum treatment, and that global methylation, as measured by averaging all 
probes across the array, increased significantly after platinum treatment. 
The absence of methylation difference in the LINE-1 assay is likely due to the 
fact that the LINE-1 assay captures only a short section (4 CpGs) of the 
widely dispersed sequence, and, therefore, does not truly reflect the variety of 
methylation occurring throughout the genome as a whole. The averaging of 
methylation across approximately 480,000 CpG sites throughout the genome 
is a far more robust indicator of the genome-wide effect of platinum treatment 
and the fact that this showed methylation predominantly increased in relapse 
patients highlights the limitations of using only LINE-1, and other repetitive 
element, assays in gauging true global methylation. Additionally, as LINE-1 
methylation was compared between presentation and relapse groups rather 
than individuals, differences such as untreated time to relapse between 
individuals may have affected the ability to detect a significant difference 
between the groups. 
 
The methylation profiles of eight CpG sites were determined to be associated 
with overall survival in this dataset. It is of interest that the methylation of 
some individual CpG sites increases while others decrease in association with 
improved survival, suggesting an absence of a specific hypermethylating or 
hypomethylating mechanism associating with survival outcome. However, 
when looking across all eight CpG sites, increased methylation at relapse 
associated with improved outcome whereas decreased methylation at relapse 
associated with worse outcome. Although this data is exciting due to the 
prospects of having additional blood biomarkers to predict survival outcomes 
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in ovarian cancer patients, the hazard ratio based on the methylation of these 
eight CpG sites is an over-estimate, as the CpG sites were initially selected to 
stratify patients based on overall survival. Validation of these CpG sites on a 
new set of matched clinical blood samples at presentation and relapse would 
be required to determine whether and to what extent the methylation of these 
eight CpG sites do actually predict survival outcome, or whether they only 
happen to associate with outcome in the samples used in this study. 
However, if the sites do validate, a blood prognostic test using these eight 
markers to predict outcome after treatment may be a very useful tool in 
making clinical decisions. Although these markers were not associated with 
survival in the presentation samples, it would also be of great benefit to 
determine whether these markers are predictive immediately after, or even 
during, chemotherapy treatment, as early prediction of outcome would further 
improve the decision making process for clinicians and patients alike, 
regarding future treatment and care. 
 
When looking at global methylation levels, although the trend across all 51 
pairs of samples showed higher methylation at relapse, two of the 51 patients 
did not display significant differences in global methylation between 
presentation and relapse, and 17 out of the remaining 49 patients 
demonstrated a decrease in global methylation at relapse. The finding that 
some patients have overall methylation decreases is possibly not one of 
significance and may be an artefact of the locations in which platinum binds to 
and damages the DNA, as platinum is thought to bind randomly across the 
genome and, therefore, it is unlikely that platinum would have bound in 
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exactly the same genomic places in multiple patients. If the mechanism of 
methylation change is that platinum damage causes methylation at a given 
region to change from its current state to the opposite one, and the reason for 
skewing towards methylation increase is potentially due to unmethylated CpG 
sites being more accessible due to being in less compact chromatin regions 
(Thurman et al., 2012), then it would follow that variations in the levels of 
global methylation in different patients would be seen due to the randomness 
of where platinum binds to DNA in a given cell in a given patient. As the 
difference between the largest global methylation decrease and the largest 
global methylation increase is a mere 3.77 % and the average and median 
changes are 0.26 % and 0.38 % respectively, it may be the case that these 
differences between patients fall within a range of expected averaged 
changes due to the stochastic and permanent differences between the 
baseline methylome of individuals, and therefore the range in which platinum 
can change methylation. The mechanism for platinum-induced 
hypomethylation may be different to that of hypermethylation, where loss of 
methylation is passive due to the removal and resynthesis of a platinum-
damaged area and gain of methylation is through the repair of a lesion via a 
DNA repair pathway, such as NER, recruiting DNMTs. Therefore, the patients 
displaying overall methylation decreases post-treatment may be more 
proficient in the hypomethylation pathway, deficient in the hypermethylation 
pathway or the proportion of different platinum lesions created is slightly 
different in these patients, leading to differences in DNA damage signalling 
and or repair. In the absence of genotype and gene expression data it is 
impossible to say whether there is a consistent genetic difference between the 
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decrease group and the increase group. However, patients with decreased 
global methylation had significantly better GI toxicity scores than patients with 
increased global methylation. As platinum drugs are known to have significant 
GI side effects (reviewed in (Hartmann and Lipp, 2003; Schnell, 2003)), it is 
possible that there is a link between the decrease in methylation and 
improved GI toxicity scoring. Platinum drugs are known to cause nausea and 
vomiting through the release of serotonin in the gastrointestinal tract 
(Cubeddu, 1996; Cubeddu et al., 1995; Markman et al., 2002), and this 
release of serotonin is thought to be regulated through the production of free 
radicals as platinum is aquated prior to DNA binding (Matsuki et al., 1993; 
Torii et al., 1993). It is, therefore, possible that patients experiencing less GI 
toxicity are doing so through the reduced production of free radicals from 
platinum, possibly because less platinum is binding to DNA in these patients, 
resulting in less DNA damage, potentially less increases in methylation and 
additionally less GI complaints. Alternatively, these patients may have an 
increased ability to deal with cisplatin-induced free radicals before they result 
in gastrointestinal release of serotonin. If this is the case, free radicals might 
also contribute to the increase in DNA methylation caused by platinum 
treatment through additional DNA damage, perhaps more often at 
unmethylated sites. Therefore, patients who display decreased global DNA 
methylation may experience less damage-induced methylation increases as 
they have an improved free radical clearance rate. This could also indicate 
that free radicals are involved in the epigenetic response to platinum, and 
possibly suggests that the mechanism of aberrant methylation induced by 
direct platinum crosslink damage and repair and by free radicals produced by 
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platinum’s aquation both exist. Indeed this notion is supported by previous 
work demonstrating that free-radicals can directly damage and alter 
methylated CpG sites and induce aberrant methylation and recruitment of 
DNMT1, DNMT3B, EZH2 and SIRT1 in cell lines (O'Hagan et al., 2011; 
Valinluck et al., 2004). 
 
Methylation changes at specific CpG sites across the genome were detected 
using the Student’s t-test on M-values from the BeadChip data. As the data 
presented in this chapter relates to clinical samples it was important to control 
for the inter-individual clinical variability that could influence the methylation 
differences detected. Conditional logistic regression was used to specifically 
detect changes in methylation between “at presentation” and “at relapse” 
samples within individuals, additionally accounting for batch effect. After this 
correction, significant bi-directional methylation changes were detected, with a 
bias towards increased methylation, as seen previously in clonal cell lines. 
This consistent pattern of methylation changes post-platinum treatment 
indicates that the clonal cell line results are representative of in vivo 
mechanisms and are therefore a relevant model for platinum-induced 
methylation changes. Strikingly, as the results presented here demonstrate 
methylation changes in peripheral blood cells of patients this shows platinum-
induced aberrant methylation changes are occurring systemically and not 
simply in tumour cells. As PBMCs have a life span of anywhere between 1 
week and a few months (Kline and Cliffton, 1952), the changes detected here 
are likely a reflection of changes in the stem cells of the bone marrow, as 
relapse samples are taken months to years after treatment. Given that 
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methylation changes have been strongly implicated in driving the occurrence 
and progression of cancer (Goelz et al., 1985; Kim et al., 1994; Roman-
Gomez et al., 2005; Widschwendter et al., 2007; Zeller et al., 2012), it is 
possible that platinum-induced changes to non-tumour cells, including bone 
marrow stem cells, are initiating steps in the development of therapy-related 
disease such as secondary acute myelocytic leukemia (sAML) and 
myelodysplastic syndromes (MDS) (Michels et al., 1985; Philpott et al., 1996). 
Indeed, a recent review discusses the epigenetic mechanisms potentially 
involved in the chromosomal translocations associated with therapy-related 
leukaemia such as the removal of nucleosomes by topoisomerase II-inhibitor 
etoposide, leading to exposed DNA more susceptible to DNase I cleavage or 
DSB-inducing damaging agents leading to NHEJ and translocations (Chamani 
et al., 2014; Gill Super, 2015; Sawyer et al., 1998). It is possible that platinum 
drug-induced DNA methylation changes are similarly involved in creating a 
chromatin environment more susceptible to these types of mutations. For 
example, the epigenetic silencing of MLH1 may occur in blood stem cells in 
addition to tumours and could result in increased genomic instability priming 
cells for translocations.  
 
Methylation changes were stratified across the various gene-centric and CGI-
related regions of the genome to determine whether platinum induced DNA 
damage caused methylation changes in particular regions. As was 
demonstrated in clonal cell line samples and discussed in the previous 
chapter, platinum induced overall increases in methylation across the 
stratified regions of the genome, despite bi-directional methylation changes 
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being detected throughout the genome, further supporting the global 
methylation data discussed previously. Methylation levels were comparable 
between cell line and SCOTROC1 in some regions, such as at TSS1500 and 
5’ UTR regions, and were divergent in others. The main differences were in 
the TSS200 and 1st exon, where the cell lines were hypomethylated in these 
regions compared to the SCOTROC1 PBMC samples, and in the gene body 
and 3’UTR regions, where the cell lines were hypermethylated compared to 
the PBMC samples. These differences are likely due to the fact that the cell 
lines are derived from cancerous tissue and are immortalised, whereas the 
SCOTROC1 samples are normal blood cells. These differences are in line 
with the main differences between cancerous and normal tissues where 
cancerous cells are typically less methylated in some areas and 
hypermethylated in gene body regions (Esteller, 2008; Gama-Sosa et al., 
1983).  Methylation differences observed across genomic and CGI-related 
regions were relatively modest (see tables 5.2 and 5.3), however this is likely 
due to the averaging of changes across a large number of CpG sites in these 
regions and individual methylation changes range from very small, <1 %, to 
large changes of up to 20 % (see figure 5.3). The fact that the size of 
methylation changes observed in the SCOTROC1 samples was smaller than 
that of the clonal cell line data could be due to a variety of factors. The type of 
platinum drugs used in cell line and SCOTROC1 samples were different 
(cisplatin vs. carboplatin), and this could have affected the methylation 
responses detected. It could be that direct treatment of cell lines with platinum 
drug does not accurately reflect the in vivo DNA methylation response to 
platinum treatment and this would not be surprising given that drugs in vivo 
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are subject to metabolic breakdown, for example in the kidneys and liver, that 
are not involved in vitro. Additionally, given that the cell line data and the 
SCOTROC1 data are derived from cancer cells and normal PBMC cells 
respectively, differences between the DNA methylation response to platinum 
treatment in these samples may be directly related to the different epigenetic 
and gene expression profiles of the types of cell in question. 
 
Interestingly, significant increases in methylation were absent in the four 
regions of the genome closest to the TSS and/or typically within the promoter 
region, namely the TSS 200 region and the north shore, CpG island and south 
shore regions. It has been shown previously that some CpG sites in TSS 
regions and in CGI, shore and shelf regions are “ultra-stable” in that they 
typically have the least variation across tissue, differentiation stage and 
disease type (Edgar et al., 2014). These regions, referred to in the literature 
as “ravines”, are either highly methylated or highly unmethylated regions 
flanked by highly methylated shelves and are shown to associate with high 
levels of transcription, typically housekeeping genes that require constant 
expression regardless of tissue determination. It is possible that in the case of 
platinum-induced DNA damage and DNA methylation changes, these ravines 
may be protected from platinum damage through the binding of transcription-
factors and other regulatory proteins to these regions and, therefore, do not 
undergo as many damage-induced methylation changes. There may be 
enough ravines or other protein-bound TSS and CGI regions to counter the 
effect of methylation increases seen in other CGI regions such that 
methylation increases in these regions are not reaching a level of significance. 
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It is possible that this is not the case for clonal cell lines due to the vast 
genetic and epigenetic changes cells undergo to become immortalised, 
possibly resulting in a lower number of these ravines remaining true to their 
constitutively expressing and/or non-changing nature. 
 
5.5 Future work 
Further bioinformatic analysis could be conducted on this data to address 
questions such as what genes and pathways are enriched amongst the genes 
altered by platinum, and further associations with clinical variables could also 
be investigated. Independent validation of the association with methylation at 
the eight CpG sites with survival will also be required.  
 
One of the major interests relating to the hypothesis of platinum-induced 
methylation changes is the way that genome sequence, structure and protein 
interactions may affect the regions that undergo these changes. It has been 
shown here that TSS and CGI regions undergo less methylation changes than 
the rest of the genome, and it would therefore be of interest to investigate 
whether these regions are correlated with increased gene expression. There 
is currently no gene expression data available for these samples, therefore, 
possible future work may include attaining gene expression data and 
correlating expressed and unexpressed genes to regions of methylation 
changes, and also stratifying for increases and decreases to determine 
whether one direction of change is more, less or equally likely at regions of 
different transcriptional activity. Any correlation, or lack thereof, between 
methylation changes and gene expression may provide insight into the 
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mechanism of platinum-induced methylation changes and may indicate 
whether platinum access to DNA is likely to be an influencing factor in the 
location and distribution of such changes. In relation to the chromatin 
environment of aberrantly methylated sites, it would also be worth 
investigating whether sites of change correlate with DNase I hypersensitivity 
sites, where DNA is more sensitive to cleavage by the enzyme DNase I due to 
the loss of condensed chromatin structure. These sites typically associate 
with transcriptional activity so this may also indicate whether active vs. 
repressive regions of the genome are more likely to undergo DNA damage or 
damage-induced methylation changes (Thurman et al., 2012). 
 
It would also be of interest to investigate whether CpG sites local to 
significantly differentially methylated sites are also undergoing changes, 
perhaps infrequently enough to prevent them appearing as significant 
themselves. This may indicate whether changes only occur very specifically at 
a single site, presumably closest to the site of damage, or whether changes 
occur throughout a region, suggesting either regional susceptibility to damage 
or a spread of epigenetic changes throughout a damaged region as previously 
proposed (Cuozzo et al., 2007). 
 
In order to get a better understanding of individual patient responses to 
platinum damage it would be valuable to genotype patient samples for 
mutations in key DNA repair genes such as BRCA1. Patients with unusual or 
outlying methylation responses, such as those with global methylation 
decreases or those with the highest overall methylation changes, may have 
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underlying genetic differences that influence the epigenetic outcome of 
platinum damage. Additionally, information relating to genes involved in free 
radical removal, such as superoxide dismutase (SOD), may give further 
insight into the potential involvement of free radicals in the platinum-induced 
epigenetic response to damage as discussed previously. 
 
Although not within the scope of this thesis, there are many interesting 
avenues to investigate on the basis of this clinical data regarding how 
treatment-induced methylation changes may influence clinical outcome. For 
example, the data shown here is in blood cells, indicating that, perhaps 
unsurprisingly, treatment for localised and/or metastatic disease affects the 
methylation of distal non-cancerous cells. An interesting line of research 
would be to analyse tumour samples from pre-chemotherapy origin tumours 
and post-platinum treatment relapse and metastatic tumours. It is highly 
possible that cancer cells undergo different levels or patterns of platinum-
induced DNA methylation changes due to dysregulated repair pathways, 
signalling pathways and/or starting methylation profiles, and that clinical 
outcome or drug resistance may be influenced by and predicted from the 
changes occurring in these types of cells. Further, differences in the 
epigenetic response to platinum in these different sample types may elucidate 
key pathways involved in the methylation response, as different genetic and 
epigenetic profiles associating with different patterns of methylation response 
may point to specific pathways or genes involved. 
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The fact that the changes demonstrated here are in non-cancerous cells is 
also an important factor to consider when thinking about the epigenetic, and 
resultant clinical effects of platinum treatment for a range of cancers, not just 
ovarian cancer. For instance, testicular cancer is primarily treated with 
platinum, and patients experience a high rate of clinical response to the drug 
with a five year survival rate of over 95 % (Ries et al., 2002). However, as 
these patients often go on to live for many decades, some return with 
radiation and chemotherapy-related sAML and the clinical outcome of this 
treatment-related cancer is much less successful, with mean survival of just 
8.4 months after AML diagnosis in one study (Travis et al., 2000). As 
discussed previously, it is possible that epigenetic changes in blood relating to 
platinum damage are also occurring in blood stem cells, and that these 
changes could contribute to the development of AML in these patients. To 
begin to probe this theory, the TGCA data resource could be mined to search 
for correlations between epigenetic changes post-platinum treatment in 
testicular and other cancers and the epigenetic profiles and methylation 
frequencies of treatment-related sAML.  
 
Finally, a further avenue worth pursuing is research into the instance of 
methylation changes occurring in genes that may go on to drive platinum 
resistance. For example, one probe from the list of most significant 
differentially methylated probes is associated with the gene CRIM1. Increased 
CRIM1 expression has been linked to increased platinum and carboplatin 
sensitivity and the increased expression of the micro RNA miR-193b* causes 
associated decreased expression of CRIM1 and decreased platinum 
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sensitivity (Ziliak et al., 2012). CRIM1 has also been implicated in the drug 
sensitivity of myloid leukemias, further indicating a possible route for 
treatment-related leukemias to arise (Prenkert et al., 2010). It is, therefore, of 
value to investigate whether methylation changes in key genes associated 
with platinum sensitivity are likely to result in differential gene expression that 
go on to drive changes in platinum sensitivity, as single methylation changes 
have been shown to affect gene expression (for example (Claus et al., 2012; 
Flanagan et al., 2013)). 
 
5.6 Summary 
In summary, this chapter discussed the effects of platinum treatment on the 
PBMC DNA of ovarian cancer patients from the SCOTROC1 clinical trial. 
PBMC DNA methylation was found to significantly change after treatment 
when comparing presentation and relapse samples, and these changes were 
bi-directional with a bias toward hypermethylation. Global methylation was 
overall significantly increased across all 51 patient samples, but 17 patients 
displayed slight global methylation decreases when looking across all probes 
of the Infinium HumanMethylation 450 BeadChip array. This decrease 
correlated with improved GI toxicity scoring. The trend for methylation 
increase was also found across different regions of the genome when 
stratified for gene-centric or CpG island-related locations, and regions closest 
to the TSS and CGIs were found to lack significant increases in methylation 
compared to other regions. This work demonstrates that platinum treatment 
causes changes in the DNA methylation of blood cells in a clinical setting and 
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future work investigating the clinical implications of this research will be of 
great value to the field. 
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Chapter 6: 
Discussion, limitations, future 
perspectives and conclusions 
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6.1 Discussion 
The occurrence of platinum drug resistance in cancer patients is a significant 
factor impeding satisfactory clinical outcome, as patients relapse with 
resistant disease that is very difficult to treat (Vaughan et al., 2011). Although 
the mechanisms driving platinum resistance remain unclear, it is known that 
epigenetic factors play a key role in the development and maintenance of 
resistant cells (Zeller et al., 2012). As DNA damage has previously been 
linked to changes in DNA methylation, this thesis aimed to address the 
hypothesis that platinum-induced DNA damage also causes DNA methylation 
changes, which could be selected for, leading to platinum resistance. Given 
that loss of mismatch repair gene MLH1 contributes to platinum resistance, 
this thesis further aimed to address the hypothesis that platinum-induced DNA 
methylation changes are mismatch repair-dependent. 
 
In clonally-derived ovarian cancer cell line models, 72 hr treatment with 5 µM 
cisplatin resulted in a significant increase in DNA methylation at the LINE-1 
repetitive element in MMR-proficient, but not MMR-deficient, clones. As the 
concentration and duration of cisplatin treatment did not result in the selection 
of more resistant clones, it was concluded that cisplatin directly alters DNA 
methylation in these cells, rather than selecting for subpopulations of cells 
with different epigenetic patterns. Additionally, given that no change was 
detected in cisplatin-treated MMR-deficient cells, it seemed likely that MMR, 
or MLH1 in a non-MMR role such as in binding and facilitating ICL repair 
through the FA and NER pathways (Peng et al., 2007; Peng et al., 2014), is 
required for this epigenetic response. 
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While the LINE-1 methylation data suggested a platinum-induced genome-
wide methylation pattern, it was important to look genome-wide using a gene-
specific method. Using the Illumina Infinium HumanMethylation450 BeadChip 
array, cisplatin-induced methylation changes were detected throughout the 
genome at individual CpG loci. Although there were significantly more 
methylation changes in MMR-proficient clones after cisplatin treatment, many 
methylation changes also occurred in MMR-deficient clones. These results 
indicated that MMR and/or MLH1 was involved in, but not solely required for, 
the epigenetic mechanism(s) leading to cisplatin-induced DNA methylation 
changes. In line with the literature, the methylation changes detected in 
cisplatin-treated clones were bi-directional, with some CpG sites losing 
methylation and others gaining it (Antwih et al., 2013; Bae et al., 2015; 
Cuozzo et al., 2007; Kaup et al., 2006; Lee et al., 2012; Lee et al., 2010; 
O'Hagan et al., 2011). 
 
Due to the difference between the number of methylation events after cisplatin 
treatment in the presence and absence of MLH1, the mechanism of platinum-
induced DNA methylation change probably involves MLH1 in some capacity. 
However, as MLH1-deficient cells still undergo some methylation changes, 
this suggests that MLH1 is only partly responsible for some aspects of the 
damage-induced epigenetic mechanism, and also suggests that there may be 
more than one pathway involved. Based on the data presented in this thesis, I 
hypothesise that DNA methylation is passively lost at sites of DNA damage 
due to the removal of sections of DNA around a platinated site by NER or by 
MMR at compound lesions. I further hypothesise that DNA methylation is 
 258 
gained at sites of damage during the repair process, where DNMTs are 
recruited, possibly through interactions with PCNA or with MMR proteins as 
demonstrated in oxidative stress-induced damage (Ding et al., 2015), to sites 
undergoing recombination-depended synthesis to fill the gaps left after lesion 
removal (see figures 4.19 and 4.20 in chapter 4). As MLH1 is required for the 
signalling step of compound platinum lesion repair, it is possible that loss of 
MLH1 results in a reduced number of NER-mediated recombination repair 
events. Therefore, although recombination repair occurs at platinated lesions 
detected by other repair mechanisms, there is a reduction in the number of 
these events in the absence of MLH1. This hypothesis is supported by 
previous studies demonstrating methylation at DSB sites that have undergone 
HR repair (Cuozzo et al., 2007; Lee et al., 2010; Mortusewicz et al., 2005; 
O'Hagan et al., 2008). 
 
DNA methylation has been linked to recombination in a number of studies. In 
Arabidopsis plants loss of methylation at a given region causes the 
redistribution of homologous recombination crossing over (CO) points across 
the genome and hypomethylation promotes recombination in cis (Melamed-
Bessudo and Levy, 2012; Mirouze et al., 2012). In humans, genome-wide 
association studies have shown recombination sites to correlate with regions 
of germline DNA methylation, and imprinted genes are known to be present in 
recombination hotspots (Sandovici et al., 2006; Sigurdsson et al., 2009). 
Various explanations for these associations have been suggested, one being 
that DNA methylation marks are deposited after recombination in order to 
prevent further recombination from occurring in that region (Sigurdsson et al., 
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2009), and another suggesting that methylation is added after recombination 
repair to silence potentially damaged genes (Cuozzo et al., 2007). It is also 
suggested that gene body methylation plays a role in maintaining genomic 
integrity by preventing multiple crossing-over events within exons (Mirouze et 
al., 2012). Mirouze et al. have shown that hypomethylation promotes crossing 
over and when methylation is monoallelic, the hypomethylation of one allele is 
dominant and continues to dictate increased crossing over events. This 
agrees with the fact that imprinted genes, where alleles are differentially 
epigenetically silenced in a parent-of-origin-dependent manner, are hotspots 
for recombination. It is further suggested that the phenomenon of imprinting 
may have arisen as a mechanism to identify the parental origin of 
chromosome homologs during DNA repair and recombination events in 
meiosis and mitosis (de la Casa-Esperón and Sapienza, 2003; Pardo-Manuel 
de Villena et al., 2000). This is supported by the fact that loci subject to female 
imprinting are typically intermediately positioned along the chromosome 
compared to those imprinted in the male, which are more often closer to the 
telomere, and that these biases correlate to the bias in location of synapsis 
initiation, and resultant CO hotspots, in females vs. males (Lercher and Hurst, 
2003; Sandovici et al., 2006; Scherthan et al., 1996; Tankimanova et al., 
2004). Additionally, loss of heterozygosity, a consequence of recombination 
events and DNA repair, is a precursor to and feature of carcinogenesis 
(Gorgoulis et al., 2005; Pierce et al., 2001; Turker et al., 1999) and has been 
shown to associate with aberrant methylation patterns (Cuozzo et al., 2007; 
Kanai et al., 1996; Makos et al., 1993; Pieretti et al., 1995).  
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As there were large numbers of DNA methylation differences between the 
MLH1-proficient and -deficient clones, in the absence of cisplatin treatment, it 
is possible that loss of MLH1 also contributes to the epigenetic landscape of 
the cell. It is particularly interesting that the methylation profile of cisplatin-
treated clones is highly similar to that of MLH1-deficient clones. This suggests 
a commonality between the cisplatin-induced epigenetic response and the 
epigenetic response due to the loss of MLH1. Given the hypothesis presented 
here, that cisplatin induces DNA methylation changes through NER and 
recombination repair, it is possible that loss of MLH1 also triggers an increase 
in aberrant, non-homologous, recombination events, which can cause a 
change in the epigenetic landscape of these cells.  
 
It has been shown in Arabidopsis and in mice that loss of MLH1 leads to an 
increase in the rate of recombination between non-homologous 
(homeologous) sequences, possibly in a tissue-specific manner, suggesting 
that MLH1 acts to prevent non-homologous recombination events (Dion et al., 
2007; Shao et al., 2004). It was further shown in mouse embryonic fibroblasts 
that DNA damage induced by ionising radiation leads to increased numbers of 
homeologous crossing over events in MLH1-deficient compared to MLH1-
proficient cells, indicating that MLH1 is involved in preventing mutational 
recombination in response to DNA damage (Wang et al., 2006). It is, 
therefore, possible that, in A2780/CP70 cells lacking MLH1, multiple 
homeologous recombination events take place either during mitosis or as a 
response to DNA damage and these events lead to the acquisition of aberrant 
DNA methylation as detailed in (Cuozzo et al., 2007).  
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One method to test these hypotheses would be to combine MLH1-deficiency 
and cisplatin treatment with an additional deficiency of a key protein involved 
in HR DNA repair, for example BRCA1 or BRCA2. If the hypothesis that 
platinum-induced aberrant DNA methylation is a direct consequence of 
recombination repair and the role of MLH1 is in triggering some but not all 
recombination repair events is correct, it would be expected that knocking out 
one of these recombination repair proteins in the MLH1-proficient and MLH1-
deficient cell lines would result in an equal loss of aberrant methylation events 
in both cell lines. The lack of difference in cisplatin-induced methylation 
between MLH1-proficient and -deficient cells in this scenario would 
demonstrate a mechanism wholly dependent on recombination repair and 
would indicate that BRCA1/2 is epistatic to MLH1, demonstrating that, 
although there are MLH1-dependent and MLH1-independent mechanisms 
involved in the aberrant methylation induced by platinum damage, 
recombination repair is required for both mechanisms. 
 
Measuring the number of RAD51 foci in MLH1-deficient vs. MLH1-proficient 
clones may indicate whether MLH1-deficiency does, in fact, result in an 
increase in recombination events within the cell. It would also be of interest to 
combine cisplatin treatment with the use of poly-ADP ribose polymerase 
(PARP) inhibitors in cell lines. As PARP is essential for the repair of single 
strand breaks, PARP inhibition leads to the accumulation of single strand 
breaks and the eventual creation of multiple double strand breaks when 
unrepaired SSBs are present during replication (McGlynn and Lloyd, 2002). If 
recombination events lead to aberrant DNA methylation, then PARP inhibitors 
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alone would be expected to result in the accumulation of aberrant DNA 
methylation due to an increase in DSBR. Additionally, as aberrant DNA 
methylation is a factor driving the occurrence of platinum drug resistance, it is 
possible that the combined use of PARP inhibitors and cisplatin could 
increase the rate at which cells develop platinum resistance. Therefore, 
experiments comparing methylation changes in cells treated with cisplatin 
alone or cisplatin with PARP inhibitors, and comparing the sensitivities of cells 
treated long-term with cisplatin alone or cisplatin with PARP inbibitors would 
indicate whether additional DSBs contribute further to DNA methylation 
changes and/or cisplatin resistance. 
 
In peripheral blood mononuclear cells of ovarian cancer patients, it has been 
possible to detect significant DNA methylation changes after platinum-based 
chemotherapy. Given that this epigenetic response to platinum damage is 
occurring in non-cancerous cells due to the systemic nature of platinum 
chemotherapy, it is assumed that similar changes occur in the disease tissue 
and may contribute to platinum resistance. It is also possible that these types 
of changes are part of the mechanism that causes secondary treatment-
induced cancers such as sAML. Clinical trials in ovarian cancer combining 
platinum treatment with the use of the demethylating agent 5-azacytidine have 
demonstrated that demethylation improves the outcome of platinum treatment 
in patients with resistant disease (Fang et al., 2010; Fu et al., 2011; Matei et 
al., 2012). As this thesis demonstrates a causative link between platinum 
treatment and aberrant DNA methylation, that may drive platinum resistance, 
combination therapies using platinum and a demethylating agent such as 5-
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azacytidine may be useful in preventing the occurrence of treatment 
resistance in the first place. However, a recent study combining the use of 5-
azacytidine with carboplatin in patients with partially sensitive ovarian cancer 
found the combination to be difficult to administer due to adverse clinical 
effects such as neutropenia and carboplatin hypersensitivity and the trial was 
subsequently aborted (Glasspool et al., 2014). This disparity between clinical 
outcomes in the Glasspool and Fang, Fu and Matei trials is unexplained, 
however the negative outcome of the most recent trial indicates that an 
alternative demethylating agent or an alternative platinum agent, such as 
cisplatin, in combination with 5-azacytidine may be worth exploring. 
 
Combined analysis of the clinical data and methylation data on the 
SCOTROC1 PBMC DNA samples demonstrated that the methylation of eight 
individual CpG sites associated with overall survival and that patients with 
higher methylation across these sites at relapse survived around four times as 
long as those with methylation decreases at relapse. In the absence of 
validation of these CpG loci in a different data set, conclusions drawn from 
this data are purely speculative. However, if these findings prove reproducible 
in other data and the eight loci do indeed predict survival outcome at relapse 
then there is the possibility of creating a diagnostic test based on the blood 
methylation for these sites. This test would be more useful still if it could 
predict outcome at earlier stages, such as during chemotherapy cycles or 
immediately after chemotherapy treatment. Additional analysis of the function 
of methylation changes at these eight loci would also be beneficial, to 
 264 
determine whether these methylation changes directly influence survival 
outcome or whether they are only indicative of changes that do. 
 
Further analysis on the clinical samples and data presented here, as well as 
the collection and analysis of tumour samples pre- and post-treatment with 
platinum, would be valuable in determining whether there is a correlation 
between epigenetic response and genotype or epigenotype in patients that 
could predict treatment outcome. For example, if the hypothesis that the 
epigenetic response to platinum damage is related to recombination repair at 
damage sites is correct, patients with BRCA1- or BRCA2-mutant tumours may 
experience less aberrant methylation post-treatment than patients with normal 
BRCA status, due to a loss of HR repair. This may additionally contribute to 
the improved response and sensitivity to platinum treatment that ovarian 
cancer patients with BRCA mutations experience due to defective HRR, as 
they may have a reduced capacity for treatment-induced aberrant methylation 
that could drive platinum resistance (Cass et al., 2003; Konstantinopoulos et 
al., 2010; Rubin et al., 1996; Teodoridis et al., 2005; Yang et al., 2011). 
Analysis of the blood cell epigenome in testicular cancer patients before and 
after platinum treatment may also provide predictive markers indicative of 
future treatment-related disease. If platinum-induced aberrant methylation 
proves to be a causative factor in secondary disease it may then be worth 
investigating the benefits of combining traditional treatment with epigenetic 
drugs such as 5-azacytidine in order to reduce the risk of such secondary 
events occurring. 
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An additional discovery from this work is that LINE-1 appears not to be a 
suitable surrogate for global-DNA methylation in PBMC samples. Although 
LINE-1 gave a strong indication as to the results of the cell line experiments, 
there was no difference detected in LINE-1 between presentation and relapse 
PBMC DNA from the SCOTROC1 clinical samples, even although significant 
changes were detected across the genome using the HumanMethylation450 
array. These results indicate that LINE-1 is not a completely reliable surrogate 
for predicting methylation response. However, as it is relatively cheap to 
perform a LINE-1 methylation assay on a large number of samples it may still 
be a useful indicator, as it can sometimes predict the outcome of other, more 
expensive, analyses. It may be that reliability of the LINE-1 assay is 
diminished when dealing with patient samples or blood samples compared to 
cell lines and that a different approach to clinical samples could be used to 
obtain better predictions of results before more expensive arrays are 
commissioned. Perhaps a panel of assays covering different regions of CpG 
sites throughout LINE-1 as well as covering the Alu repetitive element may be 
more reliable in reflecting global methylation data, however these findings 
ultimately support the use of extensive methylation arrays or whole-genome 
bisulphite sequencing techniques before drawing firm conclusions regarding 
global methylation. 
 
6.2 Limitations 
There were several limitations in this study that must be considered, both 
when interpreting the data and designing future experiments. The first major 
limitation was that the cell lines, from which clonal data was derived, were not 
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truly isogenic. Although clonally derived themselves from parental cell line 
A2780/CP70, these cells contain fragments of chromosome 3 inserted in 
potentially differing locations and they have been grown through numerous 
passages, allowing genetic and epigenetic drift to potentially affect the 
outcomes of experimental work to determine the difference of effect on 
methylation induced by cisplatin caused by differential MLH1 expression. This 
could be tested by comparing the DNA methylation of the MLH1+ and MLH1- 
cell lines with that of earlier passages of the MLH1+ and MLH1- cell lines, as 
a reduced number of methylation differences between the MLH1+ and MLH1- 
cell lines in early passages would indicate that drift is at least partially 
responsible for the differences detected between these two lines here. An 
optimal alternative to the cell lines used here would be a cell line with 
temporally controllable MLH1 expression, to minimise the effect of drift on 
experimental results. However, with a more isogenic system it may not have 
been possible to detect the vast difference in epigenomes between the 
clonally derived MLH1-proficient and -deficient cell lines. Although this would 
have reduced the potentially confounding effects of the variance in 
epigenomes of these two cell lines in determining the role of MLH1 in the 
response to cisplatin, it may have prevented the discovery that loss of certain 
repair pathways may also contribute to the epigenetic landscape of the cell. 
This may, in turn, have limited the understanding of the role of MLH1 and the 
possible mechanisms involved in the aberrant methylation of DNA after 
platinum-induced damage. 
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The second limitation in this study was the absence of single-cell 
experiments. The mechanism of DNA damage-induced aberrant DNA 
methylation proposed by Cuozzo et al. suggests that DNA at a damaged site 
is methylated on one strand and under-methylated on the other, resulting in a 
1:1 ratio of cells methylated and unmethylated at that locus after cell division 
(Cuozzo et al., 2007). However, it was not possible to test whether this is the 
mechanism of cisplatin-induced aberrant methylation occurring in the 
experiments presented here, as they do not measure single cell and single 
molecule events. Although the cell line data is derived from clonal 
populations, epigenetic changes continue to occur during cell culture until 
harvest, which is why methylation levels measured in clones are not rigidly 0, 
50 or 100 %, but are rather a range of values between these three states. In a 
single cell experiment or in the absence of epigenetic drift, it would be 
expected that the methylation at any CpG site would be 0, 50 or 100 %, and 
sites of damage, if repaired and methylated according to the Cuozzo 
hypothesis, would be 50 % methylated at all times. However, as epigenetic 
drift does occur in these cells, as evidenced by the range of methylation 
values detected, the Cuozzo mechanism cannot be demonstrated or ruled out 
in these experiments. In order to test the Cuozzo mechanism, future 
experiments would require treatment with cisplatin followed by the immediate 
isolation of single cells and the subsequent collection of cells from the first cell 
division after treatment. These cells could then be analysed at the single cell 
level to determine whether a true 1:1 ratio of methylated to unmethylated DNA 
exists at sites that have, presumably, undergone DNA damage and repair. 
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The third limitation of this work is the use of the Infinium 
HumanMethylation450 arrays. Although these arrays provide an in-depth 
analysis of methylation across the genome, there is significant bias in the 
coverage of the array. The array covers CpG islands preferentially and there 
is limited coverage of repetitive sequences and non-annotated RefSeq genes, 
as defined by the ENSEMBL annotation. Although the array method is reliable 
and robust, in order to gain a more evenly distributed measure of methylation 
across the genome a method such as MeDIP-seq would be an improvement. 
This method uses immunoprecipitation to capture regions of the genome 
methylated or hydroxymethylated, followed by high-throughput sequencing of 
the regions (Jacinto et al., 2008). This method is also reliable but additionally 
covers more non-RefSeq and repetitive regions of the genome than the 
Illumina Infinium array, is able to detect up to twice as many differentially 
methylated sequences compared to the Infinium array and, importantly, also 
allows the detection of hydroxymethyl cytosine, which may allow more 
detailed analysis of aberrant methylation mechanisms post-platinum treatment 
(Clark et al., 2012). 
 
Finally, although the number of clones and the number of patient samples 
used in these studies have allowed the detection of statistically significant 
changes in methylation in response to platinum treatment, the use of 
additional ovarian cell lines, higher numbers of clones and higher numbers of 
matched patient samples would improve the robustness and the power to 
detect changes in the experiments presented here. This may lead to more 
 269 
detailed findings regarding the nature of platinum-induced epigenetic changes 
in terms of location, sequence preference and overall number of changes. 
 
6.3 Future Perspectives 
The findings of this thesis lead to new questions relating to the mechanism(s) 
driving aberrant DNA methylation and platinum resistance. The hypothesis 
arising from this work is that recombination repair is required for aberrant 
methylation to occur post-platinum treatment and, if supported by future 
research, this may lead to novel approaches to treatment for patients. Options 
to inhibit recombination or methylation in combination with platinum-based 
chemotherapy may be explored in chemotherapy-naïve patients in an attempt 
to prevent platinum resistance arising in the first instance. This may also 
prove useful in preventing treatment-induced secondary cancers that may 
arise from epimutations caused by the epigenetic response to platinum 
chemotherapy. If such treatment regimens are considered trial-worthy it 
should also be possible to stratify patients better suited to such trials based on 
the genotype of the patient or of their tumour(s), as patients with BRCA 
mutations, for example, may not benefit from additional inhibition of 
recombination repair. 
 
As this thesis demonstrated both hypomethylation and hypermethylation in 
response to platinum treatment, it is possible that both of these alterations 
contribute to the epigenetic landscape that drives platinum resistance. This 
may, therefore, explain why use of demethylating agents in patients 
previously exposed to platinum therapy has yielded uncertain and negative 
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results. If hypomethylation is driving resistance in some of these patients then 
the additional use of a demethylating agent may have no effect and may even 
increase the resistance. It may, therefore, be more prudent to trial 
demethylating agents in platinum-naïve patients, in the hope that this 
decreases the likelihood of resistance occurring in the first place. A better 
option still would be to find a therapeutic target that prevents both aberrant 
hypomethylation and hypermethylation from occurring by blocking the action 
of proteins found to be essential for the aberrant methylation response to 
platinum. Ultimately, understanding the mechanism(s) behind the epigenetic 
response to platinum chemotherapy will provide the best possible basis from 
which to develop novel approaches to treatment to prevent platinum 
resistance from occurring and, therefore, to improve the survival prospects of 
future patients. 
 
6.4 Conclusions 
In conclusion, this thesis provided several novel findings, first and foremost 
that platinum-induced damage causes changes to DNA methylation, in 
ovarian cancer cell line models treated with cisplatin and in the peripheral 
blood DNA of ovarian cancer patients treated with carboplatin. MLH1 
contributes towards the methylation response to platinum in cell lines, likely 
through recognition and signalling of certain platinum lesions, but is not 
essential for the mechanism(s) of methylation changes. Finally, loss of MLH1 
causes a change in the DNA methylation profile of ovarian cancer cells in 
culture that is similar to the change induced by platinum damage. Together, 
the data presented here support the hypothesis that platinum treatment 
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causes epigenetic changes that could be selected for, leading to platinum 
resistance, and there are MLH1-dependent and MLH1-independent 
mechanisms leading to damage-induced methylation changes.  
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Supplementary figure 1. Second array sample-independent quality 
controls 
Plots of red and green channel signal intensities per sample across 
BeadChips for: staining control probes (A and B), with spots marking high 
(turquoise) or background (blue) DNP signal and high (red) or background 
(green) biotin signal; extension control probes (C and D), with spots marking 
signal correlating to the extension of T (turquoise), A (red), G (blue) and C 
(green); target removal control probes (E and F), with spots indicating the 
signal after target removal of type I (green) and type II (red) probes; and 
hybridisation control probes (G and H), with spots indicating signal intensity 
for low (blue), medium (green) and high (red) hybridisation.  
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Supplementary figure 2. Second array sample-dependent quality 
controls 
Plots of red and green channel signal intensities per sample across 
BeadChips for; bisulphite conversion control probes (A and B) with spots 
indicating unconverted control for type I (blue) and type II (turquoise) probes 
and converted control for type I (red) and type II (green) probes; specificity 
control probes (C and D) with spots indicating type I perfectly matched (PM) 
(green) and mismatched (MM) (turquoise) probes and type II PM (red) and 
MM (blue) probes; negative control probes (E and F) with spots representing 
signal across different negative probes; and non-polymorphic control probes 
(G and H) with spots indicating signal intensity for A (red), C (green), G (blue), 
and T (turquoise) bases.  
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Supplementary figure 3. Second array correction of batch effect using 
ComBat 
Distribution of probes by β value for chip 1 (red) and chip 2 (green) before (A) 
and after (B) ComBat batch correction. 
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Supplementary figure 4. Second array correction of probe type bias 
through peak-based correction 
Distribution of probes by β value for type I (red) and type II (green) probes 
before (A) and after (B) peak-based correction. 
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Supplementary figure 5. SCOTROC1 sample-independent quality 
controls 
Plots of red and green channel signal intensities per sample across chips for: 
staining control probes (A and B), with spots marking high (turquoise) or 
background (blue) DNP signal and high (red) or background (green) biotin 
signal; extension control probes (C and D), with spots marking signal 
correlating to the extension of A (red), C (green), G (blue) and T (turquoise); 
target removal control probes (E and F), with spots indicating the signal after 
target removal or type I (green) and type II (red) probes; and hybridisation 
control probes (G and H), with spots indicating signal intensity for low (blue), 
medium (green) and high (red) hybridisation.  
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Supplementary figure 6. SCOTROC1 sample-dependent quality controls 
Plots of red and green channel signal intensities per sample across chips for; 
bisulphite conversion control probes (A and B) with spots indicating 
unconverted control for type I (blue) and type II (turquoise) probes and for 
converted control for type I (red) and type II (green) probes; specificity control 
probes (C and D) with spots indicating type I perfectly matched (PM) (green) 
and mismatched (MM) (turquoise) probes and type II PM (red) and MM (blue) 
probes; negative control probes (E and F) with spots representing signal 
across different negative probes; and non-polymorphic control probes (G and 
H) with spots indicating signal intensity for A (red), C (green), G (blue), and T 
(turquoise) bases.  
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Supplementary figure 7. SCOTROC1 correction of batch effect using 
ComBat 
Distribution of probes by β value for chips 1-14 (colour indicated in key) before 
(A) and after (B) ComBat batch correction. 
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Supplementary figure 8. SCOTROC1 correction of probe type bias using 
peak-based correction 
Distribution of probes by β value for type I (red) and type II (green) probes 
before (A) and after (B) peak-based correction. 
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